[
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#learning-objectives",
    "href": "lectures/lec_5b.cea-fundamentals2.html#learning-objectives",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Learning Objectives",
    "text": "Learning Objectives\n\nUnderstand the concepts of summary measures of health, specifically, quality-adjusted life years (QALYs)\nDescribe the general differences between direct and indirect methods for estimating health state utilities\nCurate model parameters for quantifying “benefits” (the denominator in the CEA ratio)"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#outline",
    "href": "lectures/lec_5b.cea-fundamentals2.html#outline",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Outline",
    "text": "Outline\n\n\n\n\nValuing health outcomes: QALYs/DALYs\nUtility weights / instruments\n\n\n\nWhere to get values"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#numerator-costs",
    "href": "lectures/lec_5b.cea-fundamentals2.html#numerator-costs",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Numerator (costs)",
    "text": "Numerator (costs)\nValued in monetary terms\n - E.g.,  $USD / ₦NGN / KES / R"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#denominator-benefits",
    "href": "lectures/lec_5b.cea-fundamentals2.html#denominator-benefits",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Denominator (benefits):",
    "text": "Denominator (benefits):\nValued in terms of clinical outcomes\n - E.g.,  # of HIV cases prevented  # of children seizure free  # of quality-adjusted life years gained \n\nWhat’s important for the question at hand\nMost analyses report several different outcomes\nQALY/DALYs enable comparability across disease areas"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#why-summary-measures-of-health",
    "href": "lectures/lec_5b.cea-fundamentals2.html#why-summary-measures-of-health",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Why summary measures of health?",
    "text": "Why summary measures of health?\n\nQALYs and DALYs both provide a summary measure of health\nAllow comparison of health attainment / disease burden\n\nAcross diseases\nAcross populations\nOver time etc."
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#qalys",
    "href": "lectures/lec_5b.cea-fundamentals2.html#qalys",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "QALYs",
    "text": "QALYs\n\nOrigin story: welfare economics\n\nUtility = holistic measure of satisfaction or wellbeing\n\nWith QALYs, two dimensions of interest:\n\nlength of life (measured in life-years)\nquality of life (measured by utility weight, usually between 0 and 1)"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#qalys-1",
    "href": "lectures/lec_5b.cea-fundamentals2.html#qalys-1",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "QALYs",
    "text": "QALYs\n\n\nQALY: A metric that reflects both changes in life expectancy and quality of life (pain, function, or both)"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#qalys-2",
    "href": "lectures/lec_5b.cea-fundamentals2.html#qalys-2",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "QALYs",
    "text": "QALYs"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#example-patient-with-coronary-heart-disease-with-surgery",
    "href": "lectures/lec_5b.cea-fundamentals2.html#example-patient-with-coronary-heart-disease-with-surgery",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Example: Patient with coronary heart disease (with surgery)",
    "text": "Example: Patient with coronary heart disease (with surgery)\n\n\nSource: Harvard Decision Science"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#example-patient-with-coronary-heart-disease-with-surgery-1",
    "href": "lectures/lec_5b.cea-fundamentals2.html#example-patient-with-coronary-heart-disease-with-surgery-1",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Example: Patient with coronary heart disease (with surgery)",
    "text": "Example: Patient with coronary heart disease (with surgery)"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#example-patient-with-coronary-heart-disease-without-surgery",
    "href": "lectures/lec_5b.cea-fundamentals2.html#example-patient-with-coronary-heart-disease-without-surgery",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Example: Patient with coronary heart disease (without surgery)",
    "text": "Example: Patient with coronary heart disease (without surgery)"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#example-patient-with-coronary-heart-disease",
    "href": "lectures/lec_5b.cea-fundamentals2.html#example-patient-with-coronary-heart-disease",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Example: Patient with coronary heart disease",
    "text": "Example: Patient with coronary heart disease\n\nWith surgery: 7.875 QALYs\nWithout surgery: 6.625 QALYs\nBenefit from surgery intervention:\n\nIn QALYs: 7.875 – 6.625 QALYs = 1.25 QALYs\nIn life years: 10 years – 10 years = 0 LYs"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#utility-weights-how-are-they-obtained",
    "href": "lectures/lec_5b.cea-fundamentals2.html#utility-weights-how-are-they-obtained",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Utility weights – How are they obtained?",
    "text": "Utility weights – How are they obtained?\n\n\nUtility weights for most health states are between 0 (death) and 1 (perfect health)\nDirect methods\n\nStandard gamble\nTime trade-Off\nRating scales\n\nIndirect methods:\n\nEQ-5D\nOther utility instrument: SF-36; Health Utilities Index (HUI)"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg",
    "href": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Direct methods - Standard Gamble (SG)",
    "text": "Direct methods - Standard Gamble (SG)\n\n\n“What risk of death would you accept in order to avoid [living with an amputated leg for the rest of your life] and live the rest of your life in perfect health?”"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg-1",
    "href": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg-1",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Direct methods - Standard Gamble (SG)",
    "text": "Direct methods - Standard Gamble (SG)\n\n\n“What risk of death you would accept in order to avoid [living with an amputated leg the rest of your life] and live the rest of your life in perfect health?”\n\n\n\n\n\n\n\n\n\n\n\n\n\nFind the threshold p that sets EV(A) = EV(B)\nAssume respondent answered that they would be indifferent between A and B at a threshold of pDeath = 0.10\nThen U(Amputation) = p*U(Death) + (1-p)*U(Perfect Health) = 0.10*0 + (1-0.10)*1 = 0.9 = threshold of indifference between surgery & no surgery (I will live with this rather than have a high risk of dying”***)\n\n\n\n\n\nThe STANDARD GAMBLE technique asks patients (FOR EXAMPLE) - I WANT YOU TO IMAGINE\nYour leg gets amputated above the knee\nThis doesn’t impact your life expectancy, but you now live your life with an amputated leg\nNow, there’s a NEW TREATMENT available where they can re-attach your leg\nBut the treatment is RISKY & those undergoing it have a probability of dying\nThe standard gamble technique asks you to find the THRESHOLD of indifference between SURGERY & NO SURGERY\nIn other words, let’s say you have a 30% probability of dying: Would you do the treatment?\n\n\nWhat about a 20% probability of dying?\nWhat about a 10%? - Ajay says yes, .90 is your utility value for the health state of living with an amputated knee Etc.\n\n\nOkay, I will live with this rather than have any high risk of dying”***\n\nThis is the STANDARD GAMBLE TECHNIQUE"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg-2",
    "href": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg-2",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Direct methods - Standard Gamble (SG)",
    "text": "Direct methods - Standard Gamble (SG)\n\n“What risk of death you would accept in order to avoid [living with an amputated leg the rest of your life] and live the rest of your life in perfect health?”"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg-3",
    "href": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg-3",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Direct methods - Standard Gamble (SG)",
    "text": "Direct methods - Standard Gamble (SG)\n\n\n“What risk of death you would accept in order to avoid [living with stroke the rest of your life] and live the rest of your life in perfect health?”"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#how-bad-is-having-a-stroke",
    "href": "lectures/lec_5b.cea-fundamentals2.html#how-bad-is-having-a-stroke",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "How bad is having a stroke?",
    "text": "How bad is having a stroke?\n\nAs a result of a stroke, you\n\n\nHave impaired use of your left arm and leg\nNeed some help bathing and dressing\nNeed a cane or other device to walk\nExperience mild pain a few days per week\nAre able to work, with some modifications\nNeed assistance with shopping, household chores, errands\nFeel anxious and depressed sometimes"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg-4",
    "href": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---standard-gamble-sg-4",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Direct methods - Standard Gamble (SG)",
    "text": "Direct methods - Standard Gamble (SG)\n\n\n“What risk of death you would accept in order to avoid [living with stroke the rest of your life] and live the rest of your life in perfect health?”\n\n\n\n\n\n\n\n\n\n\n\n\n\nFind the threshold p_T that sets EV(A) = EV(B)\nAssume respondent answered that they would be indifferent between A and B at a threshold p_T = 0.2\nThen U(Stroke) = p_T*U(Death) + (1-p_T)*U(Perfect Health) = 0.2*0 + (1-0.2)*1 = 0.8"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---time-trade-off-tto",
    "href": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---time-trade-off-tto",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Direct Methods - Time Trade-Off (TTO)",
    "text": "Direct Methods - Time Trade-Off (TTO)\n\nAn alternative to standard gamble\nInstead of risk of death, TTO uses time alive to value health states\nDoes not involve uncertainty in choices\nTask might be easier for some respondents compared to standard gamble"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---time-trade-off-tto-1",
    "href": "lectures/lec_5b.cea-fundamentals2.html#direct-methods---time-trade-off-tto-1",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Direct Methods - Time Trade-Off (TTO)",
    "text": "Direct Methods - Time Trade-Off (TTO)\n\n\n“What portion of your current life expectancy of 40 years would you give up to improve your current health state (stroke) to ‘perfect health’?”\n\n\n\n\n\n\n\n\n\n\nU(Post-Stroke) * 40 years = U(Perfect Health) * 25 years + U(Dead) * 15 years\nU(Post-Stroke) * 40 years = 1 * 25 years + 0 * 15 years\nU(Post-Stroke) = 25/40 = 0.625"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#sg-vs-tto",
    "href": "lectures/lec_5b.cea-fundamentals2.html#sg-vs-tto",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "SG vs TTO",
    "text": "SG vs TTO\n\nSG represents decision-making under uncertainty; TTO is decision-making under certainty\nTTO might inadvertently capture time preference (i.e., we might value health in the future less than we do today) as opposed to only valuing the health states\nRisk posture is captured in SG (risk aversion for death) but not in TTO\nUtility values from SG usually &gt; TTO for same state"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#direct-methods-rating-scales",
    "href": "lectures/lec_5b.cea-fundamentals2.html#direct-methods-rating-scales",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Direct methods – Rating scales",
    "text": "Direct methods – Rating scales\n\n“On a scale where 0 represents death and 100 represents perfect health, what number would you say best describes your health state over the past 2 weeks?”\n\n\nProblem: It does not have the interval property we desire\n\nA value of “90” on this scale is not necessarily twice as good as a value of “45”"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#visual-analogue-scale-vas",
    "href": "lectures/lec_5b.cea-fundamentals2.html#visual-analogue-scale-vas",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Visual Analogue Scale (VAS)",
    "text": "Visual Analogue Scale (VAS)\nThe Visual Analog Scale (VAS) is a commonly-used rating scale\n\n\n\n\nSource: https://assessment-module.yale.edu/im-palliative/visual-analogue-scale"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#direct-methods-rating-scales-1",
    "href": "lectures/lec_5b.cea-fundamentals2.html#direct-methods-rating-scales-1",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Direct methods – Rating scales",
    "text": "Direct methods – Rating scales\n\nEasy to use: Rating scales often used where time or cognitive ability/literacy prevents use of other methods\nVery subjective and prone to more extreme answers! Usually, utilities for VAS &lt; TTO &lt; SG"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#practical-issue-keep-an-eye-out-for-cheaters",
    "href": "lectures/lec_5b.cea-fundamentals2.html#practical-issue-keep-an-eye-out-for-cheaters",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Practical issue – keep an eye out for “cheaters”",
    "text": "Practical issue – keep an eye out for “cheaters”\nHypothetical “cheating” example:\n\nDrug company X has discovered a drug that prevents diabetes but causes migraines (side-effect)\nThey use VAS to estimate the utility of diabetes in their decision model and SG to estimate the utility of migraines\nIs there a problem here? (yes, there is!!)\n\nRecall, usually utilities for VAS &lt; TTO &lt; SG\nThus, this approach overstates the benefit by using a lower U(Diabetes) and higher U(migraines)\n\n\n\n\nSG will usually have a higher utility (so better quality of life) - so they are downplaying the migraine side effect\nWhereas VAS usually has a lower utility, so they will gain MORE from preventing diabetes since a lower utility = worse off."
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#indirect-methods---eq-5d",
    "href": "lectures/lec_5b.cea-fundamentals2.html#indirect-methods---eq-5d",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Indirect Methods - EQ-5D",
    "text": "Indirect Methods - EQ-5D\n\n\n\nSystem for describing health states\n5 domains: mobility; self-care; usual activities; pain/discomfort; and anxiety/depression\n3 levels: 243 distinct health states (e.g. 11223)\nValuations elicited through population based surveys with VAS, TTO\n\n\n\n\n\n\n\nIndirect utility measures map preferences onto a utility scale via a generic health-related quality of life questionnaire"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#indirect-methods",
    "href": "lectures/lec_5b.cea-fundamentals2.html#indirect-methods",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Indirect Methods",
    "text": "Indirect Methods\n\nINDIRECT UTILITY MEASURES \n\nHUI – Health Utility Index\nEQ5D – EuroQol health status measure\nSF-6D – Converts SF-36 & SF-12 scores to utilities\nQWB – Quality of well-being scale\n\n\n\nI’m not going to get into detail for each of these since you don’t need to know the granularity of each right now until you start exploring for your studies in the future, but just as an overview of some of the more well-known ones:\nHUI (Health Utility Index), based on a large, Canadian community sample (copyrighted, not free to use), patients are asked to consider their health over the past 2, 3, & 4 weeks\nEQ5D, European & US-based, asks participants to consider their health during the day of the interview; free but need to request permission & if you need to translate into other languages then it can be quite pricey\nSF-6D, 4 to 1-week recall period, converts the SF-36 & SF-12 (validated, generic quality of life measures) into utility scores, conversion done by University of Sheffield developer John Brazier; published articles on the methodology to convert these\nQWB (Quality of Well-Being scale), asks participants to consider their health over the previous three days, primary care patients in San Diego, CA; contact UCSD health outcomes assessment program for access"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#indirect-methods-1",
    "href": "lectures/lec_5b.cea-fundamentals2.html#indirect-methods-1",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Indirect Methods",
    "text": "Indirect Methods\n\nCAUTION – \nYou may see articles / studies that report “NON-PREFERENCED-BASED” quality of life measures (e.g. measuring burden, ”quality of life”, symptoms; usually not on 0 to 1 scale), which often report “summary scores”, but these are NOT THE SAME as PREFERENCE-BASED measures (e.g., how one VALUES different health states)\n\nThe latter of which can be used in economic evaluations"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#disease-specific-measures",
    "href": "lectures/lec_5b.cea-fundamentals2.html#disease-specific-measures",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Disease specific measures",
    "text": "Disease specific measures\n\nMore sensitive to changes in a particular disease \nDisadvantages – \n\nMany people have multiple health conditions\nCan not be transferred to QALY/Utility unless statistically mapped to generalized measures (EQ5D, etc.)\n\n\n\nDisease specific measures are more sensitive to changes in a particular disease\nFor example, **Using a disease-specific quality of life measure for epilepsy"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#off-the-shelf-numbers-for-your-own-ceas",
    "href": "lectures/lec_5b.cea-fundamentals2.html#off-the-shelf-numbers-for-your-own-ceas",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Off-the-shelf numbers for your own CEAs?",
    "text": "Off-the-shelf numbers for your own CEAs?\n\n\nLarge scale utility studies\nBalancing tradeoffs between different measures\n\nSensitivity analyses!\n\nTufts CEA registry\nAlongside RCTs"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#dalys",
    "href": "lectures/lec_5b.cea-fundamentals2.html#dalys",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "DALYs",
    "text": "DALYs\nYou, furthermore, will not be tested on DALYs, but for your reference/interest:\n\n\nOrigin story: Global Burden of Disease Study\nDeliberately a measure of health, not welfare/utility\nSimilar to QALYs, two dimensions of interest:\n\nlength of life (differences in life expectancy)\nquality of life (measured by disability weight)"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#dalys-1",
    "href": "lectures/lec_5b.cea-fundamentals2.html#dalys-1",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "DALYs",
    "text": "DALYs\n\n\nDALYs = YLL + YLD\n\nYLL (Years of Life Lost)\nYLD (Years Lived with Disability)"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#dalys-yll-yld",
    "href": "lectures/lec_5b.cea-fundamentals2.html#dalys-yll-yld",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "DALYs = YLL + YLD",
    "text": "DALYs = YLL + YLD\n\nYears of Life Lost (YLL): changes in life expectancy, calculated from comparison to synthetic life table\nYLL example: Providing HIV treatment delays death from age 30 to age 50\n\nLife years gained = 20 years\nYLL?"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#synthetic-reference-life-table",
    "href": "lectures/lec_5b.cea-fundamentals2.html#synthetic-reference-life-table",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Synthetic, Reference Life Table",
    "text": "Synthetic, Reference Life Table\n\n\n\n\nAge\nLife Expectancy\nAge\nLife Expectancy\n\n\n\n\n0\n88.9\n50\n39.6\n\n\n1\n88.0\n55\n34.9\n\n\n5\n84.0\n60\n30.3\n\n\n10\n79.0\n65\n25.7\n\n\n15\n74.1\n70\n21.3\n\n\n20\n69.1\n75\n17.1\n\n\n25\n64.1\n80\n13.2\n\n\n30\n59.2\n85\n10.0\n\n\n35\n54.3\n90\n7.6\n\n\n40\n49.3\n95\n5.9\n\n\n45\n44.4\n\n\n\n\n\nSource: http://ghdx.healthdata.org/record/ihme-data/global-burden-disease-study-2019-gbd-2019-reference-life-table"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#synthetic-reference-life-table-1",
    "href": "lectures/lec_5b.cea-fundamentals2.html#synthetic-reference-life-table-1",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Synthetic, Reference Life Table",
    "text": "Synthetic, Reference Life Table\n\n\n\n\nAge\nLife Expectancy\nAge\nLife Expectancy\n\n\n\n\n0\n88.9\n50\n39.6\n\n\n1\n88.0\n55\n34.9\n\n\n5\n84.0\n60\n30.3\n\n\n10\n79.0\n65\n25.7\n\n\n15\n74.1\n70\n21.3\n\n\n20\n69.1\n75\n17.1\n\n\n25\n64.1\n80\n13.2\n\n\n30\n59.2\n85\n10.0\n\n\n35\n54.3\n90\n7.6\n\n\n40\n49.3\n95\n5.9\n\n\n45\n44.4\n\n\n\n\n\nSource: http://ghdx.healthdata.org/record/ihme-data/global-burden-disease-study-2019-gbd-2019-reference-life-table"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#dalys-yll-yld-1",
    "href": "lectures/lec_5b.cea-fundamentals2.html#dalys-yll-yld-1",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "DALYs = YLL + YLD",
    "text": "DALYs = YLL + YLD\n\n\nYears of Life Lost (YLL): changes in life expectancy, calculated from comparison to synthetic life table\nYLL example: Providing HIV treatment delays death from age 30 to age 50\n\nLife years (LYs) gained: 20 years\nYLL: LE(50) - LE(30) = 39.6 - 59.2 = -19.6 DALYs = 19.6 DALYs averted\n\n\n\n\n\n\n\n\n\n\nNote\n\n\nYLL (measured as DALYs averted) \\neq LYs gained!"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#dalys-yll-yld-2",
    "href": "lectures/lec_5b.cea-fundamentals2.html#dalys-yll-yld-2",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "DALYs = YLL + YLD",
    "text": "DALYs = YLL + YLD\n\nYears Lived with Disability (YLD): calculated similar to QALYs, utility weight ≈ 1 - disability weight\nYLD example: Effective asthma control for 10 years\n\nDisability weight (uncontrolled asthma) = ?\nDisability weight (controlled asthma) = ?"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#disability-weights",
    "href": "lectures/lec_5b.cea-fundamentals2.html#disability-weights",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "Disability Weights",
    "text": "Disability Weights\n\n\n\nCommon values for small set of named health conditions (e.g. early/late HIV, HIV/ART)\nFirst iteration: expert opinion\nSecond iteration: Pop-based HH surveys in several world regions (13,902 respondents)\n\nPaired comparison of two health state descriptions which worse\nProbit regression to calculate disability weights\n235 unique health states\n\n\n\n\n\n\n\nSource: Salomon, Joshua A., et al. “Disability weights for the Global Burden of Disease 2013 study.” The Lancet Global Health 3.11 (2015): e712-e723."
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#dalys-yll-yld-3",
    "href": "lectures/lec_5b.cea-fundamentals2.html#dalys-yll-yld-3",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "DALYs = YLL + YLD",
    "text": "DALYs = YLL + YLD\n\n\nYears Lived with Disability (YLD): calculated similar to QALYs, utility weight ≈ 1 - disability weight\nYLD example: Effective asthma control for 10 years\n\nDisability weight (uncontrolled asthma) = 0.133\nDisability weight (controlled asthma) = 0.015\nYLD = 10 * 0.015 - 10 * 0.133 = -1.18 DALYs = 1.18 DALYs averted"
  },
  {
    "objectID": "lectures/lec_5b.cea-fundamentals2.html#dalys-for-cea",
    "href": "lectures/lec_5b.cea-fundamentals2.html#dalys-for-cea",
    "title": "CEA Fundamentals: Valuing Outcomes",
    "section": "DALYs for CEA",
    "text": "DALYs for CEA\n\n\nRecommended calculation approach has changed over time (age weighting, discounting, now both out)\nSome will calculate a “QALY-like” DALY, using utility weight = 1- disability weight\nDiscounting still generally done for CEA\n\n\n\n\n\n\n\n\n\nImportant\n\n\nCommon practice\n\nHigh-income setting: QALYs\nLow- and middle- income setting = DALYs ***Since disability weights are freely & publicly available (these weights are required for DALY calculations), it can reduce costs/time/resources compared to collecting QALY estimates"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#esquema",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#esquema",
    "title": "Introducción al análisis de decisiones",
    "section": "Esquema {{< fa regular clipboard >}}",
    "text": "Esquema {{&lt; fa regular clipboard &gt;}}\n\n\nPresentaciones\nMotivación\nEjemplos de análisis de decisiones\nObjetivos del taller"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#curso-sitio-web",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#curso-sitio-web",
    "title": "Introducción al análisis de decisiones",
    "section": "Curso Sitio web",
    "text": "Curso Sitio web\n\nhttps://github.com/graveja0/bogota-vital-strategies\n\n\n\nTodos los materiales del curso (diapositivas, casos prácticos) se publican aquí.\nNuestro calendario (que probablemente evolucione) también se publicará aquí y se actualizará periódicamente."
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#presentaciones",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#presentaciones",
    "title": "Introducción al análisis de decisiones",
    "section": "Presentaciones",
    "text": "Presentaciones\n\nPor favor, ¡preséntese!"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#las-dos-últimas-décadas",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#las-dos-últimas-décadas",
    "title": "Introducción al análisis de decisiones",
    "section": "Las dos últimas décadas …",
    "text": "Las dos últimas décadas …\n\n\nHepatitis C curada\nReducción significativa de la incidencia del VIH\nPosible cura de la leucemia y el linfoma recidivantes o refractarios\nVacunas perfeccionadas (por ejemplo, la vacuna contra el VPH) para prevenir enfermedades como el cáncer de cuello de útero y otros tipos de cáncer.\nAvances en la prevención de enfermedades cardiovasculares"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#a-pesar-de-estos-avances",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#a-pesar-de-estos-avances",
    "title": "Introducción al análisis de decisiones",
    "section": "A pesar de estos avances …",
    "text": "A pesar de estos avances …\n\nLa carga de enfermedades no transmisibles (ENT) como el cáncer, las enfermedades cardiovasculares y la diabetes va en aumento.\nSon la causa del 74% de las muertes en el mundo, y la mayoría (86%) en los países de renta baja y media (PRMB).\n\nFuente: OMS\n\nLas tasas de malnutrición, necesidad insatisfecha de servicios de salud sexual y reproductiva y mortalidad materna también siguen siendo elevadas en muchas partes del mundo."
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ejemplos-de-análisis-de-decisiones",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ejemplos-de-análisis-de-decisiones",
    "title": "Introducción al análisis de decisiones",
    "section": "Ejemplos de Análisis de Decisiones",
    "text": "Ejemplos de Análisis de Decisiones"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-1.-vih",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-1.-vih",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 1. VIH",
    "text": "Ej 1. VIH\n\n\n\nHa sido nombrado director de un comité de asignación de fondos responsable de las iniciativas de prevención y tratamiento del VIH.\n\n\n\n\n\nCómo decidirá el comité la proporción de fondos para las iniciativas de prevención frente a las de tratamiento?\n\n¿Debería destinarse parte de los fondos a la investigación?\n\n¿Cómo responder a un miembro que argumenta que los fondos están mejor gastados en vacunación infantil?"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 2. Defectos de nacimiento",
    "text": "Ej 2. Defectos de nacimiento\n\n\nUn hipotético defecto congénito está presente en 1 de cada 1.000 niños nacidos\nA menos que se trate, esta condición tiene una tasa de mortalidad del 50"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-1",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-1",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 2. Defectos de nacimiento",
    "text": "Ej 2. Defectos de nacimiento\n\n\n\n¿Deberíamos comprobar este hipotético defecto de nacimiento?\n\n\n\n\n\n\n\nUn hipotético defecto congénito está presente en 1 de cada 1.000 niños nacidos.\nA menos que se trate, esta condición tiene una tasa de mortalidad del 50%."
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-2",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-2",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 2. Defectos de Nacimiento",
    "text": "Ej 2. Defectos de Nacimiento\n\n\n\n¿Deberíamos probar este hipotético defecto de nacimiento?\n\n\n\n\n\n\n\n\nPrueba diagnóstica: Perfectamente preciso\nTodos los recién nacidos en los que se identifica el defecto pueden ser curados con éxito\nPERO la prueba en sí puede ser letal:\n\n4 de cada 10.000 bebés sometidos a la prueba morirán como resultado directo y observable del procedimiento de la prueba"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-3",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-3",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 2. Defectos de nacimiento",
    "text": "Ej 2. Defectos de nacimiento\n\n\n\nObjetivo: Minimizar el total de muertes esperadas"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-4",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-4",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 2. Defectos de Nacimiento",
    "text": "Ej 2. Defectos de Nacimiento\n\n\n\nObjetivo: Minimizar el total de muertes esperadas\n\n\n\n\n\nConsiderar una población de 100.000 recién nacidos\nLa prueba produce: (0,0004 x 100.000) = 40 muertes esperadas\nSin pruebas produce: (0,001 x 0,5 x 100.000) = 50 muertes esperadas"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-5",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-5",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 2. Defectos de nacimiento",
    "text": "Ej 2. Defectos de nacimiento\n\n\n\nObjetivo: Minimizar el total de muertes esperadas\n\n\n\n\nConsidere una población de 100.000 recién nacidos\nLa prueba produce: (0,0004 x 100.000) = 40 muertes esperadas\nSin pruebas produce: (0,001 x 0,5 x 100.000) = 50 muertes esperadas\n\n¡Parece que GANA LA PRUEBA!"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-6",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-2.-defectos-de-nacimiento-6",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 2. Defectos de nacimiento",
    "text": "Ej 2. Defectos de nacimiento\n\n\n\nObjetivo: Minimizar el total de muertes esperadas\n\n\n\n\nConsidere una población de 100.000 recién nacidos\nLa prueba produce: (0,0004 x 100.000) = 40 muertes esperadas\nSin pruebas produce: (0,001 x 0,5 x 100.000) = 50 muertes esperadas\n\n¡Parece que GANA LA PRUEBA!\n¿Alguien tiene un problema con esto??"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#diferentes-vidas-se-pierden",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#diferentes-vidas-se-pierden",
    "title": "Introducción al análisis de decisiones",
    "section": "Diferentes vidas se pierden",
    "text": "Diferentes vidas se pierden\n\n\nCon pruebas, prácticamente las 40 muertes ocurren en bebés nacidos sin la enfermedad mortal.\nCon sin pruebas, las 50 muertes previstas se producen por “causas naturales” (es decir, por un defecto congénito que no se puede prevenir)."
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#se-pierden-vidas-diferentes",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#se-pierden-vidas-diferentes",
    "title": "Introducción al análisis de decisiones",
    "section": "Se pierden vidas diferentes",
    "text": "Se pierden vidas diferentes\n\n\n“Muertes inocentes” infligidas a niños que no tenían “nada que ganar” con el programa de pruebas\nPodemos tratar la muerte de un niño como más tolerable que la de otro, incluso cuando no tenemos forma, antes del hecho, de distinguir a un bebé del otro."
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 3. Cáncer de colon",
    "text": "Ej 3. Cáncer de colon\n\n\n3ª causa de muerte por cáncer.\nHombres, mujeres, todas las razas.\nLa detección precoz ayuda a prevenirlo y mejora la salud.\n\\sim80\\% prevenible."
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon-prevención",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon-prevención",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 3. Cáncer de colon – Prevención",
    "text": "Ej 3. Cáncer de colon – Prevención\n\n\n¿Cuándo realizar el cribado?\n¿Qué prueba y con qué frecuencia?\nSi se encuentra/extrae un pólipo, ¿cuándo repetir?"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon-prevención-1",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon-prevención-1",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 3. Cáncer de colon – Prevención",
    "text": "Ej 3. Cáncer de colon – Prevención\n\n\n¿Coste-efectividad de pruebas de cribado alternativas?\n¿Frecuencias alternativas de cribado?\n¿Cómo debería variar el cribado según los grupos de riesgo?"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon---estimación-de-probabilidades",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon---estimación-de-probabilidades",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 3. Cáncer de colon - Estimación de probabilidades",
    "text": "Ej 3. Cáncer de colon - Estimación de probabilidades\n\n\nPredecir el riesgo/incidencia del cáncer de colon\n\nAntecedentes familiares, pólipos anteriores, otros factores\nProbabilidad de padecer cáncer de colon\n\nPredecir el impacto del cáncer de colon\n\nProbabilidad de curación\nProbabilidad de muerte\nProbabilidad de morbilidad"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon---estimación-de-probabilidades-1",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#ej-3.-cáncer-de-colon---estimación-de-probabilidades-1",
    "title": "Introducción al análisis de decisiones",
    "section": "Ej 3. Cáncer de colon - Estimación de probabilidades",
    "text": "Ej 3. Cáncer de colon - Estimación de probabilidades\n\n\nPredecir el “beneficio” del cribado\n\nTodas las probabilidades anteriores\nProbabilidad de detección precoz\nProbabilidad de complicaciones derivadas de las pruebas\nProbabilidad de falso positivo\nProbabilidad de falsos negativos\nProbabilidad de pruebas positivas = cáncer\nProbabilidad de pruebas negativas = sin cáncer"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#la-estimación-de-probabilidades-es-fundamental-para-la-toma-de-decisiones",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#la-estimación-de-probabilidades-es-fundamental-para-la-toma-de-decisiones",
    "title": "Introducción al análisis de decisiones",
    "section": "La estimación de probabilidades es fundamental para la toma de decisiones",
    "text": "La estimación de probabilidades es fundamental para la toma de decisiones\n\n\nNo se pueden obtener fácilmente las probabilidades necesarias\nPeríodos de tiempo / duraciones variables\nMétodos para estimar probabilidades"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#commonality-of-cases",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#commonality-of-cases",
    "title": "Introducción al análisis de decisiones",
    "section": "Commonality of cases",
    "text": "Commonality of cases\n\n\nCompromisos inevitables\nDiferentes perspectivas pueden llevar a conclusiones diferentes\nMúltiples objetivos contrapuestos\nComplejidad\nIncertidumbre"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#análisis-de-decisiones",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#análisis-de-decisiones",
    "title": "Introducción al análisis de decisiones",
    "section": "Análisis de decisiones",
    "text": "Análisis de decisiones\n\n\n\nTiene como objetivo informar la elección bajo incertidumbre utilizando un enfoque explícito y cuantitativo\nSu objetivo es identificar, medir y valorar las consecuencias de las decisiones en situaciones de incertidumbre cuando hay que tomar una decisión, más apropiadamente a lo largo del tiempo."
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#diseño-del-taller",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#diseño-del-taller",
    "title": "Introducción al análisis de decisiones",
    "section": "Diseño del taller",
    "text": "Diseño del taller\n\nSomos flexibles – si hay algún tema que no te queda claro, o que te gustaría que se ampliara, ¡háznoslo saber!\nContenido mixto\n\n\nConferencias\nCasos prácticos en grupos reducidos\nCasos prácticos en grupos grandes y ejercicios prácticos de Excel"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#contenido-del-taller",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#contenido-del-taller",
    "title": "Introducción al análisis de decisiones",
    "section": "Contenido del taller",
    "text": "Contenido del taller\n\nFundamentos del análisis de decisiones (Días 1-2)\n\n\nÁrboles de decisión\nTeorema de Bayes y umbrales de tratamiento\nIncertidumbre y priorización de la investigación futura"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#contenido-del-taller-1",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#contenido-del-taller-1",
    "title": "Introducción al análisis de decisiones",
    "section": "Contenido del taller",
    "text": "Contenido del taller\n\nFundamentos del análisis coste-eficacia (Días 3-4)\n\n\nValoración de costes y resultados sanitarios\nAnálisis coste-efectividad incremental\nIntroducción a los modelos de Markov"
  },
  {
    "objectID": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#contenido-del-taller-2",
    "href": "lectures/ESP_lec_1a.introduction-to-decision-analysis.html#contenido-del-taller-2",
    "title": "Introducción al análisis de decisiones",
    "section": "Contenido del taller",
    "text": "Contenido del taller\n\nAvance de temas avanzados (Día 5)\n\n\nAnálisis de sensibilidad\nMarcos avanzados de modelización CEA."
  },
  {
    "objectID": "lectures/lec_sensitivity.html#learning-objectives",
    "href": "lectures/lec_sensitivity.html#learning-objectives",
    "title": "Deterministic & Scenario Analysis",
    "section": "Learning Objectives",
    "text": "Learning Objectives\n\nExplain the purpose of deterministic sensitivity analysis and provide examples of one-way versus two-way analyses.\nDetail the advantages/disadvantages of deterministic sensitivity analysis."
  },
  {
    "objectID": "lectures/lec_sensitivity.html#outline",
    "href": "lectures/lec_sensitivity.html#outline",
    "title": "Deterministic & Scenario Analysis",
    "section": "Outline",
    "text": "Outline\n\nOne-way sensitivity analysis.\nExamples from publications.\nTwo-way sensitivity analysis.\nExamples from publications.\nLimitations and extensions.\nScenario analysis\nThreshold analysis"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#one-way-sensitivity-analysis-1",
    "href": "lectures/lec_sensitivity.html#one-way-sensitivity-analysis-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "One-way sensitivity analysis",
    "text": "One-way sensitivity analysis\n\n\nUsually the starting point for sensitivity analyses\nSequentially testing one variable at a time (i.e., Age, BMI, QALY, other clinically important parameters), while holding everything else constant\nDetermining how this variation impacts the results\nOne-way sensitivity analyses are often presented in a tornado diagram\n\nUsed to visually rank the different variables in order of their overall influence on the magnitude of the model outputs"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#a-simple-decision-tree",
    "href": "lectures/lec_sensitivity.html#a-simple-decision-tree",
    "title": "Deterministic & Scenario Analysis",
    "section": "A simple decision tree",
    "text": "A simple decision tree"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#a-simple-decision-tree-1",
    "href": "lectures/lec_sensitivity.html#a-simple-decision-tree-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "A simple decision tree",
    "text": "A simple decision tree"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#a-simple-decision-tree-2",
    "href": "lectures/lec_sensitivity.html#a-simple-decision-tree-2",
    "title": "Deterministic & Scenario Analysis",
    "section": "A simple decision tree",
    "text": "A simple decision tree"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#rotavirus-case-study-from-capstone",
    "href": "lectures/lec_sensitivity.html#rotavirus-case-study-from-capstone",
    "title": "Deterministic & Scenario Analysis",
    "section": "Rotavirus case study from Capstone",
    "text": "Rotavirus case study from Capstone"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#rotavirus-case-study-from-capstone-1",
    "href": "lectures/lec_sensitivity.html#rotavirus-case-study-from-capstone-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "Rotavirus case study from Capstone",
    "text": "Rotavirus case study from Capstone"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#rotavirus-case-study-from-capstone-2",
    "href": "lectures/lec_sensitivity.html#rotavirus-case-study-from-capstone-2",
    "title": "Deterministic & Scenario Analysis",
    "section": "Rotavirus case study from Capstone",
    "text": "Rotavirus case study from Capstone"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#other-examples",
    "href": "lectures/lec_sensitivity.html#other-examples",
    "title": "Deterministic & Scenario Analysis",
    "section": "Other examples",
    "text": "Other examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#other-examples-1",
    "href": "lectures/lec_sensitivity.html#other-examples-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "Other examples",
    "text": "Other examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#other-examples-2",
    "href": "lectures/lec_sensitivity.html#other-examples-2",
    "title": "Deterministic & Scenario Analysis",
    "section": "Other examples",
    "text": "Other examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#other-examples-3",
    "href": "lectures/lec_sensitivity.html#other-examples-3",
    "title": "Deterministic & Scenario Analysis",
    "section": "Other examples",
    "text": "Other examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#two-way-sensitivity-analysis-1",
    "href": "lectures/lec_sensitivity.html#two-way-sensitivity-analysis-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "Two-way sensitivity analysis",
    "text": "Two-way sensitivity analysis\n\n\nA way to map the interaction effects between two parameters in a decision analysis model\nVaries 2 parameters at a time\nExplores the robustness of results in more depth"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#hiv-prevention",
    "href": "lectures/lec_sensitivity.html#hiv-prevention",
    "title": "Deterministic & Scenario Analysis",
    "section": "HIV prevention",
    "text": "HIV prevention"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#hiv-prevention-1",
    "href": "lectures/lec_sensitivity.html#hiv-prevention-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "HIV prevention",
    "text": "HIV prevention\n\n\nMarkov model examining strategies for HIV prevention among serodiscordant couples seeking conception (woman does not have HIV and male has HIV)\nWe know that if the male partner is consistently on medication for HIV (i.e., resulting in virologic suppression), then the risk of transmission is small regardless of the woman taking PrEP (pre-exposure prophylaxis)\nAnd we also know that PrEP has traditionally been really costly"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#hiv-prevention-2",
    "href": "lectures/lec_sensitivity.html#hiv-prevention-2",
    "title": "Deterministic & Scenario Analysis",
    "section": "HIV prevention",
    "text": "HIV prevention"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#financial-incentives-for-acute-stroke-care",
    "href": "lectures/lec_sensitivity.html#financial-incentives-for-acute-stroke-care",
    "title": "Deterministic & Scenario Analysis",
    "section": "Financial incentives for acute stroke care",
    "text": "Financial incentives for acute stroke care"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#financial-incentives-for-acute-stroke-care-1",
    "href": "lectures/lec_sensitivity.html#financial-incentives-for-acute-stroke-care-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "Financial incentives for acute stroke care",
    "text": "Financial incentives for acute stroke care\n\n\nUnder pay for performance policies in the US, physicians or hospitals are paid more for meeting evidence-based quality targets\nStudy objective: Illustrate how pay-for-performance incentives can be quantitatively bounded using cost-effectiveness modeling, through the application of reimbursement to hospitals for faster time-to-tPA for acute ischemic stroke"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#financial-incentives-for-acute-stroke-care-2",
    "href": "lectures/lec_sensitivity.html#financial-incentives-for-acute-stroke-care-2",
    "title": "Deterministic & Scenario Analysis",
    "section": "Financial incentives for acute stroke care",
    "text": "Financial incentives for acute stroke care\n\nWhen administered quickly after stroke onset (within three hours, as approved by the FDA), tPA helps to restore blood flow to brain regions affected by a stroke, thereby limiting the risk of damage and functional impairment"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#financial-incentives-for-acute-stroke-care-3",
    "href": "lectures/lec_sensitivity.html#financial-incentives-for-acute-stroke-care-3",
    "title": "Deterministic & Scenario Analysis",
    "section": "Financial incentives for acute stroke care",
    "text": "Financial incentives for acute stroke care"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#caution-limitations",
    "href": "lectures/lec_sensitivity.html#caution-limitations",
    "title": "Deterministic & Scenario Analysis",
    "section": "Caution: Limitations!",
    "text": "Caution: Limitations!\n\nLimited by the subjectivity of the choice of parameters to analyze\nThat’s why we also run PSAs!, i.e., varying ALL input parameters at the same time, using priors to play a distribution around each value"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#scenario-analysis-1",
    "href": "lectures/lec_sensitivity.html#scenario-analysis-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "Scenario analysis",
    "text": "Scenario analysis\n\nFocuses more on model assumptions rather than parameter uncertainty\nCould include separate analysis on:\n\n\nSubgroups/sub-populations, including different age cohorts & risk levels\n\n\n\nDifferent perspectives (societal; modified societal; etc)"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#scenario-analysis-2",
    "href": "lectures/lec_sensitivity.html#scenario-analysis-2",
    "title": "Deterministic & Scenario Analysis",
    "section": "Scenario analysis",
    "text": "Scenario analysis\n\nHypothetical scenarios (“optimistic” and “conservative” scenarios; for example, if we have little evidence of long-term survival associated with medication X, we might have an optimistic versus conservative scenario)\n\n\n\nTime horizons"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#examples",
    "href": "lectures/lec_sensitivity.html#examples",
    "title": "Deterministic & Scenario Analysis",
    "section": "Examples",
    "text": "Examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#examples-1",
    "href": "lectures/lec_sensitivity.html#examples-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "Examples",
    "text": "Examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#examples-2",
    "href": "lectures/lec_sensitivity.html#examples-2",
    "title": "Deterministic & Scenario Analysis",
    "section": "Examples",
    "text": "Examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#examples-3",
    "href": "lectures/lec_sensitivity.html#examples-3",
    "title": "Deterministic & Scenario Analysis",
    "section": "Examples",
    "text": "Examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#examples-4",
    "href": "lectures/lec_sensitivity.html#examples-4",
    "title": "Deterministic & Scenario Analysis",
    "section": "Examples",
    "text": "Examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#examples-5",
    "href": "lectures/lec_sensitivity.html#examples-5",
    "title": "Deterministic & Scenario Analysis",
    "section": "Examples",
    "text": "Examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#threshold-analysis-1",
    "href": "lectures/lec_sensitivity.html#threshold-analysis-1",
    "title": "Deterministic & Scenario Analysis",
    "section": "Threshold analysis",
    "text": "Threshold analysis\n\nAnswers the question: What the input parameter need be to meet the country thresholds of:\n\n$50,000/QALY gained\n$100,000/QALY gained\n$150,000/QALY gained\n$200,000/QALY gained"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#examples-6",
    "href": "lectures/lec_sensitivity.html#examples-6",
    "title": "Deterministic & Scenario Analysis",
    "section": "Examples",
    "text": "Examples"
  },
  {
    "objectID": "lectures/lec_sensitivity.html#examples-7",
    "href": "lectures/lec_sensitivity.html#examples-7",
    "title": "Deterministic & Scenario Analysis",
    "section": "Examples",
    "text": "Examples"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#outline",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#outline",
    "title": "Introduction to Decision Analysis",
    "section": "Outline {{< fa regular clipboard >}}",
    "text": "Outline {{&lt; fa regular clipboard &gt;}}\n\n\nIntroductions\nMotivation\nExamples of Decision Analysis\nWorkshop objectives"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#course-website",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#course-website",
    "title": "Introduction to Decision Analysis",
    "section": "Course Website",
    "text": "Course Website\n\nhttps://github.com/graveja0/bogota-vital-strategies\n\n\n\nAll course materials (slides, case studies) are posted here.\nOur (likely evolving) schedule will also be posted here, and updated regularly."
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#introductions",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#introductions",
    "title": "Introduction to Decision Analysis",
    "section": "Introductions",
    "text": "Introductions\n\nPlease introduce yourself!"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#the-past-two-decades",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#the-past-two-decades",
    "title": "Introduction to Decision Analysis",
    "section": "The Past Two Decades …",
    "text": "The Past Two Decades …\n\n\nCured Hepatitis C\nSignificantly reduced incidence of HIV\nPotential cure for relapsed/refractory leukemia & lymphoma\nPerfected vaccines (e.g. HPV vaccine) to prevent diseases such as cervical & other cancers\nStrides in preventing cardiovascular disease"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#despite-these-advances",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#despite-these-advances",
    "title": "Introduction to Decision Analysis",
    "section": "Despite these advances …",
    "text": "Despite these advances …\n\nBurden of non-communicable diseases (NCDs) like cancer, cardiovascular disease, and diabetes is growing.\nNCDs are the cause of 74 percent of deaths globally, with most (86%) of those deaths in low- and middle-income countries (LMICs)\n\nSource: WHO\n\nRates also remain high in many parts of the world for malnutrition, unmet need for sexual and reproductive health services, and maternal mortality."
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-1.-hiv",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-1.-hiv",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 1. HIV",
    "text": "Ex 1. HIV\n\n\n\nYou have been appointed as Director of a funding allocation committee responsible for prevention & treatment initiatives for HIV.\n\n\n\n\n\nHow will the committee decide on the proportion of funds for prevention efforts versus treatment?\nShould any of the funds be used for research?\nHow do you respond to a member who argues that the funds are better spent on childhood vaccinations?"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 2. Birth Defects",
    "text": "Ex 2. Birth Defects\n\n\nA hypothetical birth defect is present in every 1 in 1,000 children born\nUnless treated, this condition has a 50% fatality rate"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-1",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-1",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 2. Birth Defects",
    "text": "Ex 2. Birth Defects\n\n\n\nShould we test for this hypothetical birth defect?\n\n\n\n\n\n\n\nA hypothetical birth defect is present in every 1 in 1,000 children born.\nUnless treated, this condition has a 50% fatality rate."
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-2",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-2",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 2. Birth Defects",
    "text": "Ex 2. Birth Defects\n\n\n\nShould we test for this hypothetical birth defect?\n\n\n\n\n\n\n\n\nDiagnostic test: Perfectly accurate\nAll newborns in whom the defect is identified can be successfully cured\nBUT the test itself can be lethal:\n\n4 in every 10,000 infants tested will die as a direct and observable result of the testing procedure"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-3",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-3",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 2. Birth Defects",
    "text": "Ex 2. Birth Defects\n\n\n\nObjective: Minimize total expected deaths"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-4",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-4",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 2. Birth Defects",
    "text": "Ex 2. Birth Defects\n\n\n\nObjective: Minimize total expected deaths\n\n\n\n\n\nConsider a population of 100,000 newborns\nTesting produces: (0.0004 x 100,000) = 40 expected deaths\nNo testing produces: (0.001 x 0.5 x 100,000) = 50 expected deaths"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-5",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-5",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 2. Birth Defects",
    "text": "Ex 2. Birth Defects\n\n\n\nObjective: Minimize total expected deaths\n\n\n\n\nConsider a population of 100,000 newborns\nTesting produces: (0.0004 x 100,000) = 40 expected deaths\nNo testing produces: (0.001 x 0.5 x 100,000) = 50 expected deaths\n\nLooks like TESTING WINS!"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-6",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-2.-birth-defects-6",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 2. Birth Defects",
    "text": "Ex 2. Birth Defects\n\n\n\nObjective: Minimize total expected deaths\n\n\n\n\nConsider a population of 100,000 newborns\nTesting produces: (0.0004 x 100,000) = 40 expected deaths\nNo testing produces: (0.001 x 0.5 x 100,000) = 50 expected deaths\n\nLooks like TESTING WINS!\nAnyone got a problem with this??"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#different-lives-are-lost",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#different-lives-are-lost",
    "title": "Introduction to Decision Analysis",
    "section": "Different lives are lost",
    "text": "Different lives are lost\n\n\nWith testing, virtually all 40 deaths occur in infants born without the fatal condition.\nWith no testing, all 50 expected deaths occur from “natural causes” (i.e. unpreventable birth defect)"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#different-lives-are-lost-1",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#different-lives-are-lost-1",
    "title": "Introduction to Decision Analysis",
    "section": "Different lives are lost",
    "text": "Different lives are lost\n\n\n“Innocent deaths” inflicted on children who had “nothing to gain” from testing program\nWe may treat one child’s death as more tolerable than some other’s – even when we have no way, before the fact, of distinguishing one infant from the other."
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 3. Colon Cancer",
    "text": "Ex 3. Colon Cancer\n\n\n3rd leading cause of cancer death.\nMen, women, all races.\nEarly detection aids in prevention & improves health outcomes .\n\\sim80\\% preventable."
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer-prevention",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer-prevention",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 3. Colon Cancer – Prevention",
    "text": "Ex 3. Colon Cancer – Prevention\n\n\nWhen to screen?\nWhich test & how often?\nIf a polyp is found/removed, when to repeat?"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer-prevention-1",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer-prevention-1",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 3. Colon Cancer – Prevention",
    "text": "Ex 3. Colon Cancer – Prevention\n\n\nCost-effectiveness of alternative screening tests?\nAlternative frequencies of screening?\nHow should screening vary by risk groups?"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer---estimating-probabilities",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer---estimating-probabilities",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 3. Colon Cancer - Estimating Probabilities",
    "text": "Ex 3. Colon Cancer - Estimating Probabilities\n\n\nPredict colon cancer risk/incidence\n\nFamily history, past polyps, other factors\nProbability of getting colon cancer\n\nPredict impact from colon cancer\n\nProbability of cure\nProbability of death\nProbability of morbidity"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer---estimating-probabilities-1",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#ex-3.-colon-cancer---estimating-probabilities-1",
    "title": "Introduction to Decision Analysis",
    "section": "Ex 3. Colon Cancer - Estimating Probabilities",
    "text": "Ex 3. Colon Cancer - Estimating Probabilities\n\n\nPredict “benefit” from screening\n\nAll previous probabilities\nProbability of early detection\nProbability of complication from testing\nProbability of false positive\nProbability of false negative\nProbability of positive tests = cancer\nProbability of negative test = no cancer"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#estimating-probabilities-is-fundamental-to-decision-making",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#estimating-probabilities-is-fundamental-to-decision-making",
    "title": "Introduction to Decision Analysis",
    "section": "Estimating probabilities is fundamental to decision making",
    "text": "Estimating probabilities is fundamental to decision making\n\n\nCannot readily obtain needed probabilities\nVarying time periods / lengths\nMethods to estimate probabilities"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#commonality-of-cases",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#commonality-of-cases",
    "title": "Introduction to Decision Analysis",
    "section": "Commonality of cases",
    "text": "Commonality of cases\n\n\nUnavoidable tradeoffs\nDifferent perspectives may lead to different conclusions\nMultiple competing objectives\nComplexity\nUncertainty"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#decision-analysis",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#decision-analysis",
    "title": "Introduction to Decision Analysis",
    "section": "Decision Analysis",
    "text": "Decision Analysis\n\n\n\nAims to inform choice under uncertainty using an explicit, quantitative approach\nAims to identify, measure, & value the consequences of decisions under uncertainty when a decision needs to be made, most appropriately over time."
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#workshop-design",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#workshop-design",
    "title": "Introduction to Decision Analysis",
    "section": "Workshop Design",
    "text": "Workshop Design\n\nWe’re flexible – if there is a topic that is unclear to you, or that you would like expanded upon, please let us know!\nMixed content\n\n\nLectures\nSmall group case studies\nLarge group case studies and “hands-on” Excel exercises"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#workshop-content",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#workshop-content",
    "title": "Introduction to Decision Analysis",
    "section": "Workshop Content",
    "text": "Workshop Content\n\nBasics of decision analysis (Days 1-2)\n\n\nDecision trees\nBayes theorem and treatment thresholds\nUncertainty and prioritizing future research"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#workshop-content-1",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#workshop-content-1",
    "title": "Introduction to Decision Analysis",
    "section": "Workshop Content",
    "text": "Workshop Content\n\nBasics of Cost-Effectiveness Analysis (Days 3-4)\n\n\nValuing cost and health outcomes\nIncremental cost-effectiveness analysis\nIntroduction to Markov Modeling"
  },
  {
    "objectID": "lectures/lec_1a.introduction-to-decision-analysis.html#workshop-content-2",
    "href": "lectures/lec_1a.introduction-to-decision-analysis.html#workshop-content-2",
    "title": "Introduction to Decision Analysis",
    "section": "Workshop Content",
    "text": "Workshop Content\n\nAdvanced Topic Preview (Day 5)\n\n\nSensitivity Analysis\nAdvanced CEA modeling frameworks."
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#learning-objectives",
    "href": "lectures/lec_5a.cea-fundamentals1.html#learning-objectives",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Learning Objectives",
    "text": "Learning Objectives\n\nIdentify theoretical and methodological differences between different economic evaluation techniques\nGrasp the foundations of cost-effectiveness analysis\nDescribe the steps of valuing costs in economic evaluations & identify ways to curate cost parameters"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#outline",
    "href": "lectures/lec_5a.cea-fundamentals1.html#outline",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Outline",
    "text": "Outline\n\n\nIntroduction to economic evaluations\nValuing costs"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#so-far",
    "href": "lectures/lec_5a.cea-fundamentals1.html#so-far",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "So far…",
    "text": "So far…\nWe’ve touched on the basic framework for decision analysis, focusing on: \n\n\n\n\n\n\nDecision trees & probabilities\n\n\n\n\n\n\n\n\n\nBayes theorem & the importance of incorporating information on testing, including the value of this additional information\n\n\n\n\n\n\n\n\n\nTreatment thresholds and constructing decision trees within varying software programs"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#today",
    "href": "lectures/lec_5a.cea-fundamentals1.html#today",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Today…",
    "text": "Today…\n\n\nWe will touch on some of the core concepts for representing costs and health benefits within decision problems"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#economic-evaluation",
    "href": "lectures/lec_5a.cea-fundamentals1.html#economic-evaluation",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Economic Evaluation",
    "text": "Economic Evaluation\n\n\n\nRelevant when decision alternatives have different costs and health consequences.\nWe want to measure the relative value of one strategy in comparison to others.\nThis can help us make resource allocation decisions in the face of constraints (e.g., budget)."
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#features-of-economic-evaluation",
    "href": "lectures/lec_5a.cea-fundamentals1.html#features-of-economic-evaluation",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Features of Economic Evaluation",
    "text": "Features of Economic Evaluation\n\n\n{{&lt; fa check-circle &gt;}} Systematic quantification of costs and consequences.\n\n\n\n{{&lt; fa check-circle &gt;}} Comparative analysis of alternative courses of action.\n\nWe’ll focus on this in the next lecture."
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#techniques-for-economic-evaluation",
    "href": "lectures/lec_5a.cea-fundamentals1.html#techniques-for-economic-evaluation",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Techniques for Economic Evaluation",
    "text": "Techniques for Economic Evaluation\n\n\n\n\n\n\n\n\n\n\nType of study\nMeasurement/valuation of costs\nIdentification of consequences\nMeasurement / valuation of consequences\n\n\n\n\nCost analysis\nMonetary units\nNone\nNone\n\n\n\n\nSource: [@drummond2015a]"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#cost-analysis",
    "href": "lectures/lec_5a.cea-fundamentals1.html#cost-analysis",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Cost analysis",
    "text": "Cost analysis\n\nOnly looks at healthcare costs\nRelevant when alternative options are equally effective (provide equal benefits)\n\nRarely the case in reality!\n\nCosts are valued in monetary terms (e.g., U.S. dollars)\nDecision criterion: often to minimize cost"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#techniques-for-economic-evaluation-1",
    "href": "lectures/lec_5a.cea-fundamentals1.html#techniques-for-economic-evaluation-1",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Techniques for Economic Evaluation",
    "text": "Techniques for Economic Evaluation\n\n\n\n\n\n\n\n\n\n\nType of study\nMeasurement/Valuation of costs both alternative\nIdentification of consequences\nMeasurement / valuation of consequences\n\n\n\n\nCost analysis\nMonetary units\nNone\nNone\n\n\nCost-effectiveness analysis\nMonetary units\nSingle effect of interest, common to both alternatives, but achieved to different degrees.\nNatural units (e.g., life-years gained, disability days saved, points of blood pressure reduction, etc.)\n\n\n\n\nSource: [@drummond2015a]"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#cost-effectiveness-analysis-cea",
    "href": "lectures/lec_5a.cea-fundamentals1.html#cost-effectiveness-analysis-cea",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Cost-Effectiveness Analysis (CEA)",
    "text": "Cost-Effectiveness Analysis (CEA)\n\n\n\nMost useful when decision makers consider multiple options within a budget, and the relevant outcome is common across strategies\n\n\n\n\nCosts are valued in monetary terms ($)\nBenefits are valued in terms of clinical outcomes (e.g., cases prevented or cured, lives saved, years of life gained, quality-adjusted life years gained)\nResults reported as a cost-effectiveness ratio"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#cost-effectiveness-analysis",
    "href": "lectures/lec_5a.cea-fundamentals1.html#cost-effectiveness-analysis",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Cost-Effectiveness Analysis",
    "text": "Cost-Effectiveness Analysis\n\n\nSuppose we are interested in the prolongation of life after an intervention.\nOutcome of interest: life-years gained.\nThe outcome is common to alternative strategies; they differ only in the magnitude of life-years gained.\nWe can report results in terms of $/Life-years gained"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#techniques-for-economic-evaluation-2",
    "href": "lectures/lec_5a.cea-fundamentals1.html#techniques-for-economic-evaluation-2",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Techniques for Economic Evaluation",
    "text": "Techniques for Economic Evaluation\n\n\n\n\n\n\n\n\n\nType of study\nMeasurement/Valuation of costs both alternative\nIdentification of consequences\nMeasurement / valuation of consequences\n\n\n\n\nCost analysis\nMonetary units\nNone\nNone\n\n\nCost-effectiveness analysis\nMonetary units\nSingle effect of interest, common to both alternatives, but achieved to different degrees.\nNatural units (e.g., life-years gained, disability days saved, points of blood pressure reduction, etc.)\n\n\nCost-utility analysis\nMonetary units\nSingle or multiple effects, not necessarily common to both alternatives.\nHealthy years (typically measured as quality-adjusted life-years)\n\n\n\n\nSource: [@drummond2015a]"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#cost-utility-analysis",
    "href": "lectures/lec_5a.cea-fundamentals1.html#cost-utility-analysis",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Cost-Utility Analysis",
    "text": "Cost-Utility Analysis\n\n\nEssentially a variant of cost-effectiveness analysis.\nMajor feature: use of generic measure of health.\nQuality-Adjusted Life Year (QALY): A metric that reflects both changes in life expectancy and quality of life (pain, function, or both).\nBy far the most widely published form of economic evaluation.\n\n\n\n\n\n\n\n\n\nWe will focus mostly on CEA (especially CUA) throughout the workshop"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#techniques-for-economic-evaluation-3",
    "href": "lectures/lec_5a.cea-fundamentals1.html#techniques-for-economic-evaluation-3",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Techniques for Economic Evaluation",
    "text": "Techniques for Economic Evaluation\n\n\n\n\n\n\n\n\n\n\nType of study\nMeasurement/Valuation of costs both alternative\nIdentification of consequences\nMeasurement / valuation of consequences\n\n\n\n\nCost analysis\nMonetary units\nNone\nNone\n\n\nCost-effectiveness analysis\nMonetary units\nSingle effect of interest, common to both alternatives, but achieved to different degrees.\nNatural units (e.g., life-years gained, disability days saved, points of blood pressure reduction, etc.)\n\n\nCost-utility analysis\nMonetary units\nSingle or multiple effects, not necessarily common to both alternatives.\nHealthy years (typically measured as quality-adjusted life-years)\n\n\nCost-benefit analysis\nMonetary units\nSingle or multiple effects, not necessarily common to both alternatives\nMonetary units"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#cost-benefit-analysis",
    "href": "lectures/lec_5a.cea-fundamentals1.html#cost-benefit-analysis",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Cost-Benefit Analysis",
    "text": "Cost-Benefit Analysis\n\nAlso known as Benefit-Cost Analysis\nRelevant for resource allocation between health care and other areas (e.g., education)\nCosts and health consequences are valued in monetary terms (e.g., U.S. dollars)\nValuation of health consequences in monetary terms ($) is obtained by estimating individuals willingness to pay for life saving or health improving interventions.\n\ne.g. US estimate of value per statistical life ~$9 million\n\nCost-benefit criterion: the benefits of a program &gt; its costs\n\nNotice that we’re not making comparisons across strategies–only comparisons of costs and benefits for the same strategy\n\nTo read more: Robinson et al, 2019"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#cost-benefit-analysis-1",
    "href": "lectures/lec_5a.cea-fundamentals1.html#cost-benefit-analysis-1",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Cost-Benefit Analysis",
    "text": "Cost-Benefit Analysis\n\nhttps://pubmed.ncbi.nlm.nih.gov/28183740/"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#cost-benefit-analysis-2",
    "href": "lectures/lec_5a.cea-fundamentals1.html#cost-benefit-analysis-2",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Cost-Benefit Analysis",
    "text": "Cost-Benefit Analysis\n\nhttps://www.cambridge.org/core/product/identifier/S2194588818000271/type/journal_article"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#back-to-cost-effectiveness-analysis",
    "href": "lectures/lec_5a.cea-fundamentals1.html#back-to-cost-effectiveness-analysis",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Back to Cost-Effectiveness Analysis!",
    "text": "Back to Cost-Effectiveness Analysis!\n\n\nRelevant when healthcare alternatives have different costs & health consequences \n\n\n \\frac{\\text{(Cost Intervention A - Cost Intervention B)}}{\\text{(Benefit A - Benefit B)}}\n\n\nRelative VALUE of an intervention in comparison to its alternative is expressed as a cost-effectiveness RATIO (the focus of next lecture!)\n\n\n\nCost-effectiveness analysis is relevant when healthcare alternatives between different services/interventions have DIFFERENT costs AND varying health consequences EXAMPLE: Different types of chemotherapy\nA KEY OUTCOME in cost-effectiveness analyses is what’s called the ICER [or incremental cost-effectiveness ratio], which gives us the relative VALUE of an intervention compared to an alternative.\nIn other words, THE PRICE PER UNIT BENEFIT of one intervention over the other\nWe have 2 full classes on ICERs in the coming weeks & how to interpret these ratios across interventions What we will focus on TODAY is the components that make up the numerator (i.e. COSTS) & the denominator (i.e. BENEFITS)\nWHAT’S IMPORTANT HERE - By estimating the magnitude of health outcomes and costs of interventions, cost-effectiveness analyses can show the trade-offs involved across interventions AND THEREFORE, hopefully contribute to better decision making"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#who-uses-economic-evaluations",
    "href": "lectures/lec_5a.cea-fundamentals1.html#who-uses-economic-evaluations",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Who uses economic evaluations?",
    "text": "Who uses economic evaluations?\n\n\nHealth Technology Advisory Committees\n\nNICE (The National Institute for Health and Care Excellence, UK)\nCanada’s Drug and Health Technology Agency\nPBAC (Pharmaceutical Benefits Advisory Committee in Australia)\nBrazil’s health technology assessment institute\n\nGroups developing clinical guidelines\n\nWHO\nCDC\nDisease-specific organizations: American Cancer Society; American Heart Association; European Stroke Organisation\n\nRegulatory agencies:\n\nFDA (U.S. Food and Drug Administration)\nEPA (U.S. Environmental Protection Agency)\n\n\n\n\nWhen we look at how cost-effectiveness is used around the world –\nUnlike the US, many country governments have their own institutional bodies that conduct formal assessments on the cost-effectiveness of drugs & devices – some of which include:\n\nThe UK - which is a single-payer system known as the NHS & has an independent body called NICE that evaluates the cost-effectiveness of health strategies for the NHS – NICE recommends to the NHS what they should cover based on VALUE (i.e. cost-effectiveness).\n\n\n& the NHS is legally obligated to fund medicines/treatments recommended by NICE\n\n\nCanada also has a health technology assessment body called the Canadian Agency for Drugs and Technologies in Health (CADTH), which works in a similar way as NICE\n& likewise, Australia as well as Brazil, Germany, France, Italy, Sweden, the Netherlands, etc. all have similar government institutions\nGroups developing clinical guidelines around CEA, includes…"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#identifying-alternatives",
    "href": "lectures/lec_5a.cea-fundamentals1.html#identifying-alternatives",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Identifying Alternatives",
    "text": "Identifying Alternatives\n\n\nDecision modeling / economic evaluation requires identifying strategies or alternative courses of action.\nThese alternatives could include different therapies / policies / technologies.\nOr, our alternatives could capture different combinations or sequences of treatment (e.g., what dose? what age to start?)\n\n\n\n\n\n\n\n\n\nOnce we have identified the alternatives, we’ll want to quantify their associated consequences in terms of:\n\nHealth outcomes\nCosts"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#cea-components",
    "href": "lectures/lec_5a.cea-fundamentals1.html#cea-components",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "CEA components",
    "text": "CEA components\n\n \\frac{\\text{(Cost Intervention A - Cost Intervention B)}}{\\text{(Benefit A - Benefit B)}}\n\n\nWe will now get into the components of cost-effectiveness analyses by first looking at what comprises the NUMERATOR of the cost-effectiveness ratio & then delving into the DENOMINATOR"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#valuing-costs-steps",
    "href": "lectures/lec_5a.cea-fundamentals1.html#valuing-costs-steps",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Valuing Costs: Steps",
    "text": "Valuing Costs: Steps\nSource: Gold 1996, Drummond 2015, Gray 2012) \n\nIdentify – Estimate the different categories of resources likely to be required (e.g., surgical staff, medical equipment, surgical complications, re-admissions)  \nMeasure – Estimate how much of each resource category is required (e.g. type of staff performing the surgery and time involved, post-surgery length of stay, re-admission rates)  \nValue – Apply unit costs to each resource category (e.g., salary scales from the relevant hospital or national wage rates for staff inputs, cost per inpatient day for the post-surgery hospital stay)"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#we-can-identify-different-types-of-healthcare-costs",
    "href": "lectures/lec_5a.cea-fundamentals1.html#we-can-identify-different-types-of-healthcare-costs",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "We can identify different types of healthcare costs",
    "text": "We can identify different types of healthcare costs\n\n\n\nDirect Health Care Costs\n\nHospital, office, home, facilities\nMedications, procedures, tests, professional fees\n\nDirect Non-Health Care Costs\n\nChildcare, transportation costs\n\nTime Costs\n\nPatient time receiving care, opportunity cost of time\n\nProductivity costs (‘indirect costs’)\n\nimpaired ability to work due to morbidity?\nlost economic productivity due to death?\n\nUnrelated healthcare costs\n\nCumulative trajectory of total healthcare costs over time (unrelated to medical interventions)"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#identifying-costs-continued",
    "href": "lectures/lec_5a.cea-fundamentals1.html#identifying-costs-continued",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Identifying costs (continued)",
    "text": "Identifying costs (continued)\n\n\nIn practice, we count what is likely to matter\n\nExclude what is likely to have little effect or equal effects across alternatives\n\nAny exclusion must be noted & possible bias examined\nWe are constrained by what data are available"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#we-can-measure-costs-using-different-approaches",
    "href": "lectures/lec_5a.cea-fundamentals1.html#we-can-measure-costs-using-different-approaches",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "We can measure costs using different approaches",
    "text": "We can measure costs using different approaches\n\n\nMicro-costing (bottom-up)\n\nMeasure all resources used by individual patients, then assign the unit cost for each type of resource consumed to calculate the total cost\n\nGross-costing (top-down)\n\nEstimate cost for a given volume of patients by dividing the total cost by the volume of service use\nExample: Downstream costs (e.g., hospitalization due to opioid overdose)\n\nIngredients-based approach (P x Q x C)\n\nProbability of occurrence (P)\nQuantity (Q)\nUnit costs (C)\n\n\n\n\n\nMicro-costing: most precise (which is a bottom up approach where we measure, for instance, all the lab tests, hospital bed, provider time, imaging tests, equipment used, etc.)\nGross-costing: Usually what we have to quantify “downstream costs” – but we can also use this approach for costing out an intervention if we don’t have the data for the micro-costing approach.\n\n\nFor example, if we know that 10 total knee replacements cost us $300,000 last month, that’s $30,000 per procedure.\n\n\nIngredients approach: Suppose we know that 10% of surgeries are complicated, and complicated surgeries require 50% more surgeon time, and surgeon time costs what $500/hr"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#whose-perspective",
    "href": "lectures/lec_5a.cea-fundamentals1.html#whose-perspective",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Whose perspective?",
    "text": "Whose perspective?\n\nSanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316:1093–1103."
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#whose-perspective-1",
    "href": "lectures/lec_5a.cea-fundamentals1.html#whose-perspective-1",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Whose perspective?",
    "text": "Whose perspective?\n\n\nPERSPECTIVE MATTERS –  \n\nFormal Healthcare Sector: Medical costs borne by third-party payers & paid for out-of-pocket by patients. Should include current + future costs, related & unrelated to the condition under consideration\n\n\nSocietal perspective: Represents the wider “public interest” & inter-sectoral distribution of resources that are important to consider - reflects costs on all affected parties\n\n\n\n\nPERSPECTIVE really matters when you’re deciding what costs to include in your analysis; we typically conduct CEAs from two different perspectives:\n\n\n\nThe formal healthcare sector perspective includes medical costs borne by third-party payers & paid for out-of-pocket by patients. Modelers should include current + future costs, related & unrelated to the condition under consideration.\n\n\nAnalysts have mostly used this perspective over the last 20 years\nIt is the most useful perspective to decision makers within the healthcare sector\nAs mentioned earlier NICE in the UK usually takes the perspective of the healthcare payer, whereas ICER tries to do analysis from both a formal healthcare sector & wider societal perspective\n\n\nSocietal perspective includes everything in the formal health sector PLUS other things like time costs of patients seeking and receiving care, time costs of informal (unpaid) caregivers, transportation costs, effects on future productivity and consumption, and other costs and effects outside the healthcare sector.\n\n\n\nThe second panel on cost-effectiveness in health & medicine (the “gold standard” CEA recommendations in the US) recommends that studies be conducted from BOTH healthcare sector + societal perspectives so then we can more fully understand the wider implications of decision making."
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#whose-perspective-2",
    "href": "lectures/lec_5a.cea-fundamentals1.html#whose-perspective-2",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Whose perspective?",
    "text": "Whose perspective?\n\nHealthcare sector perspective\n\nMAMMOGRAPHY (Healthcare Sector): \n\nCosts associated with the screening itself [mammogram procedure + physician time]\nCosts of follow-up tests for both false-positive & true positive results\nDownstream costs (or savings) associated with cases of breast cancer, such as: Hospitalization + treatment costs\nCosts unrelated to medical intervention/disease; of living longer due to mammography\n\n\n\nLet’s look at an example - Mammography for breast cancer screening\nIf we were going to cost this out from a Healthcare Sector perspective, we would need to account for:\n\n\nCosts associated with the screening itself – accounting for the costs of the procedure + clinician time\nCosts of follow-up tests for both false-positive & true positive results\nDownstream costs (or savings) associated with cases of breast cancer, including hospitalizations & treatment costs\n\n***EXAMPLE: Let’s say that we wanted to examine the difference between routine mammography screening at age 40 versus 50 – - There will be higher upfront costs for Age 40, BUT if we catch more cases of breast cancer than if we waited, then that could potentially save a lot of treatment/hospitalization costs down the line\nLISA, BOOK says AVERTED COSTS for downstream costs\n\nCosts unrelated to the medical intervention due to living longer (we will discuss in the next few slides)"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#whose-perspective-3",
    "href": "lectures/lec_5a.cea-fundamentals1.html#whose-perspective-3",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Whose perspective?",
    "text": "Whose perspective?\n\nSocietal perspective\n\nMAMMOGRAPHY (Societal perspective): \n\nCosts associated with the screening itself [mammogram procedure + physician time]\nCosts of follow-up tests for both false-positive & true positive results\nDownstream costs (or savings) associated with cases of breast cancer, such as: Hospitalization + treatment costs\nCosts unrelated to medical intervention/disease; of living longer due to mammography\nPatient productivity losses associated with the screening or cancer treatment\nChildcare/transportation costs"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#two-approaches",
    "href": "lectures/lec_5a.cea-fundamentals1.html#two-approaches",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Two approaches:",
    "text": "Two approaches:\n (1) Alongside clinical trials  (2) Using secondary data"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-secondary-data",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-secondary-data",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (secondary data)",
    "text": "Costs (secondary data)\n\n\nInternational versus US will have different approaches"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-international",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-international",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (International)",
    "text": "Costs (International)\n\n\nIn country/hospital/donor data registries - key is to get as close to the “true” cost associated with each procedure per patient\n\nE.g., “TB healthcare & diagnostics are from official price list of the National Health Laboratory Service in South Africa; Costs for follow-up reflect local clinic and culture-based screening for active-tuberculosis”\n\nReview of published literature\nTufts CEA Registry\nDCP3: Disease Control Priorities"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-published-literature",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-published-literature",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (Published Literature)",
    "text": "Costs (Published Literature)"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-published-literature-1",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-published-literature-1",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (Published Literature)",
    "text": "Costs (Published Literature)"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (Tufts CEVR)",
    "text": "Costs (Tufts CEVR)\n\nhttps://cevr.tuftsmedicalcenter.org/databases/cea-registry"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr-1",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr-1",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (Tufts CEVR)",
    "text": "Costs (Tufts CEVR)"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr-2",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr-2",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (Tufts CEVR)",
    "text": "Costs (Tufts CEVR)"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr-3",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr-3",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (Tufts CEVR)",
    "text": "Costs (Tufts CEVR)\n\nhttp://ghcearegistry.org/ghcearegistry/"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr-4",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-tufts-cevr-4",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (Tufts CEVR)",
    "text": "Costs (Tufts CEVR)"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#costs-dcp3",
    "href": "lectures/lec_5a.cea-fundamentals1.html#costs-dcp3",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Costs (DCP3)",
    "text": "Costs (DCP3)\n\n\n\nThe Disease Control Priorities is a multi-year project funded in 2010 by the Bill & Melinda Gates Foundation.\nFrom 2010 – 2017, it was led by the University of Washington, which worked with local organizations to promote and support the use of economic evaluation (CEAs) for priority setting at both global and national levels\nThe DCP3 is now hosted at the London School of Hygiene and Tropical Medicine (LSHTM). It is currently collaborating with a number of pilot countries in the area of priority setting, development and implementation of UHC Essential Packages of Health Services."
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#adjustments-needed-for-valuing-costs",
    "href": "lectures/lec_5a.cea-fundamentals1.html#adjustments-needed-for-valuing-costs",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Adjustments needed for Valuing Costs",
    "text": "Adjustments needed for Valuing Costs\n\n\nAdjusting for currency and currency year\nDiscounting"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#inflation-adjustment-motivation",
    "href": "lectures/lec_5a.cea-fundamentals1.html#inflation-adjustment-motivation",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Inflation Adjustment: Motivation",
    "text": "Inflation Adjustment: Motivation\n\n\n$100 in 2000 is not equivalent to $100 in 2020\n\n$100 could buy a lot more in 2000!\n\nImportant to adjust for the price difference over time, especially when working with cost sources from multiple years"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#inflation-adjustment-example",
    "href": "lectures/lec_5a.cea-fundamentals1.html#inflation-adjustment-example",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Inflation Adjustment: Example",
    "text": "Inflation Adjustment: Example"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#inflation-adjustment-method",
    "href": "lectures/lec_5a.cea-fundamentals1.html#inflation-adjustment-method",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Inflation Adjustment: Method",
    "text": "Inflation Adjustment: Method\n\nChoose a reference year (usually the current year of analysis)\nConvert all costs to the reference year\n\n\nConverting cost in Year X to Year Y (reference year):\n\n    \\textbf{Cost(Year Y)} = \\textbf{Cost(Year X)} \\times \\frac{\\textbf{Price index(Year Y)}}{\\textbf{Price index(Year X)}}"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#inflation-adjustment-example-1",
    "href": "lectures/lec_5a.cea-fundamentals1.html#inflation-adjustment-example-1",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Inflation Adjustment: Example",
    "text": "Inflation Adjustment: Example\n\n\nCost of hospitalization for mild stroke in the US was ~15,000 USD in 2016. What if we want to convert this number to 2020 USD?\n\n\nPCE (Personal Consumption Expenditure Health Price Index) in 2016: 105.430 (second column of Table 3 (PCE, health)\nPCE in 2020: 112.978\n\n\n\n\\textbf{Cost(2020)} = \\textbf{Cost(2016)} \\times \\frac{\\textbf{PCE(2020)}}{\\textbf{PCE(2016)}} \\\\\n= 15,000 \\times \\frac{112.978}{105.430} \\\\\n= 16,674 \\ (\\text{2020 USD})"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#currency-conversion-1",
    "href": "lectures/lec_5a.cea-fundamentals1.html#currency-conversion-1",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Currency Conversion",
    "text": "Currency Conversion\n\n\nIsn’t required for CEA but may be useful in some situations:\n\nExample: may need to convert local currency to USD because cost-effectiveness thresholds are often estimated in the unit of USD per DALY.\n\nHow do we convert 1,000 Nairas to USD?\nCurrent exchange rate in 2023: 1 Naira = ~0.0013 USD\n1,000 Nairas = 1.3 USD"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#why-discounting",
    "href": "lectures/lec_5a.cea-fundamentals1.html#why-discounting",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Why discounting?",
    "text": "Why discounting?\n\nAdjust costs at social discount rate to reflect social “rate of time preference”\n\nPure time preference (“inpatience”)\nPotential catastrophic risk in the future\nEconomic growth/return"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#discounting-1",
    "href": "lectures/lec_5a.cea-fundamentals1.html#discounting-1",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Discounting",
    "text": "Discounting\n\n\n\n\nIf you have $100 now, this could either be consumed or invested in the most profitable alternative (e.g., risk free government bond)\nLet’s say the net return on the bond is 2%, then this means that next year the current $100 has grown to $102\nThe “present value” of $102 next year is $100 today\nSimilarly, $100 next year = $98.04 today"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#discounting-2",
    "href": "lectures/lec_5a.cea-fundamentals1.html#discounting-2",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Discounting",
    "text": "Discounting\n\n\n\n\nInflation: We convert PAST cost to present-day values\n\n\n\n\n\n\nDiscounting: We convert FUTURE costs to present-day values"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#how-do-we-discount",
    "href": "lectures/lec_5a.cea-fundamentals1.html#how-do-we-discount",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "How do we discount?",
    "text": "How do we discount?\n\n\nPresent value: PV = FV/(1+r)^t\n\nFV = future value, the nominal cost incurred in the future\nr = annual discount rate (analogous to interest rate)\nt = number of years in future when cost is incurred\n\nReasonable consensus around 3% per year\nMay vary according to country guidelines\n\n\n\n\n\n\n\n\nAdjust for inflation and currency first, then discount"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#intuition",
    "href": "lectures/lec_5a.cea-fundamentals1.html#intuition",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Intuition",
    "text": "Intuition\n\n\nr = 0.03\nRecall that PV = FV/(1+r)^t, and we’re at Year 0:\n\n$1 in Year 0 is valued as 1/1.03^0 = \\$ 1\n$1 in Year 1 is valued as 1/1.03^1 = \\$0.97\n$1 in Year 2 is valued as 1/1.03^2 = \\$0.94\n$1 in Year 3 is valued as 1/1.03^3 = \\$0.92\n…\nIn other words, we are converting what a $1 would be in Year 2, for example, to the PRESENT VALUE of today. Today, it will be 0.94.\n\n\n\n\n\nWe generally value future costs and effects less than current costs and effects AND their value diminishes the more distant into the future they occur\nBecause we can invest in a dollar today to yield a higher return on investment later"
  },
  {
    "objectID": "lectures/lec_5a.cea-fundamentals1.html#example",
    "href": "lectures/lec_5a.cea-fundamentals1.html#example",
    "title": "CEA Fundamentals: Valuing Costs",
    "section": "Example",
    "text": "Example\n\n\nAssume in year 5, a patient develops disease, and there is a treatment cost of $500\n\nThis is the future value (FV) of the cost!\n\nPresent value PV = PV = FV/(1+r)^t = 500/(1+0.03)^5 = \\$ 431.3"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "Instructores",
    "section": "",
    "text": "John Graves (Vanderbilt University)\n\n\n\n\n\nJohn A. Graves, Ph.D. es catedrático de Política Sanitaria y Medicina en la Facultad de Medicina de la Universidad de Vanderbilt, y catedrático de Gestión en la Vanderbilt Owen Graduate School of Management de Nashville (Tennessee, EE.UU.). Dirige el Centro de Modelización Económica Sanitaria del Centro Médico de la Universidad de Vanderbilt y es miembro del profesorado del Instituto Vanderbilt de Salud Global (VIGH) y del Centro Oncológico Vanderbilt Ingram.\nEl Dr. Graves tiene más de veinte años de experiencia en la intersección de la investigación y la formulación de políticas, habiendo contribuido a los esfuerzos de modelado de políticas que informaron el diseño y la ejecución de la legislación de la reforma sanitaria de Massachusetts de 2006 y la Ley de Asistencia Asequible de 2010, para la que se desempeñó como modelador principal de la Oficina de Reforma Sanitaria de la Casa Blanca. Desde que se incorporó a la facultad de Vanderbilt en 2011, el Dr. Graves ha dirigido grandes proyectos de investigación centrados en el diseño de seguros de salud, los rendimientos del gasto y la calidad de la atención sanitaria, y la rentabilidad de las pruebas genéticas en diversas poblaciones del sistema sanitario.\nEl Dr. Graves imparte cursos de econometría, estadística y política sanitaria a estudiantes de máster y doctorado de toda la Universidad de Vanderbilt, y es director del curso de contenidos de política y economía sanitaria para estudiantes de medicina de la Facultad de Medicina de Vanderbilt. También codirige el Health Care Valuation Lab, un novedoso curso de colaboración entre la Owen Graduate School of Management, la Facultad de Medicina de Vanderbilt y la iniciativa [Project Healthcare] del Nashville Entrepreneur Center (https://www.ec.co/programs/project-healthcare/). Antes de incorporarse a Vanderbilt, impartió clases en el Máster de Administración Pública en Desarrollo Internacional de la Harvard Kennedy School, y está afiliado al Abdul Latif Jameel Poverty Action Lab del MIT.\nEl Dr. Graves es Doctor en Política Sanitaria por la Universidad de Harvard y licenciado en Economía y Literatura Inglesa por la Universidad del Sur en Sewanee, Tennessee. Es miembro electo de la Academia Nacional de Seguros Sociales, y su trabajo ha sido reconocido con becas y premios del Instituto Nacional de Gestión Sanitaria, la Oficina Nacional de Investigación Económica y la Asociación Estadística Americana."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Taller de análisis de decisiones",
    "section": "",
    "text": "Calendario de talleres\n\n\n\n\n\n\n\n\n\nFecha\nHora programada\nTema\nNotas\n\n\n\n\nMartes\n9:00 - 9:45 am\nBienvenida y presentaciones\n\n\n\n\n9:45 - 10:00\nIntroducción al análisis de decisiones\n\n\n\n\n10:00-11:00\nÁrboles de decisión y probabilidades\n\n\n\n\n11:00-11:15\nPausa\n\n\n\n\n11:15 - 11:00\nCaso práctico: Probabilidades y árboles de decisión\n\n\n\n\n1:00 - 2:00 pm\nPausa\n\n\n\n\n1:45 - 3:15 pm\nCCaso práctico: Construir un árbol de decisión en Excel\n\n\n\n\n3:15 - 4:00 pm\nRevisión de casos prácticos / Debate en grupo: Árboles de decisión; Instalar Amua\n\n\n\nMiércoles\n9:00-9:15\nResumen diario\n\n\n\n\n9:15 - 10:30\nFundamentos CEA 1: Costes\n\n\n\n\n10:30 - 10:45\nPausa\n\n\n\n\n10:45 - 12:00\nFundamentos CEA 2: Resultados sanitarios\n\n\n\n\n12:00 - 1:30\nFundamentos del ACE 3: Análisis coste-eficacia incremental\n\n\n\n\n1:30 - 2:30\nAlmuerzo\n\n\n\n\n2:30 - 4:30\nEstudio de caso: Análisis coste-eficacia incremental\n\n\n\nJueves\n9:00 - 1:00\nModelos de Markov\n\n\n\n\n1:00 - 2:00\nAlmuerzo\n\n\n\n\n2:00 - 2:45\nAnálisis determinista y de escenarios\n\n\n\n\n2:45-4:00\nTécnicas avanzadas de modelización\n\n\n\nViernes\n\n\n\n\n\n\n9:00- 11:00\nCaso práctico: Modelos de Markov\n\n\n\n\n11:00 - 11:45\nEstudio de caso en grupo: Resultados y CEA incremental\n\n\n\n\n11:45 - 12:00\nCeremonia de entrega de certificados"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#learning-objectives",
    "href": "lectures/lec_7.MarkovModels1.html#learning-objectives",
    "title": "Markov Models",
    "section": "Learning Objectives",
    "text": "Learning Objectives\n\n\nDiscuss pros and cons of decision modeling using decision trees vs. a formal deterministic model\nUnderstand the components and structure of discrete time Markov models\nCalculate Markov cycles by hand, using Markov bubble diagram\nApply methods for Markov cycle correction"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a-simple-disease-process",
    "href": "lectures/lec_7.MarkovModels1.html#a-simple-disease-process",
    "title": "Markov Models",
    "section": "A Simple Disease Process",
    "text": "A Simple Disease Process\n\n\nSuppose we want to model the cost-effectiveness of alternative strategies to prevent a disease from occurring.\nWe start with a healthy population of 25 year olds and there are three health states people can experience:\n\nRemain Healthy\nBecome Sick\nDeath"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a-simple-disease-process-1",
    "href": "lectures/lec_7.MarkovModels1.html#a-simple-disease-process-1",
    "title": "Markov Models",
    "section": "A Simple Disease Process",
    "text": "A Simple Disease Process\n\n\nRemaining healthy carries no utility decrement (utility weight = 1.0 per cycle in healthy state)\nBecoming sick carries a 0.25 utility decrement for the remainder of the person’s life (utility weight = 0.75)\nDeath carries a utility value of 0."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a-simple-disease-process-2",
    "href": "lectures/lec_7.MarkovModels1.html#a-simple-disease-process-2",
    "title": "Markov Models",
    "section": "A Simple Disease Process",
    "text": "A Simple Disease Process\n\n\nThere is no cost associated with remaining healthy.\nBecoming sick incurs $1,000 / year in costs.\nBecoming sick increases the risk of death by 300%."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a-simple-disease-process-3",
    "href": "lectures/lec_7.MarkovModels1.html#a-simple-disease-process-3",
    "title": "Markov Models",
    "section": "A Simple Disease Process",
    "text": "A Simple Disease Process\nA country’s health institute is considering five preventive care strategies that reduce the risk of becoming sick:\n\n\n\n\n\n\n\n\nStrategy\nDescription\nCost\n\n\n\n\nA\nStandard of Care\n$25/year\n\n\nB\nAdditional 4% reduction in risk of becoming sick\n$1,000/year\n\n\nC\n12% reduction in risk\n$3,100/year\n\n\nD\n8% reduction in risk\n$1,550/year\n\n\nE\n8% reduction in risk\n$5,000/year"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#model-option-1-decision-tree",
    "href": "lectures/lec_7.MarkovModels1.html#model-option-1-decision-tree",
    "title": "Markov Models",
    "section": "Model Option 1: Decision Tree",
    "text": "Model Option 1: Decision Tree\n\nOne option would be to use a decision tree to model the expected utility and costs associated with each strategy.\nModel time horizon: 10 years\nThe next slide shows the decision tree for outcomes experienced in the first year."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#model-option-1-decision-tree-1",
    "href": "lectures/lec_7.MarkovModels1.html#model-option-1-decision-tree-1",
    "title": "Markov Models",
    "section": "Model Option 1: Decision Tree",
    "text": "Model Option 1: Decision Tree\n\nWhat limitations do you see?"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-1",
    "href": "lectures/lec_7.MarkovModels1.html#section-1",
    "title": "Markov Models",
    "section": "",
    "text": "Decision tree for two full cycles."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-2",
    "href": "lectures/lec_7.MarkovModels1.html#section-2",
    "title": "Markov Models",
    "section": "",
    "text": "Strategy A decision tree for 5 cycles."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#decision-trees",
    "href": "lectures/lec_7.MarkovModels1.html#decision-trees",
    "title": "Markov Models",
    "section": "Decision Trees",
    "text": "Decision Trees\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nSimple, rapid & can provide insights"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#decision-trees-1",
    "href": "lectures/lec_7.MarkovModels1.html#decision-trees-1",
    "title": "Markov Models",
    "section": "Decision Trees",
    "text": "Decision Trees\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nSimple, rapid & can provide insights\n\n\n\nEasy to describe & understand"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#decision-trees-2",
    "href": "lectures/lec_7.MarkovModels1.html#decision-trees-2",
    "title": "Markov Models",
    "section": "Decision Trees",
    "text": "Decision Trees\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nSimple, rapid & can provide insights\n\n\n\nEasy to describe & understand\n\n\n\nWorks well with limited time horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#decision-trees-3",
    "href": "lectures/lec_7.MarkovModels1.html#decision-trees-3",
    "title": "Markov Models",
    "section": "Decision Trees",
    "text": "Decision Trees\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nSimple, rapid & can provide insights\nDifficult to include clinical detail\n\n\nEasy to describe & understand\n\n\n\nWorks well with limited time horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#decision-trees-4",
    "href": "lectures/lec_7.MarkovModels1.html#decision-trees-4",
    "title": "Markov Models",
    "section": "Decision Trees",
    "text": "Decision Trees\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nSimple, rapid & can provide insights\nDifficult to include clinical detail\n\n\nEasy to describe & understand\nElapse of time is not readily evident.\n\n\nWorks well with limited time horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#decision-trees-5",
    "href": "lectures/lec_7.MarkovModels1.html#decision-trees-5",
    "title": "Markov Models",
    "section": "Decision Trees",
    "text": "Decision Trees\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nSimple, rapid & can provide insights\nDifficult to include clinical detail\n\n\nEasy to describe & understand\nElapse of time is not readily evident.\n\n\nWorks well with limited time horizon\nDifficult to model longer (&gt;1 cycle) time horizons"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#decision-trees-6",
    "href": "lectures/lec_7.MarkovModels1.html#decision-trees-6",
    "title": "Markov Models",
    "section": "Decision Trees",
    "text": "Decision Trees"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#next-steps",
    "href": "lectures/lec_7.MarkovModels1.html#next-steps",
    "title": "Markov Models",
    "section": "Next Steps",
    "text": "Next Steps\n\nIdeally we want a modeling approach that can incorporate flexibility and handle the complexities that make decision trees difficult/unwieldy."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-models-1",
    "href": "lectures/lec_7.MarkovModels1.html#markov-models-1",
    "title": "Markov Models",
    "section": "Markov Models",
    "text": "Markov Models\nCommon approach in decision analyses that adds additional flexibility.\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nCan model repeated events\n\n\n\n\\quad \\quad \\quad \\quad \\quad \\quad"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-models-2",
    "href": "lectures/lec_7.MarkovModels1.html#markov-models-2",
    "title": "Markov Models",
    "section": "Markov Models",
    "text": "Markov Models\nCommon approach in decision analyses that adds additional flexibility.\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nCan model repeated events\n\n\n\nCan model more complex + longitudinal clinical events"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-models-3",
    "href": "lectures/lec_7.MarkovModels1.html#markov-models-3",
    "title": "Markov Models",
    "section": "Markov Models",
    "text": "Markov Models\nCommon approach in decision analyses that adds additional flexibility.\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nCan model repeated events\n\n\n\nCan model more complex + longitudinal clinical events\n\n\n\nNot computationally intensive; efficient to model and debug"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-models-4",
    "href": "lectures/lec_7.MarkovModels1.html#markov-models-4",
    "title": "Markov Models",
    "section": "Markov Models",
    "text": "Markov Models\n\n\nThe advantages of Markov models derive from their structure around mutually exclusive disease states.\nThese disease states represent the possible states or consequences of strategies or options under consideration.\nBecause there are a fixed number of disease states the population can be in, there is no need to model complex pathways, as we saw in the decision tree “explosion” a few slides back."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-trees",
    "href": "lectures/lec_7.MarkovModels1.html#markov-trees",
    "title": "Markov Models",
    "section": "Markov Trees",
    "text": "Markov Trees\nIt is also common to pair a Markov model with a decision tree.1\n\n\n\n\n\n\n\n\n\n\n\nGasauskas et al. 2022"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-trees-1",
    "href": "lectures/lec_7.MarkovModels1.html#markov-trees-1",
    "title": "Markov Models",
    "section": "Markov Trees",
    "text": "Markov Trees\nIt is also common to pair a Markov model with a decision tree.1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nGasauskas et al. 2022"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-tree",
    "href": "lectures/lec_7.MarkovModels1.html#markov-tree",
    "title": "Markov Models",
    "section": "Markov Tree",
    "text": "Markov Tree\nA simple decision tree is implicit in nearly every decision analysis."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-tree-example",
    "href": "lectures/lec_7.MarkovModels1.html#markov-tree-example",
    "title": "Markov Models",
    "section": "Markov Tree: Example",
    "text": "Markov Tree: Example\n\n\n\n\n\n\n\n\nTreatment A:"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-tree-example-1",
    "href": "lectures/lec_7.MarkovModels1.html#markov-tree-example-1",
    "title": "Markov Models",
    "section": "Markov Tree: Example",
    "text": "Markov Tree: Example\n\n\n\n\n\n\n\n\nTreatment A:"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#when-choosing-a-model-structure",
    "href": "lectures/lec_7.MarkovModels1.html#when-choosing-a-model-structure",
    "title": "Markov Models",
    "section": "When choosing a model structure…",
    "text": "When choosing a model structure…\n\n\n“Things should be made as simple as possible, but not simpler” - Albert Einstein\n\n\n\nWhen choosing a model structure, you want to choose one that best fits your research question & one that adequately represents the clinical background/problem – zeroing in on what’s most important\nYou always want to first build the structure completely independently & data free AND then see how hard it is to get data + calibrate\nYou never want to model based on the data* nor do you ever want to make something complicated just to make it complicated**\nJust because a model is “super complicated/complex” doesn’t mean it’s more publishable or better than something that’s more simplistic"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#key-characteristics",
    "href": "lectures/lec_7.MarkovModels1.html#key-characteristics",
    "title": "Markov Models",
    "section": "Key characteristics",
    "text": "Key characteristics\n\n\nAllows for health state transitions over time\nIndividuals can only exist in one state at a time (mutually exclusive health states)\nAt the beginning or end of each cycle, patients transition across health states via transition probabilities & individuals stay in health state for entire cycle length\nProbability of transitioning depends on the current state (“no memory”); (tunnel states can account for this potential limitation)\nTransition probabilities remain constant over time (apart from embedded lifetables)\nResults report “average” of cohort"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#key-characteristics-1",
    "href": "lectures/lec_7.MarkovModels1.html#key-characteristics-1",
    "title": "Markov Models",
    "section": "Key characteristics",
    "text": "Key characteristics\n\n\n“CYCLE” = Minimum amount of time that any individual will spend in a state before possible transition to another state\n\n\nMore on this in the next slides"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#steps",
    "href": "lectures/lec_7.MarkovModels1.html#steps",
    "title": "Markov Models",
    "section": "Steps",
    "text": "Steps\n\nDefine the decision problem\nConceptualize the model\nParameterize the model\nCalculate or define the transition probability matrix\nRun the model"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#step-1-define-the-decision-problem",
    "href": "lectures/lec_7.MarkovModels1.html#step-1-define-the-decision-problem",
    "title": "Markov Models",
    "section": "Step 1: Define the Decision Problem",
    "text": "Step 1: Define the Decision Problem\nWe defined the decision problem earlier in this lecture, so we’ll repeat the basic objectives briefly here."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#step-1-define-the-decision-problem-1",
    "href": "lectures/lec_7.MarkovModels1.html#step-1-define-the-decision-problem-1",
    "title": "Markov Models",
    "section": "Step 1: Define the Decision Problem",
    "text": "Step 1: Define the Decision Problem\nGoal: model the cost-effectiveness of alternative strategies to prevent a disease from occurring.\n\n\n\n\n\n\n\n\nStrategy\nDescription\nCost\n\n\n\n\nA\nStandard of Care\n$25/year\n\n\nB\nAdditional 4% reduction in risk of becoming sick\n$1,000/year\n\n\nC\n12% reduction in risk\n$3,100/year\n\n\nD\n8% reduction in risk\n$1,550/year\n\n\nE\n8% reduction in risk\n$5,000/year"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#step-1-define-the-decision-problem-2",
    "href": "lectures/lec_7.MarkovModels1.html#step-1-define-the-decision-problem-2",
    "title": "Markov Models",
    "section": "Step 1: Define the Decision Problem",
    "text": "Step 1: Define the Decision Problem"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#conceptualize-the-markov-model-1",
    "href": "lectures/lec_7.MarkovModels1.html#conceptualize-the-markov-model-1",
    "title": "Markov Models",
    "section": "2. Conceptualize the Markov Model",
    "text": "2. Conceptualize the Markov Model\nTwo major steps:\n{{&lt; fa check-circle &gt;}} 2a. Determine health states\n{{&lt; fa check-circle &gt;}} 2b. Determine transitions"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#step-2-conceptualize-the-model",
    "href": "lectures/lec_7.MarkovModels1.html#step-2-conceptualize-the-model",
    "title": "Markov Models",
    "section": "Step 2: Conceptualize the Model",
    "text": "Step 2: Conceptualize the Model\n{{&lt; fa check-circle &gt;}} 2a. Determine health states\n\n\nThere are three health states people can experience:\n\nRemain Healthy\nBecome Sick\nDeath"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#step-2-conceptualize-the-model-1",
    "href": "lectures/lec_7.MarkovModels1.html#step-2-conceptualize-the-model-1",
    "title": "Markov Models",
    "section": "Step 2: Conceptualize the Model",
    "text": "Step 2: Conceptualize the Model\n{{&lt; fa check-circle &gt;}} 2a. Determine health states\n\n\nThere three health states people can experience:\n\nRemain Healthy\nBecome Sick\nDeath\n\n\n\n{{&lt; fa check-circle &gt;}} 2b. Determine transitions\n\n\nIndividuals who become sick cannot transition back to healthy."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#bubble-diagram",
    "href": "lectures/lec_7.MarkovModels1.html#bubble-diagram",
    "title": "Markov Models",
    "section": "“Bubble Diagram”",
    "text": "“Bubble Diagram”\nState transition (“bubble”) diagrams are useful visualizations of a Markov model.\n\n\n\n\n\n\n\nG\n\n\n\nHealthy\n\nHealthy\n\n\n\nHealthy-&gt;Healthy\n\n\n\n\n\nSick\n\nSick\n\n\n\nHealthy-&gt;Sick\n\n\n\n\n\nDead\n\nDead\n\n\n\nHealthy-&gt;Dead\n\n\n\n\n\nSick-&gt;Sick\n\n\n\n\n\nSick-&gt;Dead\n\n\n\n\n\nDead-&gt;Dead\n\n\n\n\n\n\n\n\n\n\n\nDiagram constructed using the Graphviz Visual Editor"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-1",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-1",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\nBasic steps\n{{&lt; fa check-circle &gt;}} 3a. Determine basic model parameters\n{{&lt; fa check-circle &gt;}} 3b. Curate and define model inputs"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-2",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-2",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\nBasic steps\n{{&lt; fa check-circle &gt;}} 3a. Determine basic model parameters\n\n\nDefine the population (e.g., 25 year old females)\nDefine the Markov cycle length (e.g., 1-year cycle)\nDefine the time horizon (e.g., followed until age 100 or death)"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\n\n\n\nFundamentally, we’re modeling a continuous time process (e.g., progression of disease).\nA discrete time Markov model “breaks up” time into “chunks” (i.e., “cycles”).\nA consequence is that the model will show us what fraction start out a cycle in a given state, and what fraction end up in each state at the end of the cycle."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-1",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-1",
    "title": "Markov Models",
    "section": "3a. Define the Markov cycle length",
    "text": "3a. Define the Markov cycle length\n\n\nSuppose we used a one-year cycle for the healthy-sick-dead model.\nThink about the underlying (continuous time) disease process.\n\nRecall that becoming sick substantially increases the likelihood of death.\n\nIf we’re not careful, what are we (implicitly) assuming can and can’t happen in a single cycle?"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-2",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-2",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-3",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-3",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\nThe challenge of selecting an appropriate cycle length boils down to how we deal with competing risks.\n\n\n\n\nCompeting risks: individuals can transition from their current health state to two or more other health states.\n\n\n\n\n\n\n\n\n\n\nG\n\n\n\nHealthy\n\nHealthy\n\n\n\nHealthy-&gt;Healthy\n\n\n\n\n\nSick\n\nSick\n\n\n\nHealthy-&gt;Sick\n\n\n\n\n\nDead\n\nDead\n\n\n\nHealthy-&gt;Dead\n\n\n\n\n\nSick-&gt;Sick\n\n\n\n\n\nSick-&gt;Dead\n\n\n\n\n\nDead-&gt;Dead"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-4",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-4",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\nThe challenge of selecting an appropriate cycle length boils down to how we deal with competing risks.\n\n\n\n\nIf we’re not careful, we could effectively rule out the possibility of Healthy {{&lt; fa arrow-right-long &gt;}} Sick{{&lt; fa arrow-right-long &gt;}} Dead within a cycle.\nThe model would look like a basic Healthy {{&lt; fa arrow-right-long &gt;}} Dead transition, but they took a detour through Sick along the way!\n\n\n\n\n\n\n\n\n\n\nG\n\n\n\nHealthy\n\nHealthy\n\n\n\nHealthy-&gt;Healthy\n\n\n\n\n\nSick\n\nSick\n\n\n\nHealthy-&gt;Sick\n\n\n\n\n\nDead\n\nDead\n\n\n\nHealthy-&gt;Dead\n\n\n\n\n\nSick-&gt;Sick\n\n\n\n\n\nSick-&gt;Dead\n\n\n\n\n\nDead-&gt;Dead"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-5",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-5",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nCan model repeated events\nCompeting risks are a challenge\n\n\nCan model more complex + longitudinal clinical events\n\n\n\nNot computationally intensive; efficient to model and debug"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-6",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-6",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\n\nIt may be tempting to simply shorten the cycle length (e.g., use 1 day cycle vs. 1 year cycle).\n\n\n\nFor a 75 year horizon, how many cycles would that be?\n\n27,375!!!\n\nAny possible issues with this?"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-7",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-7",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\n\nShortening the cycle creates a computational challenge.\n\n\n\nBase case requires 27,375 daily cycles.\nNow suppose we want to run 2,000 probabilistic sensitivity analysis model runs.\n\nWe now have 57,750,000 cycle runs to contend with!"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-8",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-8",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nCan model repeated events\nCan only transition once in a given cycle\n\n\nCan model more complex + longitudinal clinical events\nShortening the cycle can create computational challenges.\n\n\nNot computationally intensive; efficient to model and debug"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-9",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-9",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\nMore challenges …"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-10",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-10",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\nMore challenges …\n\nMarkov models are “memoryless” – they don’t remember what happened before the current cycle.\n\nIf your risk of transition to a sicker health state depends on events that happened earlier in time, the model can’t explicitly account for this."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-11",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-11",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\nMore challenges …\n\nThere are workarounds known as “tunnel states” to get around this problem, though these are difficult to do and present their own challenges\n\nWe won’t cover them this week but we can provide references if you want to explore!"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-12",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-12",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nCan model repeated events\nCan only transition once in a given cycle\n\n\nCan model more complex + longitudinal clinical events\nShortening the cycle can create computational challenges.\n\n\nNot computationally intensive; efficient to model and debug\nShortening cycle can cause “state explosion” if tunnel states are used"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-13",
    "href": "lectures/lec_7.MarkovModels1.html#a.-define-the-markov-cycle-length-13",
    "title": "Markov Models",
    "section": "3a. Define the Markov Cycle Length",
    "text": "3a. Define the Markov Cycle Length\n\n\n\n\nIt’s also advisable to pick a cycle length that aligns with the clinical/disease timelines of the decision problem.\n\nTreatment schedules.\nAcute vs. chronic condition.\n\nAnother option is to incorporate “short-run” events that happen early in the course of a disease/intervention within the decision tree, then allow the Markov model to model longer-term health consequences.\n\n\n\n\n\n\n\n\n\n\nG\n\n\n\nHealthy\n\nHealthy\n\n\n\nHealthy-&gt;Healthy\n\n\n\n\n\nSick\n\nSick\n\n\n\nHealthy-&gt;Sick\n\n\n\n\n\nDead\n\nDead\n\n\n\nHealthy-&gt;Dead\n\n\n\n\n\nSick-&gt;Sick\n\n\n\n\n\nSick-&gt;Dead\n\n\n\n\n\nDead-&gt;Dead"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-3",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-3",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\n{{&lt; fa check-circle &gt;}} 3b. Curate and define model inputs\n\n\n{{&lt; fa check-circle &gt;}} 3b.i. Source and define the base case values.\n{{&lt; fa check-circle &gt;}} 3b.ii. Source and define sources of uncertainty."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-4",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-4",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\n{{&lt; fa check-circle &gt;}} 3b. Curate and define model inputs\n\n\nRate of disease onset\nHealth state utilities and costs\nHazard ratios, odds ratios or relative risks for different strategies.\n… and so on."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-5",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-5",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\nWe defined many of the underlying parameters earlier in this lecture, so we’ll repeat them briefly here."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-6",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-6",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\n\nWe start with a healthy population of 25 year olds and follow them until age 100 (or death, if earlier).\n\n\n\nRemaining healthy carries no utility decrement (utility weight= 1.0)\nBecoming sick carries a 0.25 utility decrement for the remainder of the person’s life (utility weight = 0.75)\nDeath carries a utility weight value of 0."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-7",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-7",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\n\nThere is no cost associated with remaining healthy.\n\n\n\nBecoming sick incurs $1,000 / year in costs.\nBecoming sick increases the risk of death by 300%."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-8",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-8",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\nEach strategy has a different cost and impact on the likelihood of becoming sick.\n\n\n\n\n\n\n\n\nStrategy\nDescription\nCost\n\n\n\n\nA\nStandard of Care\n$25/year\n\n\nB\nAdditional 4% reduction in risk of becoming sick\n$1,000/year\n\n\nC\n12% reduction in risk\n$3,100/year\n\n\nD\n8% reduction in risk\n$1,550/year\n\n\nE\n8% reduction in risk\n$5,000/year"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-9",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-9",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\n\n\n\n\n\n\nIt is critical to follow a formal process for parameterizing your model.\n\n\n\n\n\nOften, parameters are drawn from the published literature, and it is important to track the source (published value, assumption, etc.) for each model parameter.\n\nFor example, the percent risk reduction parameter for each strategy may come from different clinical trials.\nThe parameter governing death from background causes may be derived from mortality data."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-10",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-10",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\n\n\n\n\n\n\nIt is critical to follow a formal process for parameterizing your model.\n\n\n\n\n\nSome parameters may just be values (e.g., cost of Strategy A is $25/yr)\nSome parameters may be functions of other parameters.\n\nFor example, suppose we want to follow a cohort of 25 year olds until age 100 or death, if it occurs earlier.\nIn that case we have two “fixed” parameters: the starting age, and the maximum age.\nWe can use these two parameters to infer the total number of cycles we need to run."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-11",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-11",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\n\n\n\n\n\n\nIt is critical to follow a formal process for parameterizing your model.\n\n\n\n\n\nParameters also have various “flavors”:\n\nProbabilities\nRates\nHazard ratios\nCosts\nUtilities\netc."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-12",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-12",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\n\n\n\n\n\n\nIt is critical to follow a formal process for parameterizing your model.\n\n\n\n\n\nAll of the above highlight the importance of adopting a formal process for naming and tracking the value, source, and uncertainty distribution of all model parameters in one place.\nWe recommend a structured approach based on parameter naming conventions and parameter tables."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-13",
    "href": "lectures/lec_7.MarkovModels1.html#parameterize-the-model-13",
    "title": "Markov Models",
    "section": "3. Parameterize the Model",
    "text": "3. Parameterize the Model\nNaming conventions:\n\n\n\n\n\ntype\nprefix\n\n\n\n\nProbability\np_\n\n\nRate\nr_\n\n\nMatrix\nm_\n\n\nCost\nc_\n\n\nUtility\nu_\n\n\nHazard Ratio\nhr_"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#parameter-table",
    "href": "lectures/lec_7.MarkovModels1.html#parameter-table",
    "title": "Markov Models",
    "section": "Parameter Table",
    "text": "Parameter Table\n\nNote: Only a subset of model parameters are shown in table.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParameter Table\n\n\nparam\nbase_case\nformula\ndescription\nnotes\ndistribution\nsource\n\n\n\n\nn_age_init\n25.00\n\n\nAge at baseline\n\n\n\n\nModeling Parameter\n\n\nn_age_max\n100.00\n\n\nMaximum age of followup\n\n\n\n\nModeling Parameter\n\n\nu_H\n1.00\n\n\nUtility weight of healthy (H)\n\n\nbeta(shape1 = 200, shape2 = 3)\nLeech et al. (2022)\n\n\nu_S\n0.75\n\n\nUtility weight of sick (S)\n\n\nbeta(shape1 = 130, shape2 = 45)\nLeech et al. (2022)\n\n\nc_S\n1000.00\n\n\nAnnual cost of sick (S)\n\n\ngamma(shape = 44.4, scale = 22.5)\nGraves et al. (2022)\n\n\nc_trtA\n25.00\n\n\nCost of treatment A\n\n\ngamma(shape = 12.5, scale = 2)\nMartin et al. (2022)\n\n\nc_trtB\n1000.00\n\n\nCost of treatment B\n\n\ngamma(shape = 12, scale = 83.3)\nAssumption\n\n\nc_trtC\n3100.00\n\n\nCost of treatment C\n\n\ngamma(shape = 36.144, scale = 83)\nAssumption\n\n\nn_cycles\n75.00\n(n_age_max - n_age_init)\nTime horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-3",
    "href": "lectures/lec_7.MarkovModels1.html#section-3",
    "title": "Markov Models",
    "section": "",
    "text": "param column is the short name of the parameter\n\nNote: Only a subset of model parameters are shown in table.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParameter Table\n\n\nparam\nbase_case\nformula\ndescription\nnotes\ndistribution\nsource\n\n\n\n\nn_age_init\n25.00\n\n\nAge at baseline\n\n\n\n\nModeling Parameter\n\n\nn_age_max\n100.00\n\n\nMaximum age of followup\n\n\n\n\nModeling Parameter\n\n\nu_H\n1.00\n\n\nUtility weight of healthy (H)\n\n\nbeta(shape1 = 200, shape2 = 3)\nLeech et al. (2022)\n\n\nu_S\n0.75\n\n\nUtility weight of sick (S)\n\n\nbeta(shape1 = 130, shape2 = 45)\nLeech et al. (2022)\n\n\nc_S\n1000.00\n\n\nAnnual cost of sick (S)\n\n\ngamma(shape = 44.4, scale = 22.5)\nGraves et al. (2022)\n\n\nc_trtA\n25.00\n\n\nCost of treatment A\n\n\ngamma(shape = 12.5, scale = 2)\nMartin et al. (2022)\n\n\nc_trtB\n1000.00\n\n\nCost of treatment B\n\n\ngamma(shape = 12, scale = 83.3)\nAssumption\n\n\nc_trtC\n3100.00\n\n\nCost of treatment C\n\n\ngamma(shape = 36.144, scale = 83)\nAssumption\n\n\nn_cycles\n75.00\n(n_age_max - n_age_init)\nTime horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-4",
    "href": "lectures/lec_7.MarkovModels1.html#section-4",
    "title": "Markov Models",
    "section": "",
    "text": "base_case is the parameter value for the base case.\n\nNote: Only a subset of model parameters are shown in table.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParameter Table\n\n\nparam\nbase_case\nformula\ndescription\nnotes\ndistribution\nsource\n\n\n\n\nn_age_init\n25.00\n\n\nAge at baseline\n\n\n\n\nModeling Parameter\n\n\nn_age_max\n100.00\n\n\nMaximum age of followup\n\n\n\n\nModeling Parameter\n\n\nu_H\n1.00\n\n\nUtility weight of healthy (H)\n\n\nbeta(shape1 = 200, shape2 = 3)\nLeech et al. (2022)\n\n\nu_S\n0.75\n\n\nUtility weight of sick (S)\n\n\nbeta(shape1 = 130, shape2 = 45)\nLeech et al. (2022)\n\n\nc_S\n1000.00\n\n\nAnnual cost of sick (S)\n\n\ngamma(shape = 44.4, scale = 22.5)\nGraves et al. (2022)\n\n\nc_trtA\n25.00\n\n\nCost of treatment A\n\n\ngamma(shape = 12.5, scale = 2)\nMartin et al. (2022)\n\n\nc_trtB\n1000.00\n\n\nCost of treatment B\n\n\ngamma(shape = 12, scale = 83.3)\nAssumption\n\n\nc_trtC\n3100.00\n\n\nCost of treatment C\n\n\ngamma(shape = 36.144, scale = 83)\nAssumption\n\n\nn_cycles\n75.00\n(n_age_max - n_age_init)\nTime horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-5",
    "href": "lectures/lec_7.MarkovModels1.html#section-5",
    "title": "Markov Models",
    "section": "",
    "text": "formula defines model parameter formulas for parameters that are functions of other model parameters.\n\nNote: Only a subset of model parameters are shown in table.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParameter Table\n\n\nparam\nbase_case\nformula\ndescription\nnotes\ndistribution\nsource\n\n\n\n\nn_age_init\n25.00\n\n\nAge at baseline\n\n\n\n\nModeling Parameter\n\n\nn_age_max\n100.00\n\n\nMaximum age of followup\n\n\n\n\nModeling Parameter\n\n\nu_H\n1.00\n\n\nUtility weight of healthy (H)\n\n\nbeta(shape1 = 200, shape2 = 3)\nLeech et al. (2022)\n\n\nu_S\n0.75\n\n\nUtility weight of sick (S)\n\n\nbeta(shape1 = 130, shape2 = 45)\nLeech et al. (2022)\n\n\nc_S\n1000.00\n\n\nAnnual cost of sick (S)\n\n\ngamma(shape = 44.4, scale = 22.5)\nGraves et al. (2022)\n\n\nc_trtA\n25.00\n\n\nCost of treatment A\n\n\ngamma(shape = 12.5, scale = 2)\nMartin et al. (2022)\n\n\nc_trtB\n1000.00\n\n\nCost of treatment B\n\n\ngamma(shape = 12, scale = 83.3)\nAssumption\n\n\nc_trtC\n3100.00\n\n\nCost of treatment C\n\n\ngamma(shape = 36.144, scale = 83)\nAssumption\n\n\nn_cycles\n75.00\n(n_age_max - n_age_init)\nTime horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-6",
    "href": "lectures/lec_7.MarkovModels1.html#section-6",
    "title": "Markov Models",
    "section": "",
    "text": "description provides a text description of the parameter.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParameter Table\n\n\nparam\nbase_case\nformula\ndescription\nnotes\ndistribution\nsource\n\n\n\n\nn_age_init\n25.00\n\n\nAge at baseline\n\n\n\n\nModeling Parameter\n\n\nn_age_max\n100.00\n\n\nMaximum age of followup\n\n\n\n\nModeling Parameter\n\n\nu_H\n1.00\n\n\nUtility weight of healthy (H)\n\n\nbeta(shape1 = 200, shape2 = 3)\nLeech et al. (2022)\n\n\nu_S\n0.75\n\n\nUtility weight of sick (S)\n\n\nbeta(shape1 = 130, shape2 = 45)\nLeech et al. (2022)\n\n\nc_S\n1000.00\n\n\nAnnual cost of sick (S)\n\n\ngamma(shape = 44.4, scale = 22.5)\nGraves et al. (2022)\n\n\nc_trtA\n25.00\n\n\nCost of treatment A\n\n\ngamma(shape = 12.5, scale = 2)\nMartin et al. (2022)\n\n\nc_trtB\n1000.00\n\n\nCost of treatment B\n\n\ngamma(shape = 12, scale = 83.3)\nAssumption\n\n\nc_trtC\n3100.00\n\n\nCost of treatment C\n\n\ngamma(shape = 36.144, scale = 83)\nAssumption\n\n\nn_cycles\n75.00\n(n_age_max - n_age_init)\nTime horizon\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNote: Only a subset of model parameters are shown in table."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-7",
    "href": "lectures/lec_7.MarkovModels1.html#section-7",
    "title": "Markov Models",
    "section": "",
    "text": "notes is an optional column where you add additional notes or context for the parameter.\n\nNote: Only a subset of model parameters are shown in table.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParameter Table\n\n\nparam\nbase_case\nformula\ndescription\nnotes\ndistribution\nsource\n\n\n\n\nn_age_init\n25.00\n\n\nAge at baseline\n\n\n\n\nModeling Parameter\n\n\nn_age_max\n100.00\n\n\nMaximum age of followup\n\n\n\n\nModeling Parameter\n\n\nu_H\n1.00\n\n\nUtility weight of healthy (H)\n\n\nbeta(shape1 = 200, shape2 = 3)\nLeech et al. (2022)\n\n\nu_S\n0.75\n\n\nUtility weight of sick (S)\n\n\nbeta(shape1 = 130, shape2 = 45)\nLeech et al. (2022)\n\n\nc_S\n1000.00\n\n\nAnnual cost of sick (S)\n\n\ngamma(shape = 44.4, scale = 22.5)\nGraves et al. (2022)\n\n\nc_trtA\n25.00\n\n\nCost of treatment A\n\n\ngamma(shape = 12.5, scale = 2)\nMartin et al. (2022)\n\n\nc_trtB\n1000.00\n\n\nCost of treatment B\n\n\ngamma(shape = 12, scale = 83.3)\nAssumption\n\n\nc_trtC\n3100.00\n\n\nCost of treatment C\n\n\ngamma(shape = 36.144, scale = 83)\nAssumption\n\n\nn_cycles\n75.00\n(n_age_max - n_age_init)\nTime horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-8",
    "href": "lectures/lec_7.MarkovModels1.html#section-8",
    "title": "Markov Models",
    "section": "",
    "text": "distribution specifies the uncertainty distribution for the parameter. It is used for probabilistic sensitivity analyses, which we cover in our intermediate (week-long) workshop.\n\nNote: Only a subset of model parameters are shown in table.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParameter Table\n\n\nparam\nbase_case\nformula\ndescription\nnotes\ndistribution\nsource\n\n\n\n\nn_age_init\n25.00\n\n\nAge at baseline\n\n\n\n\nModeling Parameter\n\n\nn_age_max\n100.00\n\n\nMaximum age of followup\n\n\n\n\nModeling Parameter\n\n\nu_H\n1.00\n\n\nUtility weight of healthy (H)\n\n\nbeta(shape1 = 200, shape2 = 3)\nLeech et al. (2022)\n\n\nu_S\n0.75\n\n\nUtility weight of sick (S)\n\n\nbeta(shape1 = 130, shape2 = 45)\nLeech et al. (2022)\n\n\nc_S\n1000.00\n\n\nAnnual cost of sick (S)\n\n\ngamma(shape = 44.4, scale = 22.5)\nGraves et al. (2022)\n\n\nc_trtA\n25.00\n\n\nCost of treatment A\n\n\ngamma(shape = 12.5, scale = 2)\nMartin et al. (2022)\n\n\nc_trtB\n1000.00\n\n\nCost of treatment B\n\n\ngamma(shape = 12, scale = 83.3)\nAssumption\n\n\nc_trtC\n3100.00\n\n\nCost of treatment C\n\n\ngamma(shape = 36.144, scale = 83)\nAssumption\n\n\nn_cycles\n75.00\n(n_age_max - n_age_init)\nTime horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-9",
    "href": "lectures/lec_7.MarkovModels1.html#section-9",
    "title": "Markov Models",
    "section": "",
    "text": "Note: Only a subset of model parameters are shown in table.\n\nsource provides the source for the parameter. It could be a published research article, an assumption, or just simply an unsourced modeling parameter (e.g., the starting age of the modeled cohort).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParameter Table\n\n\nparam\nbase_case\nformula\ndescription\nnotes\ndistribution\nsource\n\n\n\n\nn_age_init\n25.00\n\n\nAge at baseline\n\n\n\n\nModeling Parameter\n\n\nn_age_max\n100.00\n\n\nMaximum age of followup\n\n\n\n\nModeling Parameter\n\n\nu_H\n1.00\n\n\nUtility weight of healthy (H)\n\n\nbeta(shape1 = 200, shape2 = 3)\nLeech et al. (2022)\n\n\nu_S\n0.75\n\n\nUtility weight of sick (S)\n\n\nbeta(shape1 = 130, shape2 = 45)\nLeech et al. (2022)\n\n\nc_S\n1000.00\n\n\nAnnual cost of sick (S)\n\n\ngamma(shape = 44.4, scale = 22.5)\nGraves et al. (2022)\n\n\nc_trtA\n25.00\n\n\nCost of treatment A\n\n\ngamma(shape = 12.5, scale = 2)\nMartin et al. (2022)\n\n\nc_trtB\n1000.00\n\n\nCost of treatment B\n\n\ngamma(shape = 12, scale = 83.3)\nAssumption\n\n\nc_trtC\n3100.00\n\n\nCost of treatment C\n\n\ngamma(shape = 36.144, scale = 83)\nAssumption\n\n\nn_cycles\n75.00\n(n_age_max - n_age_init)\nTime horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#defining-the-transition-probability-matrix",
    "href": "lectures/lec_7.MarkovModels1.html#defining-the-transition-probability-matrix",
    "title": "Markov Models",
    "section": "Defining the Transition Probability Matrix",
    "text": "Defining the Transition Probability Matrix\n\nThe transition probability matrix is a square matrix that defines the probability of transitioning from one health state to another health state in a single time step.\nConstructing the matrix is a fairly technical, but fairly straightforward process.\n\nWe could spend an entire day of lecture and case studies on this alone (and we do in our weeklong intermediate course!)\nHowever, in the interest of time, we’ll skip over these technical details today."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#transition-probability-matrix",
    "href": "lectures/lec_7.MarkovModels1.html#transition-probability-matrix",
    "title": "Markov Models",
    "section": "Transition Probability Matrix",
    "text": "Transition Probability Matrix\n\n\n\n\n\n\n\n\n\nG\n\n\n\nHealthy\n\nHealthy\n\n\n\nHealthy-&gt;Healthy\n\n\n0.856\n\n\n\nSick\n\nSick\n\n\n\nHealthy-&gt;Sick\n\n\n0.138\n\n\n\nDead\n\nDead\n\n\n\nHealthy-&gt;Dead\n\n\n0.007\n\n\n\nSick-&gt;Sick\n\n\n0.982\n\n\n\nSick-&gt;Dead\n\n\n0.018\n\n\n\nDead-&gt;Dead\n\n\n1.0\n\n\n\n\n\n\n\n\n\n\n\n\n\nHealthy\nSick\nDead\n\n\n\n\nHealthy\n0.856\n0.138\n0.007\n\n\nSick\n0\n0.982\n0.018\n\n\nDead\n0\n0\n1"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#executing-the-model-requires-two-inputs",
    "href": "lectures/lec_7.MarkovModels1.html#executing-the-model-requires-two-inputs",
    "title": "Markov Models",
    "section": "Executing the model requires two inputs",
    "text": "Executing the model requires two inputs\n\n\nHealth State Occupancy at Beginning of Cycle\n\n\nTransition Probability Matrix"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-10",
    "href": "lectures/lec_7.MarkovModels1.html#section-10",
    "title": "Markov Models",
    "section": "",
    "text": "Health State Occupancy at Beginning of Cycle\n\n\nTransition Probability Matrix"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-11",
    "href": "lectures/lec_7.MarkovModels1.html#section-11",
    "title": "Markov Models",
    "section": "",
    "text": "Health State Occupancy at Beginning of Cycle\n\n\nTransition Probability Matrix\n\n\n\\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad\n\n\n\n\ns =\n\n\n H S D\n 1 0 0\n\n\n\nP =\n\n\n      H     S     D\nH 0.856 0.138 0.007\nS 0.000 0.982 0.018\nD 0.000 0.000 1.000\n\n\n\n\\quad \\quad \\quad \\quad"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-12",
    "href": "lectures/lec_7.MarkovModels1.html#section-12",
    "title": "Markov Models",
    "section": "",
    "text": "Health State Occupancy at Beginning of Cycle\n\n\nTransition Probability Matrix\n\n\nHealth State Occupancy at End of Cycle\n\n\n\n\ns =\n\n\n H S D\n 1 0 0\n\n\n\nP =\n\n\n      H     S     D\nH 0.856 0.138 0.007\nS 0.000 0.982 0.018\nD 0.000 0.000 1.000\n\n\n\ns \\cdot P=\n\n\n     H     S     D\n 0.856 0.138 0.007"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-13",
    "href": "lectures/lec_7.MarkovModels1.html#section-13",
    "title": "Markov Models",
    "section": "",
    "text": "Health State Occupancy at Beginning of Cycle\n\n\nTransition Probability Matrix\n\n\nHealth State Occupancy at End of Cycle\n\n\n\n\ns =\n\n\n H S D\n 1 0 0\n\n\n\nP =\n\n\n      H     S     D\nH 0.856 0.138 0.007\nS 0.000 0.982 0.018\nD 0.000 0.000 1.000\n\n\n\ns \\cdot P=\n\n\n     H     S     D\n 0.856 0.138 0.007"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-14",
    "href": "lectures/lec_7.MarkovModels1.html#section-14",
    "title": "Markov Models",
    "section": "",
    "text": "Health State Occupancy at Beginning of Cycle\n\n\nTransition Probability Matrix\n\n\nHealth State Occupancy at End of Cycle\n\n\n\n\ns =\n\n\n H S D\n 1 0 0\n\n\n\n\n\n\n\n\n     H     S     D\n 0.856 0.138 0.007\n\n\n\n\nP =\n\n\n      H     S     D\nH 0.856 0.138 0.007\nS 0.000 0.982 0.018\nD 0.000 0.000 1.000\n\n\n\n\n      H     S     D\nH 0.856 0.138 0.007\nS 0.000 0.982 0.018\nD 0.000 0.000 1.000\n\n\n\ns \\cdot P=\n\n\n     H     S     D\n 0.856 0.138 0.007\n\n\n\n\n\n\n\n     H     S     D\n 0.733 0.254 0.015"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-15",
    "href": "lectures/lec_7.MarkovModels1.html#section-15",
    "title": "Markov Models",
    "section": "",
    "text": "Health State Occupancy at Beginning of Cycle\n\n\nTransition Probability Matrix\n\n\nHealth State Occupancy at End of Cycle\n\n\n\n\ns =\n\n\n H S D\n 1 0 0\n\n\n\n\n\n\n\n\n     H     S     D\n 0.856 0.138 0.007\n\n\n\n\n\n\n\n\n\n     H     S     D\n 0.733 0.254 0.015\n\n\n\n\nP =\n\n\n      H     S     D\nH 0.856 0.138 0.007\nS 0.000 0.982 0.018\nD 0.000 0.000 1.000\n\n\n\n\n      H     S     D\nH 0.856 0.138 0.007\nS 0.000 0.982 0.018\nD 0.000 0.000 1.000\n\n\n\n\n      H     S     D\nH 0.856 0.138 0.007\nS 0.000 0.982 0.018\nD 0.000 0.000 1.000\n\n\n\ns \\cdot P=\n\n\n     H     S     D\n 0.856 0.138 0.007\n\n\n\n\n\n\n\n     H     S     D\n 0.733 0.254 0.015\n\n\n\n\n\n\n\n\n     H    S     D\n 0.627 0.35 0.025"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#section-16",
    "href": "lectures/lec_7.MarkovModels1.html#section-16",
    "title": "Markov Models",
    "section": "",
    "text": "Health State Occupancy at End of Cycle\n\n\n\n\n     H     S     D\n 0.856 0.138 0.007\n\n\n\n\n\n\n       H       S        D\n 0.73274 0.25364 0.015476\n\n\n\n\n\n\n       H      S        D\n 0.62722 0.3502 0.025171"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-trace",
    "href": "lectures/lec_7.MarkovModels1.html#markov-trace",
    "title": "Markov Models",
    "section": "Markov Trace",
    "text": "Markov Trace\n\nHealth State Occupancy Over Ten Cycles\n\n\n\n cycle       H       S        D\n     0 1.00000 0.00000 0.000000\n     1 0.85600 0.13800 0.007000\n     2 0.73274 0.25364 0.015476\n     3 0.62722 0.35020 0.025171\n     4 0.53690 0.43045 0.035865\n     5 0.45959 0.49679 0.047371\n     6 0.39341 0.55127 0.059531\n     7 0.33676 0.59564 0.072207\n     8 0.28826 0.63139 0.085286\n     9 0.24675 0.65981 0.098669\n    10 0.21122 0.68198 0.112273"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#in-class-example",
    "href": "lectures/lec_7.MarkovModels1.html#in-class-example",
    "title": "Markov Models",
    "section": "In-class example",
    "text": "In-class example\n\n\nA new drug was developed for cancer patients in remission to decrease their chance of relapse\nThis drug is $10,000 per year (2022 USD)\nResearch question: Is the new drug cost-effective compared to the current standard of care?\nLet’s say we want to model this over a 4-year time horizon"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#in-class-example-1",
    "href": "lectures/lec_7.MarkovModels1.html#in-class-example-1",
    "title": "Markov Models",
    "section": "In-class example",
    "text": "In-class example\n\n\n\n\n\n\nStandard of Care\nNew Drug\n\n\n\n\nHealthy to Stage 1\n5%\n\n\n\nHealthy to Stage 2\n2%\n\n\n\nHealthy to Stage 3\n1%\n\n\n\nStage 1 to Stage 2\n10%\n\n\n\nStage 1 to Remission\n25%\n\n\n\nStage 2 to Stage 1\n5%\n\n\n\nStage 2 to Stage 3\n15%\n\n\n\nStage 2 to Remission\n20%\n\n\n\nStage 3 to Stage 2\n5%\n\n\n\nStage 3 to Death\n45%\n\n\n\nRemission to Stage 1\n10%\n2%\n\n\nRemission to Stage 2\n5%\n1%"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#in-class-example-2",
    "href": "lectures/lec_7.MarkovModels1.html#in-class-example-2",
    "title": "Markov Models",
    "section": "In-class example",
    "text": "In-class example"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#in-class-example-3",
    "href": "lectures/lec_7.MarkovModels1.html#in-class-example-3",
    "title": "Markov Models",
    "section": "In-class example",
    "text": "In-class example"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#in-class-example-4",
    "href": "lectures/lec_7.MarkovModels1.html#in-class-example-4",
    "title": "Markov Models",
    "section": "In-class example",
    "text": "In-class example"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#in-class-example-5",
    "href": "lectures/lec_7.MarkovModels1.html#in-class-example-5",
    "title": "Markov Models",
    "section": "In-class example",
    "text": "In-class example"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#in-class-example-6",
    "href": "lectures/lec_7.MarkovModels1.html#in-class-example-6",
    "title": "Markov Models",
    "section": "In-class example",
    "text": "In-class example"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#in-class-example-7",
    "href": "lectures/lec_7.MarkovModels1.html#in-class-example-7",
    "title": "Markov Models",
    "section": "In-class example",
    "text": "In-class example"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#an-example-markov-trace-75-year-horizon",
    "href": "lectures/lec_7.MarkovModels1.html#an-example-markov-trace-75-year-horizon",
    "title": "Markov Models",
    "section": "An example Markov Trace (75 year horizon)",
    "text": "An example Markov Trace (75 year horizon)\n\n\n\n\nCycle\nHealthy\nSick\nDead\n\n\n\n\n0\n1.000\n0.000\n0.000\n\n\n1\n0.856\n0.138\n0.007\n\n\n2\n0.732\n0.253\n0.015\n\n\n3\n0.626\n0.349\n0.025\n\n\n4\n0.536\n0.429\n0.035\n\n\n5\n0.458\n0.495\n0.046\n\n\n…\n…\n…\n…\n\n\n75 (End)\n0\n0.282\n0.718"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-traces",
    "href": "lectures/lec_7.MarkovModels1.html#markov-traces",
    "title": "Markov Models",
    "section": "Markov Traces",
    "text": "Markov Traces\n\nOften we are modeling several competing strategies.\nEach strategy has its own transition probability matrix.\nTherefore, each strategy will have it’s own Markov trace."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#calculating-outcomes-1",
    "href": "lectures/lec_7.MarkovModels1.html#calculating-outcomes-1",
    "title": "Markov Models",
    "section": "Calculating Outcomes",
    "text": "Calculating Outcomes\n\nWith our markov traces complete, we can calculate expected outcomes (e.g., costs, QALYs, DALYs, etc.).\nMuch like we did with decision trees, we need to define “payoffs” for each health state."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#defining-payoffs",
    "href": "lectures/lec_7.MarkovModels1.html#defining-payoffs",
    "title": "Markov Models",
    "section": "Defining Payoffs",
    "text": "Defining Payoffs\n\nCost outcomes: Cost of being healthy, sick, dead (including any additional costs of treatment/intervention, if applicable).\nQALY outcomes: Utility weight of being healthy (usually 1.0), sick, dead (usually 0.0).\nDALY outcomes: Disability weights of being sick (YLD) and remaining life expectancy based on reference life table (YLL)"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#defining-payoffs-1",
    "href": "lectures/lec_7.MarkovModels1.html#defining-payoffs-1",
    "title": "Markov Models",
    "section": "Defining Payoffs",
    "text": "Defining Payoffs\n\n\nWe can calculate the total payoff for each cycle by multiplying the number or fraction of the cohort in each health state by its payoff value, and adding them together.\n\n\nExample Markov Trace (two cycles):\n\n\n\n\nCycle\nHealthy\nSick\nDead\n\n\n\n\n0\n1.000\n0.000\n0.000\n\n\n1\n0.856\n0.138\n0.007"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-life-years",
    "href": "lectures/lec_7.MarkovModels1.html#example-life-years",
    "title": "Markov Models",
    "section": "Example: Life Years",
    "text": "Example: Life Years\n\nWe’ll build our example using a simple outcome: expected life years under a given strategy.\nPayoffs:\n\nHealthy: 1.0\nSick: 1.0 [they’re still alive!]\nDead: 0.0"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-life-years-1",
    "href": "lectures/lec_7.MarkovModels1.html#example-life-years-1",
    "title": "Markov Models",
    "section": "Example: Life Years",
    "text": "Example: Life Years\n\nTo get the total “payoff” for a given cycle, we multiply the fraction of the cohort in a given health state by the payoff associated with that health state.\nDo this for each health state, and add them together to get the total.\n\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY\n\n\n\n\n0\n1.000\n0.000\n0.000\n\n\n\n1\n0.856\n0.138\n0.007"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-life-years-2",
    "href": "lectures/lec_7.MarkovModels1.html#example-life-years-2",
    "title": "Markov Models",
    "section": "Example: Life Years",
    "text": "Example: Life Years\nWhat is the LY “payoff” for Cycle 0?\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY\n\n\n\n\n0\n1.000\n0.000\n0.000\n\n\n\n1\n0.856\n0.138\n0.007"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-life-years-3",
    "href": "lectures/lec_7.MarkovModels1.html#example-life-years-3",
    "title": "Markov Models",
    "section": "Example: Life Years",
    "text": "Example: Life Years\nWhat is the LY “payoff” for Cycle 0?\n\n\n\n\n\n\n\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY\n\n\n\n\n0\n1.000\n0.000\n0.000\n1.0 = 1.0 * 1.0 + 0.0 * 1.0 + 0.0 * 0.0\n\n\n1\n0.856\n0.138\n0.007"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-life-years-4",
    "href": "lectures/lec_7.MarkovModels1.html#example-life-years-4",
    "title": "Markov Models",
    "section": "Example: Life Years",
    "text": "Example: Life Years\nWhat is the LY “payoff” for Cycle 1?\n\n\n\n\n\n\n\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY\n\n\n\n\n0\n1.000\n0.000\n0.000\n1.0\n\n\n1\n0.856\n0.138\n0.007\n0.994 = 0.856 * 1.0 + 0.138 * 1.0 + 0.007 * 0.0\n\n\n\n\n… and so on."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-life-years-5",
    "href": "lectures/lec_7.MarkovModels1.html#example-life-years-5",
    "title": "Markov Models",
    "section": "Example: Life Years",
    "text": "Example: Life Years\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY\n\n\n\n\n0\n1.000\n0.000\n0.000\n1\n\n\n1\n0.856\n0.138\n0.007\n0.993\n\n\n2\n0.732\n0.253\n0.015\n0.985\n\n\n3\n0.626\n0.349\n0.025\n0.975\n\n\n4\n0.536\n0.429\n0.035\n0.965\n\n\n5\n0.458\n0.495\n0.046\n0.954\n\n\n…\n…\n…\n…\n\n\n\n75 (End)\n0\n0.282\n0.718\n0.282"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-costs",
    "href": "lectures/lec_7.MarkovModels1.html#example-costs",
    "title": "Markov Models",
    "section": "Example: Costs",
    "text": "Example: Costs\n\nNow suppose we want to calculate costs.\nPayoffs:\n\nHealthy: $0\nSick: $1,000\nDead: $0"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-costs-1",
    "href": "lectures/lec_7.MarkovModels1.html#example-costs-1",
    "title": "Markov Models",
    "section": "Example: Costs",
    "text": "Example: Costs\nWhat is the Cost “payoff” for Cycle 0?\n\n\n\n\nCycle\nHealthy\nSick\nDead\nCost\n\n\n\n\n0\n1.000\n0.000\n0.000\n\n\n\n1\n0.856\n0.138\n0.007"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-costs-2",
    "href": "lectures/lec_7.MarkovModels1.html#example-costs-2",
    "title": "Markov Models",
    "section": "Example: Costs",
    "text": "Example: Costs\nWhat is the Cost “payoff” for Cycle 0?\n\n\n\n\n\n\n\n\n\n\n\nCycle\nHealthy\nSick\nDead\nCost\n\n\n\n\n0\n1.000\n0.000\n0.000\n0 = 1.00 * 0 + 0.0 * 1000 + 0.0 * 0\n\n\n1\n0.856\n0.138\n0.007"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#example-costs-3",
    "href": "lectures/lec_7.MarkovModels1.html#example-costs-3",
    "title": "Markov Models",
    "section": "Example: Costs",
    "text": "Example: Costs\nWhat is the cost “payoff” for Cycle 1?\n\n\n\n\n\n\n\n\n\n\n\nCycle\nHealthy\nSick\nDead\nCost\n\n\n\n\n0\n1.000\n0.000\n0.000\n0\n\n\n1\n0.856\n0.138\n0.007\n138 = 0.856*0+0.138*1000+0.007*0\n\n\n\n\n… and so on."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#other-outcomes",
    "href": "lectures/lec_7.MarkovModels1.html#other-outcomes",
    "title": "Markov Models",
    "section": "Other Outcomes",
    "text": "Other Outcomes\n\nWe can repeat a similar process for health outcomes (e.g., QALYs, YLDs) by multiplying the “payoff” (e.g., utility weight, disability weight) for a given health state by the fraction of the cohort in that health state in the cycle."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#total-outcomes",
    "href": "lectures/lec_7.MarkovModels1.html#total-outcomes",
    "title": "Markov Models",
    "section": "Total Outcomes",
    "text": "Total Outcomes"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#total-life-years",
    "href": "lectures/lec_7.MarkovModels1.html#total-life-years",
    "title": "Markov Models",
    "section": "Total Life Years",
    "text": "Total Life Years\nLet’s look at the Markov trace and cycle outcomes for the Life Year outcome.\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY (single cycle)\n\n\n\n\n0\n1.000\n0.000\n0.000\n1\n\n\n1\n0.856\n0.138\n0.007\n0.993\n\n\n2\n0.732\n0.253\n0.015\n0.985\n\n\n3\n0.626\n0.349\n0.025\n0.975\n\n\n4\n0.536\n0.429\n0.035\n0.965\n\n\n5\n0.458\n0.495\n0.046\n0.954\n\n\n…\n…\n…\n…\n\n\n\n75 (End)\n0\n0.282\n0.718\n0.282"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#life-years",
    "href": "lectures/lec_7.MarkovModels1.html#life-years",
    "title": "Markov Models",
    "section": "Life years",
    "text": "Life years\nWe can create a new column that accumulates life years over each cycle.\n\n\n\n\n\n\n\n\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY (single cycle)\nLY (cumulative)\n\n\n\n\n0\n1.000\n0.000\n0.000\n1\n1\n\n\n1\n0.856\n0.138\n0.007\n0.993\n1 + 0.993 = 1.993\n\n\n2\n0.732\n0.253\n0.015\n0.985\n\n\n\n3\n0.626\n0.349\n0.025\n0.975\n\n\n\n4\n0.536\n0.429\n0.035\n0.965\n\n\n\n5\n0.458\n0.495\n0.046\n0.954\n\n\n\n…\n…\n…\n…\n…\n\n\n\n75 (End)\n0\n0.282\n0.718\n0.282"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#life-years-1",
    "href": "lectures/lec_7.MarkovModels1.html#life-years-1",
    "title": "Markov Models",
    "section": "Life years",
    "text": "Life years\n\n\n\n\n\n\n\n\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY (single cycle)\nLY (cumulative)\n\n\n\n\n0\n1.000\n0.000\n0.000\n1\n1\n\n\n1\n0.856\n0.138\n0.007\n0.993\n1.993\n\n\n2\n0.732\n0.253\n0.015\n0.985\n1 + 0.993 + 0.985 = 2.978\n\n\n3\n0.626\n0.349\n0.025\n0.975\n\n\n\n4\n0.536\n0.429\n0.035\n0.965\n\n\n\n5\n0.458\n0.495\n0.046\n0.954\n\n\n\n…\n…\n…\n…\n…\n\n\n\n75 (End)\n0\n0.282\n0.718\n0.282"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#life-years-2",
    "href": "lectures/lec_7.MarkovModels1.html#life-years-2",
    "title": "Markov Models",
    "section": "Life years",
    "text": "Life years\n\nThe cumulative LYs for an individual starting in the Healthy state is 44.825\nNote that this is within a 75 years time horizon\n\n\n\n\n\n\n\n\n\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY (single cycle)\nLY (cumulative)\n\n\n\n\n0\n1.000\n0.000\n0.000\n1\n1\n\n\n1\n0.856\n0.138\n0.007\n0.993\n1.993\n\n\n2\n0.732\n0.253\n0.015\n0.985\n2.978\n\n\n3\n0.626\n0.349\n0.025\n0.975\n3.954\n\n\n4\n0.536\n0.429\n0.035\n0.965\n4.919\n\n\n5\n0.458\n0.495\n0.046\n0.954\n5.872\n\n\n…\n…\n…\n…\n…\n…\n\n\n75 (End)\n0\n0.282\n0.718\n0.282\n44.825"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#total-outcomes-1",
    "href": "lectures/lec_7.MarkovModels1.html#total-outcomes-1",
    "title": "Markov Models",
    "section": "Total Outcomes",
    "text": "Total Outcomes\n\nWe can do a similar exercise to get total costs, total QALYs, total DALYs, etc.\nHowever, it’s not that simple. There are some extra complications we have to deal with.\n\nDiscounting\nCycle correction"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#the-problem",
    "href": "lectures/lec_7.MarkovModels1.html#the-problem",
    "title": "Markov Models",
    "section": "The problem",
    "text": "The problem\n\nIn real life, events could occur at any points in a given cycle, but a Markov model assumes all events occur either at the beginning or end of each cycle\nTime is continuous, so are survival/event-free survival curves\nWhen we discretize time by using a fixed cycle length, we can make two assumptions\n\nSuppose this is a simple Well \\rightarrow Dead process"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#the-problem-1",
    "href": "lectures/lec_7.MarkovModels1.html#the-problem-1",
    "title": "Markov Models",
    "section": "The problem",
    "text": "The problem\n\n\n\nAssuming death happens at the end of cycle (A)\n\n\nOverestimates state membership in Well\n\n\n\nAssuming death happens at the start of cycle (B)\n\n\nUnderestimates state membership in Well\n\n\n\nSource"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#the-problem-2",
    "href": "lectures/lec_7.MarkovModels1.html#the-problem-2",
    "title": "Markov Models",
    "section": "The problem",
    "text": "The problem\n\n\n\nWhen counting subjects at the END of cycle (top visual) (transition happens at beginning of cycle) - you would be underestimating LYs\n\n\nSay you have 10 people & 5 die halfway through, you wouldn’t be counting the 5 that started that has accumulated SOME costs & benefits in that cycle; you would only be counting the “end” survivors.\n\n\nIf you counted subjects at BEGINNING of cycle (the bottom visual) (transition happens at end of previous cycle), you would be overestimating LYs\n\n\nFor example, for these 10 people, they die halfway through the cycle, but you already gave that person the full cycle’s benefits & costs at the beginning (even though they shouldn’t get the full benefits & costs because they died halfway through)"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#half-cycle-correction",
    "href": "lectures/lec_7.MarkovModels1.html#half-cycle-correction",
    "title": "Markov Models",
    "section": "Half-cycle correction",
    "text": "Half-cycle correction\n\n\n\n\n\n\n\nSource"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#half-cycle-correction-1",
    "href": "lectures/lec_7.MarkovModels1.html#half-cycle-correction-1",
    "title": "Markov Models",
    "section": "Half-cycle correction",
    "text": "Half-cycle correction\n\n\n\n\n\n\n\n\n\nSource"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#half-cycle-correction-2",
    "href": "lectures/lec_7.MarkovModels1.html#half-cycle-correction-2",
    "title": "Markov Models",
    "section": "Half-cycle correction",
    "text": "Half-cycle correction\n\n\nMultiply the outcomes by 1/2 in the first and last cycle.\nShifting the computed, discrete state membership curve to the left by 1/2 cycle.\nEssentially assuming that events happen in the middle of cycle\n\nSource"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#half-cycle-correction-3",
    "href": "lectures/lec_7.MarkovModels1.html#half-cycle-correction-3",
    "title": "Markov Models",
    "section": "Half-cycle correction",
    "text": "Half-cycle correction\n\n\n\n\nIntuition behind it – the image to the left represents underestimation\n& you can see if you line that up to the Y-AXIS (center figures), the triangular areas can be seen to be equal to a rectangle one-half cycle wide extending from 0 to 1.\nIf you add back the original rectangles, the approximation is NOW BETTER – it has corrected for the underestimation."
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#half-cycle-correction-4",
    "href": "lectures/lec_7.MarkovModels1.html#half-cycle-correction-4",
    "title": "Markov Models",
    "section": "Half-cycle correction",
    "text": "Half-cycle correction\n\nMultiply the outcomes by 1/2 in the first and last cycle.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCycle\nHealthy\nSick\nDead\nLY (single cycle, adjusted)\nLY (cumulative)\n\n\n\n\n0\n1.000\n0.000\n0.000\n1*0.5\n0.5\n\n\n1\n0.856\n0.138\n0.007\n0.993\n0.5 + 0.993 = 1.493\n\n\n2\n0.732\n0.253\n0.015\n0.985\n2.478\n\n\n3\n0.626\n0.349\n0.025\n0.975\n3.454\n\n\n4\n0.536\n0.429\n0.035\n0.965\n4.419\n\n\n5\n0.458\n0.495\n0.046\n0.954\n5.372\n\n\n…\n…\n…\n…\n…\n…\n\n\n75 (End)\n0\n0.282\n0.718\n0.282 *0.5\n44.184\n\n\n\n\n\n\n\n\n\n\n\n\nThis number is smaller than our original estimate without half-cycle correction (44.825!)"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#summary",
    "href": "lectures/lec_7.MarkovModels1.html#summary",
    "title": "Markov Models",
    "section": "Summary",
    "text": "Summary\n\nOnce we have total (discounted, half-cycle corrected) outcomes for each strategy, we can turn to conducting incremental cost-effectiveness analysis.\nWe covered these methods yesterday!"
  },
  {
    "objectID": "lectures/lec_7.MarkovModels1.html#markov-models-5",
    "href": "lectures/lec_7.MarkovModels1.html#markov-models-5",
    "title": "Markov Models",
    "section": "Markov Models",
    "text": "Markov Models\n\n\n\n\n\n\n\nPros\nCons\n\n\n\n\nCan model repeated events\nCan only transition once in a given cycle\n\n\nCan model more complex + longitudinal clinical events\nShortening the cycle can create computational challenges.\n\n\nNot computationally intensive; efficient to model and debug\nShortening cycle can cause “state explosion” if tunnel states are used"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#learning-objectives",
    "href": "lectures/lec_advanced-modeling-techniques.html#learning-objectives",
    "title": "Advanced Modeling Techniques",
    "section": "Learning Objectives",
    "text": "Learning Objectives\n\nBe able to understand the basic concepts and identify the strengths and limitations of alternative modeling techniques, including:\n\n\nMicrosimulation (Monte Carlo simulation)\nDiscrete event simulation\nInfectious disease (dynamic) models"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#outline",
    "href": "lectures/lec_advanced-modeling-techniques.html#outline",
    "title": "Advanced Modeling Techniques",
    "section": "Outline",
    "text": "Outline\n\nMicrosimulation (Monte Carlo simulation)\nDiscrete event simulation\nInfectious disease (dynamic) models\nComparison of model types"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#microsimulation-models",
    "href": "lectures/lec_advanced-modeling-techniques.html#microsimulation-models",
    "title": "Advanced Modeling Techniques",
    "section": "Microsimulation models",
    "text": "Microsimulation models\n\nMarkov simulation\n\nFocuses on the average: essentially assuming infinite cohort of individuals transitions through the model simultaneously to obtain the expected values\n\nMicrosimulation\n\nSynonyms = stochastic microsimulation, individual-based model, 1st order Monte Carlo simulation\nHypothetical individuals transition through the model, one at a time"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#steps",
    "href": "lectures/lec_advanced-modeling-techniques.html#steps",
    "title": "Advanced Modeling Techniques",
    "section": "Steps",
    "text": "Steps\n\nDetermine initial state, using the distribution of starting probabilities\n\ne.g. probability of starting in sick/healthy\n\nSimulate individual trajectory through health states, using random numbers to determine actual transitions (yes/no) from transition probabilities\nRecord # of cycles in each state\nRepeat steps 1-3 many times (N)\nCalculate mean # of cycles from sample of N\n\nCan weight states by utility, cost, discount factor (same as with Markov models)"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#random-numbers",
    "href": "lectures/lec_advanced-modeling-techniques.html#random-numbers",
    "title": "Advanced Modeling Techniques",
    "section": "Random numbers",
    "text": "Random numbers"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#markov-cohort-vs-microsimulation",
    "href": "lectures/lec_advanced-modeling-techniques.html#markov-cohort-vs-microsimulation",
    "title": "Advanced Modeling Techniques",
    "section": "Markov cohort vs Microsimulation",
    "text": "Markov cohort vs Microsimulation\n[Shift to Powerpoint…]"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#example",
    "href": "lectures/lec_advanced-modeling-techniques.html#example",
    "title": "Advanced Modeling Techniques",
    "section": "Example",
    "text": "Example\nContext: Economic evaluation of TB prevention among people living with HIV in Tanzania\n\n\n\nZhu et al., The Lancet Global Health, 2022"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#example-1",
    "href": "lectures/lec_advanced-modeling-techniques.html#example-1",
    "title": "Advanced Modeling Techniques",
    "section": "Example",
    "text": "Example\n\nTB accounts for &gt;25% deaths among people living with HIV\nIsoniazid preventive therapy (IPT) can prevent TB among people receiving antiretroviral therapy (ART)\nHIV programmes are now initiating patients on ART with higher average CD4 cell counts and lower tuberculosis risks under test-and-treat guidelines\nWe aimed to investigate how this change has affected the health impact and cost-effectiveness of IPT"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#example-2",
    "href": "lectures/lec_advanced-modeling-techniques.html#example-2",
    "title": "Advanced Modeling Techniques",
    "section": "Example",
    "text": "Example\n\nZhu et al, The Lancet Global Health, 2022"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#example-3",
    "href": "lectures/lec_advanced-modeling-techniques.html#example-3",
    "title": "Advanced Modeling Techniques",
    "section": "Example",
    "text": "Example\n\n\n\n\n\n\n\nWhy choose a microsimulation model?\n\n\n\n\n\nIndividual-level characteristics on age, sex, CD4 cell count\nTracking individual trajectory is crucial for this question\n\nCD4 cell counts change with HIV treatment\nEvent rates (mortality and TB progression rates) are dependent on CD4 cell counts\n\nA markov cohort model wouldn’t be able to capture these complex mechanisms!"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#microsimulation-vs-des",
    "href": "lectures/lec_advanced-modeling-techniques.html#microsimulation-vs-des",
    "title": "Advanced Modeling Techniques",
    "section": "Microsimulation vs DES",
    "text": "Microsimulation vs DES\n\n\nMiscrosimulation\n\n\n\n\n\n\n\n\n\nDiscrete event simulation"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#des",
    "href": "lectures/lec_advanced-modeling-techniques.html#des",
    "title": "Advanced Modeling Techniques",
    "section": "DES",
    "text": "DES\n\n\nSimilar to microsimulation, DES simulates one individual at a time \\rightarrow Subject to stochasticity\nDifferent from microsimulation (where time is discretized), DES models time continuously\nPros:\n\nFaster: Skips unnecessary cycles where no events happen\nMore natural to implement when data are presented as time-to-event distributions (wait time, length of stay in hospital, onset-to-treatment time for acute conditions)\n\nCons:\n\nLess intuitive: “time to death is sampled from a Weibull distribution of shape = 2.72, scale = 58.5” (DES) vs. “the probability of death in year 1 is 0.038” (Microsim)\nThose time steps may be useful even if there’s no event! (In the HIV/TB example, CD4 cell count is updated every cycle to recalculate TB and death risks)"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#example-4",
    "href": "lectures/lec_advanced-modeling-techniques.html#example-4",
    "title": "Advanced Modeling Techniques",
    "section": "Example",
    "text": "Example"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#example-5",
    "href": "lectures/lec_advanced-modeling-techniques.html#example-5",
    "title": "Advanced Modeling Techniques",
    "section": "Example",
    "text": "Example\n\nGraves et al, 2017"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#why-dynamic-models",
    "href": "lectures/lec_advanced-modeling-techniques.html#why-dynamic-models",
    "title": "Advanced Modeling Techniques",
    "section": "Why dynamic models?",
    "text": "Why dynamic models?\n\nSo far all model types we discussed assume that individuals in the model cohort experience events independently\n\nAppropriate assumption for most chronic disease models\n\nBut what about infectious diseases (e.g. COVID) where individuals interact with each other?\n\nE.g. the risk of acquiring COVID for a healthy (susceptible) individual depends on how many individuals current have COVID in the population"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#the-sir-model",
    "href": "lectures/lec_advanced-modeling-techniques.html#the-sir-model",
    "title": "Advanced Modeling Techniques",
    "section": "The SIR model",
    "text": "The SIR model\nThe most classic model in infectious disease epidemiology. Appropriate for many common infectious diseases (e.g., the flu)."
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#the-sir-model-1",
    "href": "lectures/lec_advanced-modeling-techniques.html#the-sir-model-1",
    "title": "Advanced Modeling Techniques",
    "section": "The SIR model",
    "text": "The SIR model\n\nSource: Vynnycky, Emilia; White, Richard. An Introduction to Infectious Disease Modelling."
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#variants-of-the-sir-model",
    "href": "lectures/lec_advanced-modeling-techniques.html#variants-of-the-sir-model",
    "title": "Advanced Modeling Techniques",
    "section": "Variants of the SIR model",
    "text": "Variants of the SIR model\n\nFrom the simple SIR process, we can add more stuctures to reflect the process of a particular disease, for example:\n\nAge- or sex- mixing: appropriate for sexually transmitted diseases\nA stage where individuals are infected but not infectious: appropriate for diseases with a latent stage, e.g., TB, COVID-19"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#section",
    "href": "lectures/lec_advanced-modeling-techniques.html#section",
    "title": "Advanced Modeling Techniques",
    "section": "",
    "text": "Dynamic models are often expressed/solved as difference/differential equations\n\n\nExample:\n\n\n\n\n\n\nThey can be solved by hand or using softwares (e.g. deSolve package in R)"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#comparison-of-model-types",
    "href": "lectures/lec_advanced-modeling-techniques.html#comparison-of-model-types",
    "title": "Advanced Modeling Techniques",
    "section": "Comparison of model types",
    "text": "Comparison of model types\n\n\n\n\n\n\n\n\n\nModel Type\nStrengths\nLimitations\n\n\n\n\nDecision tree\nTransparent\nStraightforward calculations\nDifficult to capture progression over time or repeated events\n\n\nMarkov cohort\nAble to capture repeated events over time\nFast run speed\nDifficult to capture individual heterogeneity or track history of events\nHard to handle complicated disease process (subject to state explosion)"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#comparison-of-model-types-1",
    "href": "lectures/lec_advanced-modeling-techniques.html#comparison-of-model-types-1",
    "title": "Advanced Modeling Techniques",
    "section": "Comparison of model types",
    "text": "Comparison of model types\n\n\n\n\n\n\n\n\n\nModel Type\nStrengths\nLimitations\n\n\n\n\nDecision tree\nTransparent\nStraightforward calculations\nDifficult to capture progression over time or repeated events\n\n\nMarkov cohort\nAble to capture repeated events over time\nFast run speed\nDifficult to capture individual heterogeneity or track history of events\nHard to handle complicated disease process (subject to state explosion)\n\n\nMicrosimulation\nEasy to track history\nVery powerful and flexible\nRequires a large number of runs to converge\nSlowest run speed"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#comparison-of-model-types-2",
    "href": "lectures/lec_advanced-modeling-techniques.html#comparison-of-model-types-2",
    "title": "Advanced Modeling Techniques",
    "section": "Comparison of model types",
    "text": "Comparison of model types\n\n\n\n\n\n\n\n\n\nModel Type\nStrengths\nLimitations\n\n\n\n\nDecision tree\nTransparent\nStraightforward calculations\nDifficult to capture progression over time or repeated events\n\n\nMarkov cohort\nAble to capture repeated events over time\nFast run speed\nDifficult to capture individual heterogeneity or track history of events\nHard to handle complicated disease process (subject to state explosion)\n\n\nMicrosimulation\nEasy to track history\nVery powerful and flexible\nRequires a large number of runs to converge\nSlowest run speed\n\n\nDiscrete event simulation\nEasy to track history\nFaster than microsimulation\nRequires a large number of runs to converge\nTime-to-event distributions are less intuitive and harder to obtain than event rates/probabilities"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#comparison-of-model-types-3",
    "href": "lectures/lec_advanced-modeling-techniques.html#comparison-of-model-types-3",
    "title": "Advanced Modeling Techniques",
    "section": "Comparison of model types",
    "text": "Comparison of model types\n\n\n\n\n\n\n\n\n\nModel Type\nStrengths\nLimitations\n\n\n\n\nDecision tree\nTransparent\nStraightforward calculations\nDifficult to capture progression over time or repeated events\n\n\nMarkov cohort\nAble to capture repeated events over time\nFast run speed\nDifficult to capture individual heterogeneity or track history of events\nHard to handle complicated disease process (subject to state explosion)\n\n\nMicrosimulation\nEasy to track history\nVery powerful and flexible\nRequires a large number of runs to converge\nSlowest run speed\n\n\nDiscrete event simulation\nEasy to track history\nFaster than microsimulation\nRequires a large number of runs to converge\nTime-to-event distributions are less intuitive and harder to obtain than event rates/probabilities\n\n\nDynamic\nAble to capture transmission of disease\nMore data requirements (e.g. contact patterns in populaton)\nMore black-box"
  },
  {
    "objectID": "lectures/lec_advanced-modeling-techniques.html#how-to-choose-the-right-model-1",
    "href": "lectures/lec_advanced-modeling-techniques.html#how-to-choose-the-right-model-1",
    "title": "Advanced Modeling Techniques",
    "section": "How to choose the right model?",
    "text": "How to choose the right model?\nFactors to consider:\n\nPolicy question/interventions\nData availability\nNatural history of disease\nComputational resources available\n\n\n\n\n\nBack to Website"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#objetivos-de-aprendizaje",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#objetivos-de-aprendizaje",
    "title": "Árboles de decisión y probabilidades",
    "section": "Objetivos de aprendizaje",
    "text": "Objetivos de aprendizaje\n\nConstruir y resolver un problema de decisión calculando el el valor esperado de una intervención entre estrategias competidoras en un árbol de decisión\nDeterminar el umbral de decisión en una serie de escenarios\nDiferenciar entre probabilidades conjuntas y condicionales y demostrar su uso en árboles de decisión"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#esquema",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#esquema",
    "title": "Árboles de decisión y probabilidades",
    "section": "Esquema",
    "text": "Esquema\n\n\n\nEstructura\nRevisión de probabilidades\nProbabilidades en los árboles de decisión\n\n\n\nPuntos fuertes/limitaciones de los árboles de decisión"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#recapitulación-análisis-de-decisión",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#recapitulación-análisis-de-decisión",
    "title": "Árboles de decisión y probabilidades",
    "section": "Recapitulación: Análisis de decisión",
    "text": "Recapitulación: Análisis de decisión\n\n\n\nTiene como objetivo informar la elección bajo incertidumbre utilizando un enfoque explícito, enfoque cuantitativo\nTiene como objetivo identificar, medir y valorar las consecuencias de las decisiones (riesgos/beneficios) y la incertidumbre cuando hay que tomar una decisión, más apropiadamente a lo largo del tiempo"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debo-ir-a-la-playa-o-quedarme-en-casa-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debo-ir-a-la-playa-o-quedarme-en-casa-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Debo ir a la playa o quedarme en casa?",
    "text": "¿Debo ir a la playa o quedarme en casa?\nPosibles estados del mundo:\n\n\nEn la playa sin lluvia.\nEn la playa con lluvia.\nEn casa sin lluvia.\nEn casa con lluvia."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Debería ir a la playa o quedarme en casa?",
    "text": "¿Debería ir a la playa o quedarme en casa?\nConsideraciones:\n\n\nProbabilidad de lluvia\nMi bienestar general cuando\n\nEn la playa sin lluvia.\nEn la playa con lluvia.\nEn casa sin lluvia.\nEn casa con lluvia."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Debería ir a la playa o quedarme en casa?",
    "text": "¿Debería ir a la playa o quedarme en casa?\nConsideraciones:\n\n\nProbabilidad de lluvia –&gt; probabilidades\nMi bienestar general cuando\n\nEn la playa sin lluvia.\nEn la playa con lluvia.\nEn casa sin lluvia.\nEn casa con lluvia."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-2",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-2",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Debería ir a la playa o quedarme en casa?",
    "text": "¿Debería ir a la playa o quedarme en casa?\nConsideraciones:\n\n\nProbabilidad de lluvia –&gt; probabilidades\nMi bienestar general cuando\n\nEn la playa sin lluvia. –&gt; probabilidades\nEn la playa con lluvia. –&gt; En casa sin lluvia.\nEn casa sin lluvia. –&gt; En casa sin lluvia.\nEn casa con lluvia. –&gt; En casa con lluvia."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#árboles-de-decisión",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#árboles-de-decisión",
    "title": "Árboles de decisión y probabilidades",
    "section": "Árboles de decisión",
    "text": "Árboles de decisión\n\n\n\n\nUn nodo de decisión cuadrado indica un punto de decisión entre opciones alternativas.\nUn nodo de azar circular indica un punto en el que son posibles dos o más alternativas para un paciente."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#árboles-de-decisión-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#árboles-de-decisión-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Árboles de decisión",
    "text": "Árboles de decisión\n\n\n\nUn nodo de decisión cuadrado indica un punto de decisión entre opciones alternativas.\nUn nodo de azar circular indica un punto en el que son posibles dos o más alternativas para un paciente.\n\n\n\n\n\n\n\nEmpezamos con un nodo de decisión – que sólo muestra visualmente el punto de decisión (por lo que no se adjuntan probabilidades aquí)\nA partir de nuestro nodo de decisión, crearemos nodos de azar, o nodos de probabilidad, para modelar las probabilidades de nuestras diferentes opciones\nLos sucesos correspondientes de los nodos de azar deben sumar 1 según según la “ley de la probabilidad total”"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#árboles-de-decisión-2",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#árboles-de-decisión-2",
    "title": "Árboles de decisión y probabilidades",
    "section": "Árboles de decisión",
    "text": "Árboles de decisión\n\n\nLos caminos son secuencias de sucesos mutuamente excluyentes y son las rutas a través del árbol.\nLas probabilidades muestran la probabilidad de que ocurra un suceso concreto en un nodo de azar."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-3",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-3",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Debería ir a la playa o quedarme en casa?",
    "text": "¿Debería ir a la playa o quedarme en casa?\nÁrbol de decisión:\n\n\n\nLos resultados que nos importan para este modelo son LLUVIA frente a NO LLUVIA, por lo que añadimos que al final de nuestras ramas, que representan la nodos terminales – o los estados finales de nuestro modelo"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-4",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-4",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Debería ir a la playa o quedarme en casa?",
    "text": "¿Debería ir a la playa o quedarme en casa?\nÁrbol de decisión:\n\n\n\nLa probabilidad de lluvia es del 30% - tanto si te quedas en casa como si vas a la playa & sabemos que las ramas tienen que sumar 1 debido a la ley de la probabilidad total\nSin embargo, no hemos terminado todavía, ya que sería útil si tuviéramos alguna manera de VALORAR los resultados - en términos de decir, la lluvia en la playa, frente a si lloviera en casa, etc.\nSi no le das valor a los diferentes resultados, entonces estamos diciendo esencialmente que valoramos la LLUVIA. esencialmente diciendo que valoramos igual la LLUVIA frente a la NO LLUVIA entre las opciones playa y casa\nPero si tuviera que adivinar, esto probablemente no es cierto a menos que usted es el que le guste tanto la lluvia en la playa como en casa). casa)"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-5",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debería-ir-a-la-playa-o-quedarme-en-casa-5",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Debería ir a la playa o quedarme en casa?",
    "text": "¿Debería ir a la playa o quedarme en casa?\nPayoffs\n\n\n\nEscenario\nPayoff\n\n\n\n\nEn la playa, sin lluvia 1.0\n\n\n\nEn la playa, lluvia 0.4\n\n\n\nEn casa, sin lluvia 0,8\n\n\n\nEn casa, lluvia 0,6\n\n\n\n\n\nEn la playa, no llueve &gt; En casa, no llueve &gt; En casa, llueve &gt; En la playa, llueve\n\n\n\nEntraremos en esto más adelante, pero las utilidades se miden entre 0 y 1.\nPara los estados de salud, por ejemplo, 0 = peor salud y 1 = perfecta salud\nAquí, estamos valorando “playa, sin lluvia” como el “estado más ideal” en el que queremos estar. en el que queremos estar"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debo-ir-a-la-playa-o-quedarme-en-casa-2",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#debo-ir-a-la-playa-o-quedarme-en-casa-2",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Debo ir a la playa o quedarme en casa?",
    "text": "¿Debo ir a la playa o quedarme en casa?\nÁrbol de decisión:"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#cuál-es-el-valor-esperado-de-ir-a-la-playa",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#cuál-es-el-valor-esperado-de-ir-a-la-playa",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Cuál es el valor esperado de ir a la playa?",
    "text": "¿Cuál es el valor esperado de ir a la playa?\n\n\n\\color{verde}{0,82} = \\color{rojo}{0,3} * \\color{blue}{0.4}}_{\\text{Rain}} + \\underbrace {color{rojo} {0,7} * \\color{azul} {1,0} {{texto{sin lluvia}}\n\nProbabilidades en rojo.\nPagos en azul.\nValor esperado en verde."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#cuál-es-el-valor-esperado-de-quedarse-en-casa",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#cuál-es-el-valor-esperado-de-quedarse-en-casa",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿Cuál es el valor esperado de quedarse en casa?",
    "text": "¿Cuál es el valor esperado de quedarse en casa?\n\n\n0,74 = 0,3. }_{} + …rojo, 0,7… ...sin lluvia…\n\nProbabilidades en rojo.\nPagos en azul.\nValor esperado en verde."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#valores-esperados",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#valores-esperados",
    "title": "Árboles de decisión y probabilidades",
    "section": "Valores esperados",
    "text": "Valores esperados\n\nValor esperado = La suma de las probabilidades multiplicadas para cada opción de azar o intervención\n\n\n\nEcuación: 1 a infinito – representa el infinito # de ramas en el árbol de decisión. En nuestro ejemplo, sólo teníamos 2 ramas, pero si tuviera 3 o 4 o 5 … que lo representaría como i = 3, 4, 5 y luego se multiplican las probabilidades.\nXi = resultado y P = probabilidad"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#valores-esperados-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#valores-esperados-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Valores Esperados",
    "text": "Valores Esperados\n\n\n\nEl valor esperado en el contexto de los árboles de decisión son los “payoffs” ponderados por sus probabilidades precedentes\nLo que obtenemos es: el resultado que se espera EN PROMEDIO para cualquier alternativa de decisión (por ejemplo, duración de la vida, calidad de vida, costes vida)\n\nEjemplo: Por término medio, los pacientes que reciban el tratamiento A vivirán 0,30 años más que los pacientes que reciban el tratamiento B\n\n\n\n\n\n\n\n\n\n\nMaximizar el valor esperado es un criterio razonable de elección ante perspectivas inciertas; aunque no necesariamente promete los mejores resultados para un individuo."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad p son iguales las dos opciones?",
    "text": "¿A qué probabilidad p son iguales las dos opciones?\n\nSupongamos que queremos saber a qué probabilidad de lluvia p nos es indiferentes entre ir a la playa o quedarnos en casa…\n\n\n\nEscribe la ecuación para cada elección utilizando una variable, p, para la probabilidad en cuestión\nEstablece las ecuaciones iguales entre sí y resuelve para p."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad p son iguales las dos opciones?",
    "text": "¿A qué probabilidad p son iguales las dos opciones?\nPlaya: 0.82 = 0.3 x 0.4 + 0.7 x 1.0\nCasa: 0.74 = 0.3 x 0.6 + 0.7 x 0.8"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-2",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-2",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad p son iguales las dos opciones?",
    "text": "¿A qué probabilidad p son iguales las dos opciones?\n{underbrace{0.3 * 0.4 + 0.7 * 1.0}_{\\text{Playa}} = \\underbrace{0.3 * 0.6 + 0.7 * 0.8}_{\\text{Casa}}"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-3",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-3",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad p son iguales las dos opciones?",
    "text": "¿A qué probabilidad p son iguales las dos opciones?\nSustituya la probabilidad de lluvia por P y 1-P y resuelva para “P”\n\np * 0.4 + (1-p) * 1.0 = p * 0.6 + (1-p) * 0.8\n\n\\underbrace{0,3 * 0,4 + 0,7 * 1,0}_{texto{Playa}} = \\underbrace{0,3 * 0,6 + 0,7 * 0,8}_{texto{Casa}}"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-4",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-4",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad p son iguales las dos opciones?",
    "text": "¿A qué probabilidad p son iguales las dos opciones?\np * 0.4 + (1-p) * 1.0 = p * 0.6 + (1-p) * 0.8"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-5",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-5",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad p son iguales las dos opciones?",
    "text": "¿A qué probabilidad p son iguales las dos opciones?\np * 0.4 + (1-p) * 1.0 = p * 0.6 + (1-p) * 0.8\n\n0,4p + 1-p = 0,6p + 0,8 - 0,8p\n1-0,6p = 0,8 - 0,2p\n1-0,8 = 0,6p - 0,2p\n0.2 = 0.4 * p\n0.5 = p"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-6",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p-son-iguales-las-dos-opciones-6",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad p son iguales las dos opciones?",
    "text": "¿A qué probabilidad p son iguales las dos opciones?\n\nCuando la probabilidad de lluvia es del 50% TANTO en la playa como en casa, dado cómo hemos ponderado los resultados, ir a la playa sería lo mismo que quedarse en casa\n\n\n\nEn otras palabras, usted sería indiferente entre los dos – permanecer en casa o ir a la playa"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-entre-las-dos-opciones",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-entre-las-dos-opciones",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente entre las dos opciones?",
    "text": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente entre las dos opciones?"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-una-de-las-dos-opciones",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-una-de-las-dos-opciones",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente una de las dos opciones?",
    "text": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente una de las dos opciones?\n\n\n\nAntes hemos calculado el beneficio esperado de quedarse en casa: 0,74 (que era un valor esperado menor que ir a la playa cuando la probabilidad de lluvia en ambos era del 30%) \n¿Cuál tendría que ser** p_B para obtener una recompensa esperada en la playa playa de 0,74?\n\nEn otras palabras, ¿con qué probabilidad de lluvia en la playa ¿le resultaría indiferente quedarse en casa o ir a la playa?\n\n\n\n\n\n\nFormulemos ahora una pregunta ligeramente distinta. probabilidad….\nSupongamos ahora que la probabilidad de lluvia para la opción CASA no cambia (por lo que se mantiene en 0,3)\nDIFERENCIA CLAVE CON RESPECTO AL ÚLTIMO EJEMPLO: En el último ejemplo, las probabilidades eran las mismas y queríamos obtener nuestro umbral de indiferencia entre la playa y quedarse en casa\n**Ahora estamos suponiendo que todavía hay una probabilidad del 30% de que que llueva si te quedas en casa, pero ¿a qué probabilidad de lluvia en la playa te sería indiferente entre las dos opciones? (Puesto que elegimos la playa cuando ambas probabilidades eran iguales al 30%)\n\n\nEn otras palabras, ¿con qué probabilidad de LLOVER EN LA PLAYA sería indiferente entre la playa y su casa"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-te-es-indiferente-entre-las-dos-opciones",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-te-es-indiferente-entre-las-dos-opciones",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad (p_B) de lluvia para la playa te es indiferente entre las dos opciones?",
    "text": "¿A qué probabilidad (p_B) de lluvia para la playa te es indiferente entre las dos opciones?\nFije 0,74 (valor esperado de quedarse en casa) igual a la playa y resuelva para p_B.\n\npB * 0.4 + (1 - pB) * 1.0 = 0.74"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-una-de-las-dos-opciones-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-una-de-las-dos-opciones-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente una de las dos opciones?",
    "text": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente una de las dos opciones?\n\npB * 0.4 + (1 - pB) * 1.0 = 0.74\n\n\npB * 0.4 + 1 - pB = 0.74"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-entre-las-dos-opciones-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-entre-las-dos-opciones-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente entre las dos opciones?",
    "text": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente entre las dos opciones?\n\npB * 0.4 + 1 - pB = 0.74\n\n\npB * -0.6 = -0.26"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-entre-las-dos-opciones-2",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-le-es-indiferente-entre-las-dos-opciones-2",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente entre las dos opciones?",
    "text": "¿A qué probabilidad (p_B) de lluvia para la playa le es indiferente entre las dos opciones?\n\npB * -0.6 = -0.26\n\n\npB = -0.26 / -0.6 = 0.43"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-te-es-indiferente-entre-las-dos-opciones-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#a-qué-probabilidad-p_b-de-lluvia-para-la-playa-te-es-indiferente-entre-las-dos-opciones-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "¿A qué probabilidad (p_B) de lluvia para la playa te es indiferente entre las dos opciones?",
    "text": "¿A qué probabilidad (p_B) de lluvia para la playa te es indiferente entre las dos opciones?\n\nCuando la probabilidad de lluvia en la playa es del 43% (la probabilidad de lluvia en casa se mantiene en el 30%), nos sería indiferente quedarnos en casa e ir a la playa.\n\n\nSi la probabilidad de que llueva en la playa es &gt; &gt; del 43%, nos quedaríamos en &gt; casa. casa"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades-en-árboles-de-decisión",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades-en-árboles-de-decisión",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidades en Árboles de Decisión",
    "text": "Probabilidades en Árboles de Decisión\nEventos mutuamente excluyentes\n\n\n2 cosas que no pueden ocurrir juntas (un suceso no puede ocurrir al mismo mismo tiempo que el otro)\n\nEjemplo: 2 sucesos, sobrevivir o morir; mutuamente excluyentes porque una persona no puede ser ambas cosas a la vez\nEjemplo: 2 sucesos, curado o no curado"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades-dentro-de-los-árboles-de-decisión",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades-dentro-de-los-árboles-de-decisión",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidades dentro de los árboles de decisión",
    "text": "Probabilidades dentro de los árboles de decisión\nSucesos mutuamente excluyentes"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades-dentro-de-los-árboles-de-decisión-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades-dentro-de-los-árboles-de-decisión-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidades dentro de los árboles de decisión",
    "text": "Probabilidades dentro de los árboles de decisión\nSucesos mutuamente excluyentes\n\nSuponiendo que los sucesos sean mutuamente excluyentes, la probabilidad de que ocurran 2 2 sucesos es la suma de las probabilidades de cada suceso ocurra individualmente\n\n\nP(A o B) = P(A) + P(B)"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades-en-árboles-de-decisión-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades-en-árboles-de-decisión-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidades en árboles de decisión",
    "text": "Probabilidades en árboles de decisión\n\n\n\n\n\n\nProbabilidad conjunta\n\n\nP(A y B): La probabilidad de que dos eventos ocurran al mismo tiempo.\n\n\n\n\n\n\n\n\n\nProbabilidad condicional\n\n\nP(A|B): La probabilidad de un suceso A dado que se sabe que ha ocurrido un suceso B. ha ocurrido."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidades",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidades",
    "text": "Probabilidades\n\n\nDesplazándose de izquierda a derecha, las primeras probabilidades del árbol muestran la probabilidad de un suceso.\nLas probabilidades siguientes son condicionales.\n\nLa probabilidad de un suceso dado que un suceso anterior ocurrió o no haya ocurrido.\n\nAl multiplicar las probabilidades a lo largo de las rutas se calcula la probabilidad de la ruta que es una probabilidad conjunta."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#caminos",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#caminos",
    "title": "Árboles de decisión y probabilidades",
    "section": "Caminos",
    "text": "Caminos\n\nCaminos = secuencia de acontecimientos que conducen a un “pago” posterior\nEn otras palabras, una secuencia de acontecimientos conduce a un resultado/consecuencia, o recompensa\nEjemplo: Nuestro ejemplo de la playa tiene 4 caminos."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#caminos-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#caminos-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Caminos",
    "text": "Caminos\n\nCamino A: Esta persona va a la playa pero llueve\nCamino B: Esta persona va a la playa pero no llueve"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidad condicional",
    "text": "Probabilidad condicional\nEjemplo: ¿Cuál es la probabilidad condicional de muerte al año de nacimiento, dado que el bebé tiene una madre fumadora?\n(Probabilidad de que ocurra un suceso (B) dado que ha ocurrido otro suceso (A))\n\nP(A|B) = P(A y B) / P(B)"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidad condicional, revisión 2x2",
    "text": "Probabilidad condicional, revisión 2x2\n\n¿Cuál es la probabilidad condicional de muerte al año de nacer, dado que el bebé tiene una madre fumadora?\n\n*A= muerte en el primer año; B= madre fumadora.\nP(A|B) = 16.712 / (1.197.142 + 16.712)  = 14 por cada 1.000 nacimientos"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidad condicional, revisión 2x2",
    "text": "Probabilidad condicional, revisión 2x2\n\nO, si quisiéramos utilizar la ecuación de probabilidad condicional\n\nP(A|B) = P(A y B)/P(B)  *A= muerte en primer año; B=madre fumadora \nP(A y B) = 16.712 / 4.111.059 = 0,0041  P(B) = 1.213.854/4.111.059 = 0,295  P(A|B) = 0.0041/0.295 = 0.014"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-2x2-revisión",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-2x2-revisión",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidad condicional, 2x2 revisión",
    "text": "Probabilidad condicional, 2x2 revisión\n\nProbabilidad de A|B es diferente de la de B|A\n\nSi A = muerte en el primer año; B=bebé con peso normal al nacer, entonces la probabilidad condicional de P(A|B) = la probabilidad de muerte del niño dado que el niño tiene un peso normal al nacer"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-2",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-2",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidad condicional, revisión 2x2",
    "text": "Probabilidad condicional, revisión 2x2\n\n¿Cuál es la probabilidad condicional de muerte de un bebé, dado que el niño tiene un peso normal al nacer\n\nSi A = muerte en el primer año; B=niño con peso normal al nacer \nP(A|B) = 14.442 / (14.442+ 3.804.294)  = 3,8 muertes por cada 1.000 nacimientos"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-3",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-3",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidad condicional, revisión 2x2",
    "text": "Probabilidad condicional, revisión 2x2\n\nO, si quisiéramos utilizar la ecuación\n\nP(A|B) = P(A y B)/P(B)\n\nP(A y B) = 14,442  P(B) = 3.818.736  P(A|B) = 14,442/3,818,736 = 0.0038"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-4",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-4",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidad condicional, revisión 2x2",
    "text": "Probabilidad condicional, revisión 2x2\n\nPor otra parte, la probabilidad condicional de P(B|A) es la probabilidad de que un bebé tenga un peso normal al nacer, dado que el murió en el plazo de 1 año desde su nacimiento\n\nB=bebé con peso normal al nacer; A = muerte en el primer año."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-5",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#probabilidad-condicional-revisión-2x2-5",
    "title": "Árboles de decisión y probabilidades",
    "section": "Probabilidad condicional, revisión 2x2",
    "text": "Probabilidad condicional, revisión 2x2\nResuelve P(B|A) – la probabilidad de que un infante tuviera peso normal al nacer dado que el bebé murió en el primer año desde su nacimiento\n\nP(B|A) = 14,442 / (14,442+ 21,054) = 0.41"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#filosofías-de-decisión",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#filosofías-de-decisión",
    "title": "Árboles de decisión y probabilidades",
    "section": "Filosofías de Decisión",
    "text": "Filosofías de Decisión\n\n\n\n\n\n\nMaximizar el valor esperado es un criterio razonable de elección dadas perspectivas inciertas; aunque no necesariamente promete los mejores resultados para cualquier individuo.\n\n\n\n\nMínimo-máximo arrepentimiento\nMáximo\nUtilidad esperada"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#filosofías-de-decisión-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#filosofías-de-decisión-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Filosofías de decisión",
    "text": "Filosofías de decisión\n\n\n\n\n\n\nMaximizar el valor esperado es un criterio razonable de elección dadas perspectivas inciertas; aunque no necesariamente promete los mejores resultados para cualquier individuo.\n\n\n\n\nEl arrepentimiento minimáximo\n\nNunca vayas a la playa si no llueve 0%.\n\nUtilidad máxima\nUtilidad esperada\n\n\n\nVeamos rápidamente las filosofías de decisión en lo que respecta a la ponderación de las preferencias. ponderación de preferencias. Existen diferentes niveles de aversión al riesgo & hay diferentes filosofías de decisión para estos comportamientos\nLa filosofía del arrepentimiento mini-max significa esencialmente que nunca irías a la playa si no llueve al 0%.\n\n\nPor ejemplo, los médicos pueden tener aversión al riesgo y, por tanto, minimizar el arrepentimiento máximo. pesar"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#decision-philosophies",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#decision-philosophies",
    "title": "Árboles de decisión y probabilidades",
    "section": "Decision Philosophies",
    "text": "Decision Philosophies\n\n\n\n\n\n\nMaximizar el valor esperado es un criterio razonable de elección dadas perspectivas inciertas; aunque no necesariamente promete los mejores resultados para cualquier individuo.\n\n\n\n\nEl arrepentimiento minimáximo\n\nNunca vayas a la playa si no llueve 0%.\n\nMaxi-max\n\nIr siempre a la playa a menos que llueva al 100%.\n\nUtilidad esperada\n\n\n(3)(a) La utilidad maxi-max es la inversa – donde siempre irías a la playa a menos que lloviera al 100% – buscas el riesgo – te gusta tanto la playa tanto que vas a intentarlo.\n(3)(b) Otro ejemplo de esto en un contexto médico es el ejemplo del paciente desesperado. desesperado: vas a morir de todos modos, así que te vamos a dar este este tratamiento, pero tiene efectos secundarios desagradables – cáncer – quimioterapias, incluso trasplantes de médula ósea, de segunda o tercera línea. alta probabilidad de un mal resultado, pero si no haces nada entonces vas a a morir."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#decision-philosophies-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#decision-philosophies-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Decision Philosophies",
    "text": "Decision Philosophies\n\n\n\n\n\n\nMaximizar el valor esperado es un criterio razonable de elección ante perspectivas inciertas; aunque no necesariamente promete los mejores resultados para cualquier individuo.\n\n\n\n\nEl arrepentimiento minimáximo\n\nNunca vayas a la playa si no llueve 0%.\n\nMaxi-max\n\nIr siempre a la playa a menos que llueva al 100%.\n\nUtilidad esperada\n\nDepende del tiempo.\n\n\nNotas (4) Si vas a basar tu decisión en la utilidad esperada, entonces tu depende del tiempo y del valor que le des a ciertos resultados. resultados – este es el enfoque del pensador racional – cuánto valoras la pérdida de utilidad de no disfrutar de la playa, por ejemplo. experiencia de ir a la playa, por ejemplo. :::"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#payoffs-1",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#payoffs-1",
    "title": "Árboles de decisión y probabilidades",
    "section": "Payoffs",
    "text": "Payoffs\n\n\nA cada estado del mundo se le asigna un coste o resultado.\nNuestro objetivo suele ser calcular el valor esperado de estos resultados.\nEn las próximas clases profundizaremos en las teorías y marcos que subyacen a los distintos resultados en las próximas clases"
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#puntos-fuertes",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#puntos-fuertes",
    "title": "Árboles de decisión y probabilidades",
    "section": "Puntos fuertes",
    "text": "Puntos fuertes\n\n\nSon fáciles de describir y entender\nFuncionan bien con un horizonte temporal limitado\nLos árboles de decisión son un marco potente para analizar decisiones y pueden proporcionar perspectivas rápidas/útiles, pero tienen limitaciones."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#limitaciones",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#limitaciones",
    "title": "Árboles de decisión y probabilidades",
    "section": "Limitaciones",
    "text": "Limitaciones\n\n\nNo tienen en cuenta explícitamente el paso del tiempo.\n\nLos sucesos recurrentes deben incorporarse por separado al modelo.\nEstá bien para ciclos de tiempo cortos (por ejemplo, 12 meses), pero a menudo queremos modelizar a lo largo de toda la vida.\n\nEs difícil incorporar detalles clínicos reales. La estructura de árbol puede volverse compleja rápidamente."
  },
  {
    "objectID": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#avance-de-lo-que-está-por-venir",
    "href": "lectures/ESP_lec_2.decision-trees-and-probabilities.html#avance-de-lo-que-está-por-venir",
    "title": "Árboles de decisión y probabilidades",
    "section": "Avance de lo que está por venir",
    "text": "Avance de lo que está por venir\n\n\n\n¡Un árbol más complejo!\n\n\n\n\n\n\nVolver al sitio web"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#learning-objectives",
    "href": "lectures/lec_6.ICERs.html#learning-objectives",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Learning Objectives",
    "text": "Learning Objectives\n\nDifferentiate between average & incremental CEA ratios\nCharacterize decision problems by whether they are competing or non-competing\nCompute and interpret ICERs\nPractice ruling out “dominated” and “extendedly dominated” strategies\nIdentify “high-value” versus “low value” care strategies, based on generally accepted cost-effectiveness thresholds"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#outline",
    "href": "lectures/lec_6.ICERs.html#outline",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Outline",
    "text": "Outline\n\n\n\n\nReview of CEA ratio\nNon-competing versus competing CEAs\nIncremental CEA\n\n\n\nDominance & extended dominance\nComparators\nCEA thresholds"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cost-effectiveness-analysis-1",
    "href": "lectures/lec_6.ICERs.html#cost-effectiveness-analysis-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Cost-Effectiveness Analysis",
    "text": "Cost-Effectiveness Analysis\n\n\nQuantifies how to maximize the quality & quantity of life from among competing alternatives, given restricted resources\nIt’s an explicit measure of value for money\nA POPULATION-LEVEL decision-making tool"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cost-effectiveness-analysis-is-not",
    "href": "lectures/lec_6.ICERs.html#cost-effectiveness-analysis-is-not",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Cost-Effectiveness Analysis IS NOT",
    "text": "Cost-Effectiveness Analysis IS NOT\n\n\nIndiscriminate cost-cutting\nDownsizing\nFor individual-level decision making\nThe only tool for decision-making"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cost-effectiveness-analysis-2",
    "href": "lectures/lec_6.ICERs.html#cost-effectiveness-analysis-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Cost-Effectiveness Analysis",
    "text": "Cost-Effectiveness Analysis\n\n\nCost of Intervention\n\n\nCost of Alternative\n\n\nBenefit of Intervention\n\n\nBenefit of Alternative"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cost-effectiveness-analysis-3",
    "href": "lectures/lec_6.ICERs.html#cost-effectiveness-analysis-3",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Cost-Effectiveness Analysis",
    "text": "Cost-Effectiveness Analysis\n\n\nCost of Intervention\n\n\nCost of Alternative\n\n\nBenefit of Intervention\n\n\nBenefit of Alternative"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cost-effectiveness-ratio",
    "href": "lectures/lec_6.ICERs.html#cost-effectiveness-ratio",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Cost-Effectiveness Ratio",
    "text": "Cost-Effectiveness Ratio\n\n\n\nCost of Intervention\n\n \\quad - \\quad \n\nCost of Alternative\n\n\n\\frac{\\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad}{\\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad}\n\n\nBenefit of Intervention\n\n \\quad - \\quad \n\nBenefit of Alternative"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cost-effectiveness-ratio-1",
    "href": "lectures/lec_6.ICERs.html#cost-effectiveness-ratio-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Cost-Effectiveness Ratio",
    "text": "Cost-Effectiveness Ratio\n\n\n\nC_1\n\n \\quad - \\quad \n\nC_0\n\n\n\\frac{\\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad}{\\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad \\quad}\n\n\nE_0\n\n \\quad - \\quad \n\nE_1"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cost-effectiveness-ratio-2",
    "href": "lectures/lec_6.ICERs.html#cost-effectiveness-ratio-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Cost-Effectiveness Ratio",
    "text": "Cost-Effectiveness Ratio\n\n\n\n\\Delta C\n\n\n\\frac{\\quad \\quad \\quad \\quad }{\\quad \\quad \\quad \\quad \\quad }\n\n\n\\Delta E"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cost-effectiveness-ratio",
    "href": "lectures/lec_6.ICERs.html#incremental-cost-effectiveness-ratio",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental Cost-Effectiveness Ratio",
    "text": "Incremental Cost-Effectiveness Ratio\nMost often used, since for most conditions there is already some available treatment.\n\n\n\n\nC_1: net present value of total lifetime costs of new treatment\nC_0: net present value of total lifetime costs of default treatment\nE_1: effectiveness of new treatment, measured in expected life expectancy, quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs), or some decision-relevant health outcome.\nE_0: effectiveness of default treatment\n\n\n\n\n\\frac{C_1 - C_0 \\quad  (\\Delta C)}{E_1 - E_0 \\quad  (\\Delta E)}"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#neurologic-disease-decision-tree",
    "href": "lectures/lec_6.ICERs.html#neurologic-disease-decision-tree",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Neurologic Disease Decision Tree",
    "text": "Neurologic Disease Decision Tree\n(From yesterday)"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#outcomes",
    "href": "lectures/lec_6.ICERs.html#outcomes",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Outcomes",
    "text": "Outcomes\n\nC_{treat} = expected cost of treat everyone strategy.\nC_{no treat} = expected cost of treat no one strategy.\nC_{biopsy} = expected cost of biopsy strategy."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#outcomes-1",
    "href": "lectures/lec_6.ICERs.html#outcomes-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Outcomes",
    "text": "Outcomes\n\nC_{treat} = expected cost of treat everyone strategy.\nC_{no treat} = expected cost of treat no one strategy.\nC_{biopsy} = expected cost of biopsy strategy.\nE_{treat} = expected life expectancy of treat everyone strategy.\nE_{no treat} = expected expectancy of treat no one strategy.\nE_{biopsy} = expected expectancy of biopsy strategy."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#outcomes-in-amua",
    "href": "lectures/lec_6.ICERs.html#outcomes-in-amua",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Outcomes in Amua",
    "text": "Outcomes in Amua"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#treat-all-vs.-treat-none",
    "href": "lectures/lec_6.ICERs.html#treat-all-vs.-treat-none",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Treat All vs. Treat None",
    "text": "Treat All vs. Treat None\nStrategy: Treat No One"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#treat-all-vs.-treat-none-1",
    "href": "lectures/lec_6.ICERs.html#treat-all-vs.-treat-none-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Treat All vs. Treat None",
    "text": "Treat All vs. Treat None\nStrategy: Treat All"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#key-takeaways-for-now",
    "href": "lectures/lec_6.ICERs.html#key-takeaways-for-now",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Key Takeaways (For Now)",
    "text": "Key Takeaways (For Now)\n\n\nTreatment yields higher life expectancy for those with disease, but comes at a cost.\nTreatment yields lower life expectancy for those without the disease, and also comes at a cost.\nBiopsy can help balance these two outcomes by better targeting treatment, but also comes with costs and risks.\nIncremental CEA provides a transparent framework for quantifying and weighing these considerations."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#average-cost-effectiveness-ratio",
    "href": "lectures/lec_6.ICERs.html#average-cost-effectiveness-ratio",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Average Cost-Effectiveness Ratio",
    "text": "Average Cost-Effectiveness Ratio\nSpecial case where C_0 and E_0 are assumed to be zero.\n\n\n\nC_1: net present value of total lifetime costs of new treatment\nC_0: Assumed zero\nE_1: effectiveness of new treatment, measured in expected life expectancy, quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs), or some decision-relevant health outcome.\nE_0: Assumed zero\n\n\n\n\n\\begin{aligned}\nICER &=  \\frac{C_1 - 0}{E_1 - 0} \\\\\n&= \\frac{C_1}{E_1 }\n\\end{aligned}"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#use-of-cea-in-two-situations",
    "href": "lectures/lec_6.ICERs.html#use-of-cea-in-two-situations",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Use of CEA in two situations",
    "text": "Use of CEA in two situations\n\nShopping Spree: Decision problem has non-competing programs/interventions.\n\n\nEach program is compared to a null alternative; therefore, you’re calculating an “average” cost-effectiveness ratio."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#use-of-cea-in-two-situations-1",
    "href": "lectures/lec_6.ICERs.html#use-of-cea-in-two-situations-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Use of CEA in two situations",
    "text": "Use of CEA in two situations\n\nCompeting Choice: Decision problem has competing programs/interventions for the same purpose; these choices are mutually exclusive.\n\n\nTwo or more active alternatives in addition to the null option.\nYou need to calculate an “incremental cost- effectiveness ratio”, which gives us the added cost per unit of added benefit of an option, relative to the next less expensive choice"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#non-competing-shopping-spree-decision-problem",
    "href": "lectures/lec_6.ICERs.html#non-competing-shopping-spree-decision-problem",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Non-Competing (Shopping Spree) Decision Problem",
    "text": "Non-Competing (Shopping Spree) Decision Problem\nHow can we measure the relative priority of various health programs that compete for limited resources?\n\n\nCardiovascular disease program\nSafe motherhood program\nHIV prevention initiative\nChild vaccination\nDepression screening"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#assumptions",
    "href": "lectures/lec_6.ICERs.html#assumptions",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Assumptions",
    "text": "Assumptions\n\n\nProgram alternatives are assumed to be independent\nBudget constraint is only limitation\nNeither the net cost nor the net effectiveness depend on what other programs are selected\nPrograms are assumed to be divisible [programs can be partially implemented]"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#objectives-shopping-spree-problem",
    "href": "lectures/lec_6.ICERs.html#objectives-shopping-spree-problem",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Objectives: Shopping Spree Problem",
    "text": "Objectives: Shopping Spree Problem\n{{&lt; fa circle-check &gt;}} Maximize the total net effectiveness (health benefit) of the programs selected.\n{{&lt; fa circle-check &gt;}} Stay within budget."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\n\n\n\nStep 1: - Rule out programs that cost $ but have negative health effects  - Dominated by alternative of “no program”"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-1",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\n\n\n\nStep 2:\n- Select programs that are cost-saving & offer benefit; net savings can also be added to budget  - Cost-saving compared to alternative of no program"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-2",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\n\n\n\nStep 3:\n- Rank other programs in ascending order by their cost-effectiveness ratio (lowest to highest)  - Programs are then selected from the LEAST to the MOST expensive until the budget is expended  - Final array of programs selected will depend on the budget constraint"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-3",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-3",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\nSteps 1 & 2: Rule out dominated options & select cost-saving interventions \n\n\n\n\n\nProgram\nCost\nQALYs\nStatus\n\n\n\n\nA\n27\n30\n\n\n\nB\n30\n20\n\n\n\nC\n56\n70\n\n\n\nD\n20\n40\n\n\n\nE\n30\n50\n\n\n\nF\n50\n75\n\n\n\nG\n40\n-30\nRuled Out\n\n\nH\n-20\n20\nAdopted"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-4",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-4",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\n\n\n\n\nInitial budget: $80\nBudget savings: $20.\nTotal budget: $80 + $20 = $100\n\n\n\n\n\n\n\n\nProgram\nCost\nQALYs\nStatus\n\n\n\n\nA\n27\n30\n\n\n\nB\n30\n20\n\n\n\nC\n56\n70\n\n\n\nD\n20\n40\n\n\n\nE\n30\n50\n\n\n\nF\n50\n75\n\n\n\nG\n40\n-30\nRuled Out\n\n\nH\n-20\n20\nAdopted"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-5",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-5",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\n\n\n\n\nCalculate average cost-effectiveness ratio.\n\n\n\n\n\n\n\n\nProgram\nCost\nQALYs\nC/E\n\n\n\n\nA\n27\n30\n0.90\n\n\nB\n30\n20\n1.50\n\n\nC\n56\n70\n0.80\n\n\nD\n20\n40\n0.50\n\n\nE\n30\n50\n0.60\n\n\nF\n50\n75\n0.67"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-6",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-6",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\n\n\n\nCalculate average cost-effectiveness ratio.\nSort (by C/E) in ascending order .\n\n\n\n\n\n\n\nProgram\nCost\nQALYs\nC/E\n\n\n\n\nD\n20\n40\n0.50\n\n\nE\n30\n50\n0.60\n\n\nF\n50\n75\n0.67\n\n\nC\n56\n70\n0.80\n\n\nA\n27\n30\n0.90\n\n\nB\n30\n20\n1.50\n\n\n\n\n\n\n\n\n\n\n\nWe want to order the RATIOS from lowest to highest for budget inclusion SINCE lower means we are gaining QALYs more efficiently – or gaining more benefit per dollar spent on care *****"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-7",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-7",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\n\n\nCalculate cumulative costs\nDetermine what is adoptable based on global budget constraint ($100)\nCalculate cumulative effects (QALYs)"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-8",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-8",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\nBudget: $100\n\n\n\n\n\nProgram\nCost\nQALYs\nC/E\nCumulative Cost\nCumulative QALYs\n\n\n\n\nD\n20\n40\n0.50\n20\n40\n\n\nE\n30\n50\n0.60\n50\n90\n\n\nF\n50\n75\n0.67\n100\n165\n\n\nC\n56\n70\n0.80\n156\n235\n\n\nA\n27\n30\n0.90\n183\n265\n\n\nB\n30\n20\n1.50\n213\n285"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-9",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-9",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\nBudget: $100\n\n\n\n\n\nProgram\nCost\nQALYs\nC/E\nCumulative Cost\nCumulative QALYs\n\n\n\n\nD\n20\n40\n0.50\n20\n40\n\n\nE\n30\n50\n0.60\n50\n90\n\n\nF\n50\n75\n0.67\n100\n165\n\n\nC\n56\n70\n0.80\n156\n235\n\n\nA\n27\n30\n0.90\n183\n265\n\n\nB\n30\n20\n1.50\n213\n285\n\n\n\n\n\n\n\n\n\n\n\n\nBudget\nAdopted\nEffect\nThreshold\n\n\n\n\n100\nD, E, F, H\n165\n0.67\n\n\n\n\n\n\n\n\n\nIf we have a budget of $100, then based on our program options, we could fund program D, E, & F – with a cumulative cost of $100\nTotal health benefit would include on average, 165 quality-adjusted life years gained from these programs together\n& we might then say that our cost effectiveness threshold would be at $0.667 per QALY gained – ** this represents the point at which the budget is “optimally” allocated given budget constraints\nMore on thresholds later"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-10",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-10",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\nBudget: $150\n\n\n\n\n\nProgram\nCost\nQALYs\nC/E\nCumulative Cost\nCumulative QALYs\n\n\n\n\nD\n20\n40\n0.50\n20\n40\n\n\nE\n30\n50\n0.60\n50\n90\n\n\nF\n50\n75\n0.67\n100\n165\n\n\nC\n56\n70\n0.80\n156\n235\n\n\nA\n27\n30\n0.90\n183\n265\n\n\nB\n30\n20\n1.50\n213\n285\n\n\n\n\n\n\n\n\n\n\n\n\nBudget\nAdopted\nCost\nEffect\nThreshold\nRemaining\n\n\n\n\n150\nD, E, F, H\n100\n165\n0.67\n50"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-11",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-11",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\nBudget: $150\n\n\n\n\n\nProgram\nCost\nQALYs\nC/E\nCumulative Cost\nCumulative QALYs\n\n\n\n\nD\n20\n40\n0.50\n20\n40\n\n\nE\n30\n50\n0.60\n50\n90\n\n\nF\n50\n75\n0.67\n100\n165\n\n\nC\n56\n70\n0.80\n156\n235\n\n\nA\n27\n30\n0.90\n183\n265\n\n\nB\n30\n20\n1.50\n213\n285\n\n\n\n\n\n\n\n\n\n\n\n\nBudget\nAdopted\nCost\nEffect\nThreshold\nRemaining\n\n\n\n\n150\nD, E, F, H\n100\n165\n0.67\n50"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#shopping-spree-problem-12",
    "href": "lectures/lec_6.ICERs.html#shopping-spree-problem-12",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Shopping Spree Problem",
    "text": "Shopping Spree Problem\nBudget: $150\n\n\n\n\n\nProgram\nCost\nQALYs\nC/E\nCumulative Cost\nCumulative QALYs\n\n\n\n\nD\n20\n40\n0.50\n20\n40\n\n\nE\n30\n50\n0.60\n50\n90\n\n\nF\n50\n75\n0.67\n100\n165\n\n\nC (89.3%)\n56\n70\n0.80\n156\n235\n\n\nA\n27\n30\n0.90\n183\n265\n\n\nB\n30\n20\n1.50\n213\n285\n\n\n\n\n\n\n\n\n\n\n\n\nBudget\nAdopted\nCost\nEffect\nThreshold\nRemaining\n\n\n\n\n150\nD, E, F, C (89.3%), H\n150\n226.6\n0.8\n0\n\n\n\n\n\n\n\n\n\n$50 left but program C costs $56 (50/56 = 0.89)\n0.89*70 QALYs of program C = 62.3 QALYs"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#summary-shopping-spree-problem",
    "href": "lectures/lec_6.ICERs.html#summary-shopping-spree-problem",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Summary: Shopping Spree Problem",
    "text": "Summary: Shopping Spree Problem\n{{&lt; fa circle-check &gt;}} Maximize the total net effectiveness (health benefit)\n{{&lt; fa circle-check &gt;}} Stay within budget\n{{&lt; fa note-sticky &gt;}} Can do the same with other objectives (e.g., Minimize costs, subject decision to ‘minimum benefit’ constraint, etc.)"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#use-of-cea-in-two-situations-2",
    "href": "lectures/lec_6.ICERs.html#use-of-cea-in-two-situations-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Use of CEA in two situations",
    "text": "Use of CEA in two situations\n\n\nShopping Spree: Decision problem has non-competing programs/interventions."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#use-of-cea-in-two-situations-3",
    "href": "lectures/lec_6.ICERs.html#use-of-cea-in-two-situations-3",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Use of CEA in two situations",
    "text": "Use of CEA in two situations\n\nCompeting Choice: Decision problem has competing programs/interventions for the same purpose; these choices are mutually exclusive."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#objectives-competing-choice-problem",
    "href": "lectures/lec_6.ICERs.html#objectives-competing-choice-problem",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Objectives: Competing Choice Problem",
    "text": "Objectives: Competing Choice Problem\n{{&lt; fa circle-check &gt;}} Cannot implement more than one strategy at a time.\n{{&lt; fa circle-check &gt;}} Incremental cost-effectiveness ratio is below a pre-specified adoption threshold."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#whats-different",
    "href": "lectures/lec_6.ICERs.html#whats-different",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "What’s different?",
    "text": "What’s different?\n\n\nShopping Spree\n\nCan select multiple programs\nDifferent costs & effects associated with each\nRequires calculation of an Average Cost-Effectiveness Ratio\n\n\nCompeting Choice\n\nPrograms are mutually exclusive.\nDifferent costs & effects associated with each.\nRequires calculation of an Incremental Cost-Effectiveness Ratio (ICER)\n\n\n\n\n(1) Opioid pharmacotherapy is the recommended treatment for OUD in pregnancy, as we know that medication reduces the risk of overdose and relapse, improves overall retention to care, and improves pregnancy & fetal outcomes.\n\nThere are three classes of medications approved by the FDA – & there are several sub-modalities that are not listed here that we are modeling – such as injectable formulations versus monotherapy / etc.\nBut overall – there are options like Methadone that are full “agonists” – where the effects of the treatment increase as the dose increases\nBuprenorphine which is a partial agonist – in other words, buprenorphine has a “ceiling effect”, so its effects can only be felt up to a certain point & then plateaus thereafter\nAnd Naltrexone, which is an “antagonist” and works by blocking opioid receptors & reduces & suppresses opioid cravings\nThe difficult tradeoffs of these therapies, include:\n\n\nAccess challenges & delays in care – for instance, there’s a limited # of methadone clinics across the US – there are only 3 methadone clinics in Nashville (22 total in the state) & 5 total in neighboring Mississippi\n& while buprenorphine & naltrexone, for example, can be administered in any office-based setting, methadone can only be dispensed in these specialty OTP clinics that I had mentioned earlier\nFor opioid recurrence or disengagement from treatment rates, Methadone may have better outcomes BUT methadone also poses a significant risk of mortality from opioid overdose due to respiratory depression during treatment induction\nRegarding infant outcomes, buprenorphine has performed better than methadone when it comes to outcomes like preterm birth, neonatal withdrawal syndrome, & length of hospital stay, but infants exposed to Naltrexone have the least severe withdrawal overall & lowest hospital length of stay\nThere are also different tradeoffs associated with treatment modalities such as tablets, film, injectables\nAnd then there’s many other things to consider such as inpatient versus outpatient induction periods versus continuation of care AND outcomes associated with injection versus non-injection users\n\n\nWhile individuals can switch back & forth between these medications, they can only be on ONE medication at a time & we have to decide what is the best option for pregnant invidivudals with OUD given all of the tradeoffs just mentioned"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#calculate-incremental-costs-and-effects",
    "href": "lectures/lec_6.ICERs.html#calculate-incremental-costs-and-effects",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "1. Calculate incremental costs and effects",
    "text": "1. Calculate incremental costs and effects\n\n\nOften, a strategy capturing current practice (‘status-quo’, ‘do nothing’, ‘natural history’) is defined.\nCosts and effects are then calculated for each strategy relative to the status-quo.\nPlot the difference in costs and effects with health effects on x-axis and cost effects on y-axis."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#calculate-cost-and-effects",
    "href": "lectures/lec_6.ICERs.html#calculate-cost-and-effects",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "1. Calculate cost and effects",
    "text": "1. Calculate cost and effects"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#identify-dominated-strategies",
    "href": "lectures/lec_6.ICERs.html#identify-dominated-strategies",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Identify Dominated Strategies",
    "text": "Identify Dominated Strategies\n\n\nWe can rule out any strategies that result in less health at higher cost."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#identify-dominated-strategies-1",
    "href": "lectures/lec_6.ICERs.html#identify-dominated-strategies-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Identify Dominated Strategies",
    "text": "Identify Dominated Strategies"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#identify-dominated-strategies-2",
    "href": "lectures/lec_6.ICERs.html#identify-dominated-strategies-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Identify Dominated Strategies",
    "text": "Identify Dominated Strategies\n\n\nWe can also rule out strategies where some other competing strategy results in more (or equal) health at lower (or equal) cost.\nThis is known as “strong” dominance."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#identify-dominated-strategies-3",
    "href": "lectures/lec_6.ICERs.html#identify-dominated-strategies-3",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Identify Dominated Strategies",
    "text": "Identify Dominated Strategies"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#identify-dominated-strategies-4",
    "href": "lectures/lec_6.ICERs.html#identify-dominated-strategies-4",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Identify Dominated Strategies",
    "text": "Identify Dominated Strategies"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#what-about-strategy-b",
    "href": "lectures/lec_6.ICERs.html#what-about-strategy-b",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "What about strategy B?",
    "text": "What about strategy B?"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#hybrid-strategies",
    "href": "lectures/lec_6.ICERs.html#hybrid-strategies",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Hybrid Strategies",
    "text": "Hybrid Strategies\n\n\nSuppose it is feasible to partially implement strategies A and D.\n\nFor example, we could implement A for 90% of the population and D for 10% of the population, or vice versa."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#a-10-d",
    "href": "lectures/lec_6.ICERs.html#a-10-d",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "90% A, 10% D",
    "text": "90% A, 10% D"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#a-90-d",
    "href": "lectures/lec_6.ICERs.html#a-90-d",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "10% A, 90% D",
    "text": "10% A, 90% D"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#a-50-d",
    "href": "lectures/lec_6.ICERs.html#a-50-d",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "50% A, 50% D",
    "text": "50% A, 50% D\n\nCan we make any statements about B now?"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#extended-weak-dominance",
    "href": "lectures/lec_6.ICERs.html#extended-weak-dominance",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Extended (Weak) Dominance",
    "text": "Extended (Weak) Dominance\n\nB is ruled out by extended (“weak”) dominance."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#extended-weak-dominance-1",
    "href": "lectures/lec_6.ICERs.html#extended-weak-dominance-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Extended (Weak) Dominance",
    "text": "Extended (Weak) Dominance"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#efficiency-frontier",
    "href": "lectures/lec_6.ICERs.html#efficiency-frontier",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Efficiency Frontier",
    "text": "Efficiency Frontier\n\n\nThe efficiency frontier is the set of non-dominated strategies."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#icers",
    "href": "lectures/lec_6.ICERs.html#icers",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "ICERs",
    "text": "ICERs\n\nThe slope of a line connecting two points is the incremental cost-effectiveness ratio comparing those strategies. More on this later!"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-1",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n    \n\n\n\n\n\n\nPlease note that the following example uses different strategies and values than the example used in the previous pictures!"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-2",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\nCalculate costs and effects for each strategy.\nSort table by costs in ascending order.1\nCalculate ICER based on difference in costs and effects.\nDetermine dominated strategies (ICER&lt;0).\nRe-calculate ICERs after eliminating dominated strategies.\nDetermine strategies ruled out by extended dominance.\nRe-calculate ICERs after ruling out all dominated strategies.\nRepeat 5-7 as needed.\n\n\nLeast costly first, most costly last"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-3",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-3",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\n1. Calculate costs and effects for each strategy.\n\n\n\n\n\n\n\n\n\nStrategy\nCost\nQALYs\n\n\n\n\nA\n16,454\n17.33\n\n\nD\n24,504\n17.49\n\n\nC\n33,443\n17.58\n\n\nB\n21,457\n17.41\n\n\nE\n43,332\n17.49"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-4",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-4",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\n\nCalculate costs and effects for each strategy.\n\n2. Sort table by costs in ascending order.1\n\n\n\n\n\n\n\n\n\nStrategy\nCost\nQALYs\n\n\n\n\nA\n16,454\n17.332\n\n\nB\n21,457\n17.409\n\n\nD\n24,504\n17.491\n\n\nC\n33,443\n17.580\n\n\nE\n43,332\n17.491\n\n\n\n\n\n\n\nLeast costly first, most costly last"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-5",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-5",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\n\nCalculate costs and effects for each strategy.\nSort table by costs in ascending order.1\n\n3. Calculate ICER based on difference in costs and effects.\n\n\n\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\nB\n21,457\n5,003\n17.409\n0.077\n64,895\n\n\nD\n24,504\n3,048\n17.491\n0.082\n36,989\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\nE\n43,332\n9,888\n17.491\n-0.088\n-112,048\n\n\n\n\n\n\n\nLeast costly first, most costly last"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-6",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-6",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\n\nCalculate costs and effects for each strategy.\nSort table by costs in ascending order.1\nCalculate ICER based on difference in costs and effects.\n\n\n4. Determine dominated strategies (ICER&lt;0)\n\n\nLeast costly first, most costly last"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determining-dominated-strategies",
    "href": "lectures/lec_6.ICERs.html#determining-dominated-strategies",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determining Dominated Strategies",
    "text": "Determining Dominated Strategies\n\n\nLet’s take a look at our table.\nNotice that strategy E has a negative ICER. Why is this?\nStrategy E raises costs but lowers QALYs.\nTherefore, we’d be better off by selecting strategy C (we would get more health gain for less money…)\n\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\n\nB\n21,457\n5,003\n17.409\n0.077\n64,895\n\n\n\nD\n24,504\n3,048\n17.491\n0.082\n36,989\n\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\n\nE\n43,332\n9,888\n17.491\n-0.088\n-112,048"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determining-dominated-strategies-1",
    "href": "lectures/lec_6.ICERs.html#determining-dominated-strategies-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determining Dominated Strategies",
    "text": "Determining Dominated Strategies\n\n\nStrong dominance refers to situations where one strategy is preferred over another on both costs and health effects (e.g., QALYs).\nWhen we identify a strongly dominated option, we remove it from the table and re-calculate ICERS based on the remaining strategies.\n\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\n\nB\n21,457\n5,003\n17.409\n0.077\n64,895\n\n\n\nD\n24,504\n3,048\n17.491\n0.082\n36,989\n\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\n\nE\n43,332\n9,888\n17.491\n-0.088\n-112,048\nDominated"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#a-brief-aside-on-negative-icers",
    "href": "lectures/lec_6.ICERs.html#a-brief-aside-on-negative-icers",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "A Brief Aside on Negative ICERs",
    "text": "A Brief Aside on Negative ICERs\n\nWe want to rule out strategies that cost more but result in less health.\n\nThis implies a negative ICER.\n\nBut what other scenario would result in a negative ICER?\n\nStrategy adds health but reduces costs.\nThis is a great strategy!"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#both-strategies-have-a-negative-icer",
    "href": "lectures/lec_6.ICERs.html#both-strategies-have-a-negative-icer",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Both Strategies Have a Negative ICER",
    "text": "Both Strategies Have a Negative ICER"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#a-brief-aside-on-negative-icers-1",
    "href": "lectures/lec_6.ICERs.html#a-brief-aside-on-negative-icers-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "A Brief Aside on Negative ICERs",
    "text": "A Brief Aside on Negative ICERs\n\nFor this reason, it is poor practice to report negative ICERs.\nBe careful when deleting a strategy becuase it has a negative ICER!\n\nIt may be a great strategy!"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-7",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-7",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\n\nCalculate costs and effects for each strategy.\nSort table by costs in ascending order.1\nCalculate ICER based on difference in costs and effects.\n\n\n4. Determine dominated strategies (ICER&lt;0)\n\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\n\nB\n21,457\n5,003\n17.409\n0.077\n64,895\n\n\n\nD\n24,504\n3,048\n17.491\n0.082\n36,989\n\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\n\nE\n43,332\n9,888\n17.491\n-0.088\n-112,048\nDominated\n\n\n\n\n\n\n\nLeast costly first, most costly last"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-8",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-8",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\n\nCalculate costs and effects for each strategy.\nSort table by costs in ascending order.1\nCalculate ICER based on difference in costs and effects.\n\n\n\nDetermine dominated strategies (ICER&lt;0).\n\n5. Re-calculate ICERs after eliminating dominated strategies.\n\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\n\nB\n21,457\n5,003\n17.409\n0.077\n64,895\n\n\n\nD\n24,504\n3,048\n17.491\n0.082\n36,989\n\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\n\nE\n43,332\n\n17.491\n\n-112,048\nDominated\n\n\n\n\n\n\n\nLeast costly first, most costly last"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-9",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-9",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\n\nCalculate costs and effects for each strategy.\nSort table by costs in ascending order.1\nCalculate ICER based on difference in costs and effects.\n\n\n\nDetermine dominated strategies (ICER&lt;0).\nRe-calculate ICERs after eliminating dominated strategies.\n\n\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\n\nB\n21,457\n5,003\n17.409\n0.077\n64,895\n\n\n\nD\n24,504\n3,048\n17.491\n0.082\n36,989\n\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\n\nE\n43,332\n\n17.491\n\n\n\n\n\n\n\n\n\n\nLeast costly first, most costly last"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determining-dominated-strategies-2",
    "href": "lectures/lec_6.ICERs.html#determining-dominated-strategies-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determining Dominated Strategies",
    "text": "Determining Dominated Strategies\n\n\nWe’re not quite done yet\nNotice something odd about strategy B?\nIts ICER is higher than the next most costly alternative (strategy D)\n\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\n\nB\n21,457\n5,003\n17.409\n0.077\n64,895\n\n\n\nD\n24,504\n3,048\n17.491\n0.082\n36,989\n\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\n\nE\n43,332\n\n17.491"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determining-dominated-strategies-3",
    "href": "lectures/lec_6.ICERs.html#determining-dominated-strategies-3",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determining Dominated Strategies",
    "text": "Determining Dominated Strategies\n\nA telltale sign of extended dominance in a (sorted) CEA table is a strategy with a higher ICER than the next most expensive option.\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\n\nB\n21,457\n5,003\n17.409\n0.077\n64,895\nDominated (Extended)\n\n\nD\n24,504\n3,048\n17.491\n0.082\n36,989\n\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\n\nE\n43,332\n\n17.491\n\n\nDominated"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determining-dominated-strategies-4",
    "href": "lectures/lec_6.ICERs.html#determining-dominated-strategies-4",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determining Dominated Strategies",
    "text": "Determining Dominated Strategies\n\n\nYou can see this in the pictures as well …."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-10",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-10",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\n\nCalculate costs and effects for each strategy.\nSort table by costs in ascending order.1\nCalculate ICER based on difference in costs and effects.\n\n\n\nDetermine dominated strategies (ICER&lt;0).\nRe-calculate ICERs after eliminating dominated strategies.\n\n6. Determine strategies ruled out by extended dominance.\n\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\n\nB\n21,457\n5,003\n17.409\n0.077\n64,895\nDominated (Extended)\n\n\nD\n24,504\n3,048\n17.491\n0.082\n36,989\n\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\n\nE\n43,332\n\n17.491\n\n\nDominated\n\n\n\n\n\n\n\nLeast costly first, most costly last"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#incremental-cea-11",
    "href": "lectures/lec_6.ICERs.html#incremental-cea-11",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Incremental CEA",
    "text": "Incremental CEA\n\n\n7. Re-calculate ICERs after ruling out all dominated strategies.\n\n\n\n\n\n\n\n\n\nStrategy\nCost\ndCost\nQALYs\ndQALYs\nICER\n\n\n\n\n\nA\n16,454\n\n17.332\n\n\n\n\n\nD\n24,504\n8,050\n17.491\n0.159\n50,478\n\n\n\nC\n33,443\n8,939\n17.580\n0.088\n101,292\n\n\n\nE\n43,332\n\n17.491\n\n\nDominated\n\n\nB\n21,457\n\n17.409\n\n\nDominated (Extended)\n\n\n\n\n\n\n\n\n\nStrategy D is more expensive than Strategy B, but Strategy D is gaining health MORE EFFICIENTLY than Strategy B"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#in-class-practice-dalys",
    "href": "lectures/lec_6.ICERs.html#in-class-practice-dalys",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "In-class practice: DALYs",
    "text": "In-class practice: DALYs\nNine different prophylaxis to prevent someone with HIV from acquiring opportunistic infections related to AIDS\n\n\n\n\n\n\nStrategy\nCost\nDALYs\n\n\n\n\nNo prophylaxis\n40,288\n9.50\n\n\nTMP-SMX\n44,786\n6.94\n\n\nTMP-SMX, azithromycin\n45,944\n6.46\n\n\nTMP-SMX, fluconazole\n47,046\n6.49\n\n\nTMP-SMX, azithromycin, fluconazole\n48,596\n5.90\n\n\nTMP-SMX, ganciclovir\n54,628\n6.30\n\n\nTMP-SMX, azithromycin, ganciclovir\n56,812\n5.67\n\n\nTMP-SMX, fluconazole, ganciclovir\n58,082\n5.70\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n61,119\n4.88"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#calculate-incremental-costs-and-dalys-averted",
    "href": "lectures/lec_6.ICERs.html#calculate-incremental-costs-and-dalys-averted",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Calculate Incremental Costs and DALYs Averted",
    "text": "Calculate Incremental Costs and DALYs Averted\n\n\n\n\n\n\nStrategy\nCost\nIncremental Cost\nDALYs\nDALYs Averted\n\n\n\n\nNo prophylaxis\n40,288\n0\n9.50\n0.00\n\n\nTMP-SMX\n44,786\n4,498\n6.94\n2.56\n\n\nTMP-SMX, azithromycin\n45,944\n1,158\n6.46\n0.48\n\n\nTMP-SMX, fluconazole\n47,046\n1,102\n6.49\n-0.03\n\n\nTMP-SMX, azithromycin, fluconazole\n48,596\n1,550\n5.90\n0.59\n\n\nTMP-SMX, ganciclovir\n54,628\n6,032\n6.30\n-0.40\n\n\nTMP-SMX, azithromycin, ganciclovir\n56,812\n2,184\n5.67\n0.63\n\n\nTMP-SMX, fluconazole, ganciclovir\n58,082\n1,270\n5.70\n-0.03\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n61,119\n3,037\n4.88\n0.82"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#calculate-incremental-costs-per-daly-averted.",
    "href": "lectures/lec_6.ICERs.html#calculate-incremental-costs-per-daly-averted.",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Calculate incremental costs per DALY averted.",
    "text": "Calculate incremental costs per DALY averted.\n\n\n\n\n\n\nStrategy\nIncremental Cost\nDALYs Averted\nIncremental Cost per DALY Averted\n\n\n\n\nNo prophylaxis\n0\n0.00\n\n\n\nTMP-SMX\n4,498\n2.56\n1,757\n\n\nTMP-SMX, azithromycin\n1,158\n0.48\n2,413\n\n\nTMP-SMX, fluconazole\n1,102\n-0.03\n-36,733\n\n\nTMP-SMX, azithromycin, fluconazole\n1,550\n0.59\n2,627\n\n\nTMP-SMX, ganciclovir\n6,032\n-0.40\n-15,080\n\n\nTMP-SMX, azithromycin, ganciclovir\n2,184\n0.63\n3,467\n\n\nTMP-SMX, fluconazole, ganciclovir\n1,270\n-0.03\n-42,333\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n3,037\n0.82\n3,704"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determine-dominated-strategies",
    "href": "lectures/lec_6.ICERs.html#determine-dominated-strategies",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determine dominated strategies",
    "text": "Determine dominated strategies\n\n\n\n\n\n\nStrategy\nIncremental Cost\nDALYs Averted\nIncremental Cost per DALY Averted\nStatus\n\n\n\n\nNo prophylaxis\n0\n0.00\n\n\n\n\nTMP-SMX\n4,498\n2.56\n1,757\n\n\n\nTMP-SMX, azithromycin\n1,158\n0.48\n2,413\n\n\n\nTMP-SMX, fluconazole\n1,102\n-0.03\n-36,733\nDominated (Strong)\n\n\nTMP-SMX, azithromycin, fluconazole\n1,550\n0.59\n2,627\n\n\n\nTMP-SMX, ganciclovir\n6,032\n-0.40\n-15,080\nDominated (Strong)\n\n\nTMP-SMX, azithromycin, ganciclovir\n2,184\n0.63\n3,467\n\n\n\nTMP-SMX, fluconazole, ganciclovir\n1,270\n-0.03\n-42,333\nDominated (Strong)\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n3,037\n0.82\n3,704"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determine-dominated-strategies-1",
    "href": "lectures/lec_6.ICERs.html#determine-dominated-strategies-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determine dominated strategies",
    "text": "Determine dominated strategies\n\n\n\n\n\n\nStrategy\nCost\nIncremental Cost\nDALYs\nDALYs Averted\n\n\n\n\nNo prophylaxis\n40,288\n0\n9.50\n0.00\n\n\nTMP-SMX\n44,786\n4,498\n6.94\n2.56\n\n\nTMP-SMX, azithromycin\n45,944\n1,158\n6.46\n0.48\n\n\nTMP-SMX, azithromycin, fluconazole\n48,596\n2,652\n5.90\n0.56\n\n\nTMP-SMX, azithromycin, ganciclovir\n56,812\n8,216\n5.67\n0.23\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n61,119\n4,307\n4.88\n0.79"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determine-dominated-strategies-2",
    "href": "lectures/lec_6.ICERs.html#determine-dominated-strategies-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determine dominated strategies",
    "text": "Determine dominated strategies\n\n\n\n\n\n\nStrategy\nIncremental Cost\nDALYs Averted\nIncremental Cost per DALY Averted\nStatus\n\n\n\n\nNo prophylaxis\n0\n0.00\n\n\n\n\nTMP-SMX\n4,498\n2.56\n1,757\n\n\n\nTMP-SMX, azithromycin\n1,158\n0.48\n2,413\n\n\n\nTMP-SMX, azithromycin, fluconazole\n2,652\n0.56\n4,736\n\n\n\nTMP-SMX, azithromycin, ganciclovir\n8,216\n0.23\n35,722\nDominated (Extended)\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n4,307\n0.79\n5,452"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determine-dominated-strategies-3",
    "href": "lectures/lec_6.ICERs.html#determine-dominated-strategies-3",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determine dominated strategies",
    "text": "Determine dominated strategies"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determine-dominated-strategies-4",
    "href": "lectures/lec_6.ICERs.html#determine-dominated-strategies-4",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determine dominated strategies",
    "text": "Determine dominated strategies\n\n\n\n\n\n\nStrategy\nCost\nIncremental Cost\nDALYs\nDALYs Averted\n\n\n\n\nNo prophylaxis\n40,288\n0\n9.50\n0.00\n\n\nTMP-SMX\n44,786\n4,498\n6.94\n2.56\n\n\nTMP-SMX, azithromycin\n45,944\n1,158\n6.46\n0.48\n\n\nTMP-SMX, azithromycin, fluconazole\n48,596\n2,652\n5.90\n0.56\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n61,119\n12,523\n4.88\n1.02"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#determine-dominated-strategies-5",
    "href": "lectures/lec_6.ICERs.html#determine-dominated-strategies-5",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Determine dominated strategies",
    "text": "Determine dominated strategies\n\n\n\n\n\n\nStrategy\nIncremental Cost\nDALYs Averted\nIncremental Cost per DALY Averted\nStatus\n\n\n\n\nNo prophylaxis\n0\n0.00\n\n\n\n\nTMP-SMX\n4,498\n2.56\n1,757\n\n\n\nTMP-SMX, azithromycin\n1,158\n0.48\n2,413\n\n\n\nTMP-SMX, azithromycin, fluconazole\n2,652\n0.56\n4,736\n\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n12,523\n1.02\n12,277"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#final-table",
    "href": "lectures/lec_6.ICERs.html#final-table",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Final Table",
    "text": "Final Table\n\n\n\n\n\n\nStrategy\nIncremental Cost\nDALYs Averted\nIncremental Cost per DALY Averted\nStatus\n\n\n\n\nNo prophylaxis\n0\n0.00\n\n\n\n\nTMP-SMX\n4,498\n2.56\n1,757\n\n\n\nTMP-SMX, azithromycin\n1,158\n0.48\n2,413\n\n\n\nTMP-SMX, azithromycin, fluconazole\n2,652\n0.56\n4,736\n\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n12,523\n1.02\n12,277\n\n\n\nTMP-SMX, fluconazole\n1,102\n-0.03\n\nDominated (Strong)\n\n\nTMP-SMX, ganciclovir\n6,032\n-0.40\n\nDominated (Strong)\n\n\nTMP-SMX, fluconazole, ganciclovir\n1,270\n-0.03\n\nDominated (Strong)\n\n\nTMP-SMX, azithromycin, ganciclovir\n8,216\n0.23\n\nDominated (Extended)"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#a-note-on-comparators",
    "href": "lectures/lec_6.ICERs.html#a-note-on-comparators",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "A note on COMPARATORS",
    "text": "A note on COMPARATORS\n\n\n\n**The comparators are REALLY IMPORTANT\nIdeally, you want to identify ALL POSSIBLE interventions applicable to the problem, including a “do nothing” option"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#a-note-on-comparators-1",
    "href": "lectures/lec_6.ICERs.html#a-note-on-comparators-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "A note on COMPARATORS",
    "text": "A note on COMPARATORS\n\n\n\n**The results can be DECEPTIVE if you decide to omit any comparators that are relevant to clinical practice\nFOR EXAMPLE, if you purposefully pick a “no treatment” comparator but leave out a closer alternative, then the analysis will grossly overstate the economic value of the drug you are assessing\nSame goes with an expensive & not very effective alternative & you leave out options that are similar in effectiveness & cost"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cea-thresholds",
    "href": "lectures/lec_6.ICERs.html#cea-thresholds",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "CEA Thresholds",
    "text": "CEA Thresholds\n\n\nSo now we have our ICERs, but how do we make a decision?\nWe must define a threshold (\\lambda), or an ICER value that determines whether or not we implement a given strategy.\n\nAlso known as “willingness-to-pay” (WTP) threshold."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cea-thresholds-1",
    "href": "lectures/lec_6.ICERs.html#cea-thresholds-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "CEA Thresholds",
    "text": "CEA Thresholds\nWhat are common thresholds and how are they determined?\n\n\nIn high income countries, common thresholds are $50,000/QALY, $100,000/QALY, and $100,000/QALY.\nIn LMICs, 0.5-3x per capita gross domestic product (GDP) per DALY averted.\nMore on this in a few minutes."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#how-do-cea-thresholds-guide-decisionmaking",
    "href": "lectures/lec_6.ICERs.html#how-do-cea-thresholds-guide-decisionmaking",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "How do CEA Thresholds Guide Decisionmaking?",
    "text": "How do CEA Thresholds Guide Decisionmaking?"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#how-do-cea-thresholds-guide-decisionmaking-1",
    "href": "lectures/lec_6.ICERs.html#how-do-cea-thresholds-guide-decisionmaking-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "How do CEA Thresholds Guide Decisionmaking?",
    "text": "How do CEA Thresholds Guide Decisionmaking?"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#how-do-cea-thresholds-guide-decisionmaking-2",
    "href": "lectures/lec_6.ICERs.html#how-do-cea-thresholds-guide-decisionmaking-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "How do CEA Thresholds Guide Decisionmaking?",
    "text": "How do CEA Thresholds Guide Decisionmaking?\n\n\n\nHow do we know whether something is “high-value” versus “low-value” or “no-value” healthcare?\nLet’s say we are comparing flu vaccination versus no vaccination & that our cost-effectiveness ratio yields a price per unit benefit of $90,000 / QALY gained\n[ASK CLASS] - Would this be considered “high-value”?\nThis price must be compared to a benchmark or threshold representing either what society is willing to pay for health gains or the opportunity costs associated with displacing interventions within a fixed budget\nIn the US, the benchmark is ROUGHLY around $100,000/QALY based on willingness to pay estimates\nA threshold’s assumed value is really important because it ultimately determines how society should invest in care, which ultimately impacts overall population health.\nAnything above this benchmark would be considered cost-Ineffective (low value care)\nAnything below would be considered high-value (gaining each quality-adjusted life-year at a lower cost)\nAnything to the left is NO value care\nThis is really important because… ***Resources invested in low or no-value interventions could be better applied to more effective prevention and treatment strategies that will yield higher population health outcomes."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cea-thresholds-2",
    "href": "lectures/lec_6.ICERs.html#cea-thresholds-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "CEA Thresholds",
    "text": "CEA Thresholds"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cea-thresholds-3",
    "href": "lectures/lec_6.ICERs.html#cea-thresholds-3",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "CEA Thresholds",
    "text": "CEA Thresholds"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cea-thresholds-4",
    "href": "lectures/lec_6.ICERs.html#cea-thresholds-4",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "CEA Thresholds",
    "text": "CEA Thresholds"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cea-thresholds-5",
    "href": "lectures/lec_6.ICERs.html#cea-thresholds-5",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "CEA Thresholds",
    "text": "CEA Thresholds\n\nDifferent ways thresholds have been estimated: - “supply-side” (UK & Europe) - “demand-side” (US) - per capita consumption (US/LMICs)\n\n\nThere are different ways to determine a cost-effective threshold & it’s done a bit differently around the world, which we talk about in a recent paper I collaborated with UK colleagues on, which discusses the evolution of these thresholds.\nSome countries like the UK, use what has been referred to as a “supply-side threshold” – which represents the notion of opportunity cost – whether the health generated from an adopted intervention from NICE, for instance, is greater than the health that could have been generated if the money had been spent on something else - Under a fixed budget.\nAnother way that countries like the US have defined CE thresholds is by what’s called a “demand-side” perspective, or society’s “willingness to pay” for health gains. There’s still an opportunity cost associated with this but it’s from the perspective of the goods & services we would be willing to forego for these additional health gains.\nSimilarly, another way that countries have looked at the threshold is in terms of per capita consumption - consistent with the idea that people living in countries with higher incomes are able and willing to pay more for health - which makes intuitive sense"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#opportunity-cost-supply-side",
    "href": "lectures/lec_6.ICERs.html#opportunity-cost-supply-side",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Opportunity cost (“supply-side”)",
    "text": "Opportunity cost (“supply-side”)\n\n\n\nDecision should be informed by the value of what will be given up as a consequence of those cost.\n\nKnown as the “opportunity cost.”\n\nIf resources are committed to the funding of one intervention, then they are not available to fund and deliver others (shopping spree concept)\nThe opportunity cost of a commitment of resources is the health forgone because these “other” interventions that are available to the health system cannot be delivered.\nSource: See K Claxton on the estimation of the NICE threshold in the UK / Woods et al, & others"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#opportunity-cost-supply-side-1",
    "href": "lectures/lec_6.ICERs.html#opportunity-cost-supply-side-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Opportunity cost (“supply-side”)",
    "text": "Opportunity cost (“supply-side”)\n\n\n\nThis is the closest to a “supply-side” CEA estimate that the US has approached\nThis simulation looked at the Opportunity Cost attributed to persons dropping health insurance due to health insurance premium increases (which often happens when intervention costs are very high – it’s often the consumers that bear the burden)\nThe authors found that the threshold should be around $100,000/QALY gained (which is typically what we use in the US)\nBut UK academics would argue that this isn’t a true opportunity cost estimate because it doesn’t evaluate the opportunity cost of displacing interventions for other more effective (but often more costly) alternatives –\n\n\neither within the health care sector or displacing other programs in other sectors because of how much we spend on health care\n& there’s many other things to consider such as effect of increasing healthcare costs on patient copays, wait times, generosity of employer plans, or on public insurance"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#opportunity-cost-supply-side-2",
    "href": "lectures/lec_6.ICERs.html#opportunity-cost-supply-side-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Opportunity cost (“supply-side”)",
    "text": "Opportunity cost (“supply-side”)\n\n\n\nIf you don’t consider the budget under which you are operating, then some medications could take up half the budget and displace interventions that produce significant health gain OR in the US, could increase premiums or take away $$ from other sectors\n\n\nAcademics have argued that the threshold should be lower/on the more conservative end for higher priced therapies (NICE uses a budget impact threshold of 20,000 GBP/QALY for these higher priced therapies as opposed to 30,000 GBP/QALY for others)"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#willingness-to-pay-demand-side",
    "href": "lectures/lec_6.ICERs.html#willingness-to-pay-demand-side",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "Willingness to pay (“demand-side”)",
    "text": "Willingness to pay (“demand-side”)\n\n\n\nGiven that our health system is more complicated & we don’t necessarily have a “fixed” budget, per se, the US has largely defined thresholds based on what is often referred to as “demand-side” or “willingness-to-pay” criteria, which can also be represented as the willingness to forego other types of consumption to improve one’s health.\nThis willingness to pay has been derived through surveys & also what Medicare has been willing to pay for interventions\nSome have argued that understanding a population’s willingness to pay is important, especially in a single-payer system that is funded through social insurance – ensuring that individuals have a role in decision-making\nBut there is huge variation in willingness to pay studies - varied substantially by condition, especially those for extending or saving life (higher WTP).\nThis very short perspective piece gives an overview of the thresholds we have used in the US in the past & what they are largely based on (has largely been arbitrary) – it’s 2 pages & would recommend reading"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cea-thresholds-in-lmics",
    "href": "lectures/lec_6.ICERs.html#cea-thresholds-in-lmics",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "CEA Thresholds in LMICs",
    "text": "CEA Thresholds in LMICs\n\n\n\nOther thresholds that countries have used are based on per capita GDP; mainly the threshold of 1-3X per capita GDP\nAlthough this threshold range roughly corresponds to what has become convention for high-income countries (1X per capita GDP in the US is around $60,000 & 3 times that is the upper end of what we use – typically use 50,000 as lower end, 100,000 as the base, and 150,000 as an upper end)\nBUT per capita consumption in wealthier countries exceeds the per capita consumption in low & middle-income countries by one-to-two orders of magnitude & therefore, some analysts have argued that healthcare spending should represent a smaller portion of per capita GDP in low to middle income countries."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cea-thresholds-in-lmics-1",
    "href": "lectures/lec_6.ICERs.html#cea-thresholds-in-lmics-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "CEA Thresholds in LMICs",
    "text": "CEA Thresholds in LMICs\n\n\n\nPast WHO guidelines recommended countries use following guidelines: An intervention is cost-effective if cost/DALY averted is less than 1-3X per capita GDP of country\nSome have argued the WHO’s guidelines may be too high and result in adoption of interventions that displace existing services that provide greater health benefit.\nSuggest 0.5 GDPpc is a more appropriate benchmark for low-income countries and 0.71 GDPpc for middle-income countries (see Woods et al 2016)\n\n\n\n\nAnalysts have also argued that the threshold should be lower for these countries based on a healthcare budget perspective\nIn Peru, for example, a study found that the addition of one breast cancer treatment could be cost-effective under the broad 1-3X per capita GDP criteria; however, the cost of adding the new drug would exceed Peru’s entire budget for breast cancer treatment."
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#cea-thresholds-in-lmics-2",
    "href": "lectures/lec_6.ICERs.html#cea-thresholds-in-lmics-2",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "CEA Thresholds in LMICs",
    "text": "CEA Thresholds in LMICs\n\n\n\nYou can see from my paper on this –\nWe found:\n\n\nThe proportion of PUBLISHED studies citing a threshold of 1-3X per capita GDP has increased over time & this largely corresponds to the WHO recognition of this threshold in the early 2000s – prior to this, most studies either cited no threshold or other CE thresholds\nThe WHO has since moved away from recommended this threshold since it has received A LOT of backlash, including from my paper\n\n\nUntil we come up with a better measure, the DSP3 & other academics have estimated more conservative thresholds (previous slide) that I would use for LMICs & would NOT use the per capita assumptions\nBut we still don’t have a perfect threshold estimate"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#hiv-example-from-earlier",
    "href": "lectures/lec_6.ICERs.html#hiv-example-from-earlier",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "HIV Example From Earlier",
    "text": "HIV Example From Earlier\n\n\n\n\n\n\nStrategy\nIncremental Cost\nDALYs Averted\nIncremental Cost per DALY Averted\nStatus\n\n\n\n\nNo prophylaxis\n0\n0.00\n\n\n\n\nTMP-SMX\n4,498\n2.56\n1,757\n\n\n\nTMP-SMX, azithromycin\n1,158\n0.48\n2,413\n\n\n\nTMP-SMX, azithromycin, fluconazole\n2,652\n0.56\n4,736\n\n\n\nTMP-SMX, azithromycin, fluconazole, ganciclovir\n12,523\n1.02\n12,277\n\n\n\nTMP-SMX, fluconazole\n1,102\n-0.03\n\nDominated (Strong)\n\n\nTMP-SMX, ganciclovir\n6,032\n-0.40\n\nDominated (Strong)\n\n\nTMP-SMX, fluconazole, ganciclovir\n1,270\n-0.03\n\nDominated (Strong)\n\n\nTMP-SMX, azithromycin, ganciclovir\n8,216\n0.23\n\nDominated (Extended)"
  },
  {
    "objectID": "lectures/lec_6.ICERs.html#hiv-example-from-earlier-1",
    "href": "lectures/lec_6.ICERs.html#hiv-example-from-earlier-1",
    "title": "Incremental Cost-Effectiveness Analysis",
    "section": "HIV Example from Earlier",
    "text": "HIV Example from Earlier\n\n\nIf our CE threshold was 2x GDP (GDP = $2,500), which option would we choose as decision makers?\nIf our CE threshold was 1x GDP (GDP = $2,500), which option would we choose as decision makers?"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#learning-objectives",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#learning-objectives",
    "title": "Decision Trees & Probabilities",
    "section": "Learning Objectives",
    "text": "Learning Objectives\n\nConstruct and solve a decision problem by calculating an intervention’s expected value across competing strategies in a decision tree\nDetermine the decision threshold across a range of scenarios\nDifferentiate between joint and conditional probabilities and demonstrate their use in decision trees"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#outline",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#outline",
    "title": "Decision Trees & Probabilities",
    "section": "Outline",
    "text": "Outline\n\n\n\nStructure\nProbability review\nProbabilities within decision trees\n\n\n\nStrengths/limitations of decision trees"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#recap-decision-analysis",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#recap-decision-analysis",
    "title": "Decision Trees & Probabilities",
    "section": "Recap: Decision Analysis",
    "text": "Recap: Decision Analysis\n\n\n\nAims to inform choice under uncertainty using an explicit, quantitative approach\nAims to identify, measure, & value the consequences of decisions (risks/benefits) & uncertainty when a decision needs to be made, most appropriately over time"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-1",
    "title": "Decision Trees & Probabilities",
    "section": "Should I go to the beach or stay home?",
    "text": "Should I go to the beach or stay home?\nPossible States of the World:\n\n\nAt the beach with no rain.\nAt the beach with rain.\nAt home with no rain.\nAt home with rain."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-2",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-2",
    "title": "Decision Trees & Probabilities",
    "section": "Should I go to the beach or stay home?",
    "text": "Should I go to the beach or stay home?\nConsiderations:\n\n\nLikelihood of rain\nMy overall well being when\n\nAt the beach with no rain.\nAt the beach with rain.\nAt home with no rain.\nAt home with rain."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-3",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-3",
    "title": "Decision Trees & Probabilities",
    "section": "Should I go to the beach or stay home?",
    "text": "Should I go to the beach or stay home?\nConsiderations:\n\n\nLikelihood of rain –&gt; probabilities\nMy overall well being when\n\nAt the beach with no rain.\nAt the beach with rain.\nAt home with no rain.\nAt home with rain."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-4",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-4",
    "title": "Decision Trees & Probabilities",
    "section": "Should I go to the beach or stay home?",
    "text": "Should I go to the beach or stay home?\nConsiderations:\n\n\nLikelihood of rain –&gt; probabilities\nMy overall well being when\n\nAt the beach with no rain. –&gt; payoff\nAt the beach with rain. –&gt; payoff\nAt home with no rain. –&gt; payoff\nAt home with rain. –&gt; payoff"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#decision-trees",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#decision-trees",
    "title": "Decision Trees & Probabilities",
    "section": "Decision Trees",
    "text": "Decision Trees\n\n\n\n\nA square decision node indicates a decision point between alternative options.\nA circular chance node shows a point where two or more alternative events for a patient are possible."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#decision-trees-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#decision-trees-1",
    "title": "Decision Trees & Probabilities",
    "section": "Decision Trees",
    "text": "Decision Trees\n\n\n\nA square decision node indicates a decision point between alternative options.\nA circular chance node shows a point where two or more alternative events for a patient are possible.\n\n\n\n\n\n\n\nWe start with a decision node – which just visually shows the decision point (so no probabilities are attached here)\nFrom our decision node, we would then want to create chance nodes, or probability nodes, to model out the probabilities of our different options\nThe corresponding events from the chance nodes need to sum to 1 as per the “law of total probability”"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#decision-trees-2",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#decision-trees-2",
    "title": "Decision Trees & Probabilities",
    "section": "Decision Trees",
    "text": "Decision Trees\n\n\nPathways are mutually exclusive sequences of events and are the routes through the tree.\nProbabilities show the likelihood of particular event occurring at a chance node."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-5",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-5",
    "title": "Decision Trees & Probabilities",
    "section": "Should I go to the beach or stay home?",
    "text": "Should I go to the beach or stay home?\nDecision Tree:\n\n\n\nThe outcomes we care about for this model are RAIN versus NO RAIN, so we add that to the end of our branches, which represent the terminal nodes – or the end states of our model"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-6",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-6",
    "title": "Decision Trees & Probabilities",
    "section": "Should I go to the beach or stay home?",
    "text": "Should I go to the beach or stay home?\nDecision Tree:\n\n\n\nThe probability of rain is 30% - whether you stay home or go to the beach & we know that the branches have to add to 1 because of the law of total probability\n\nHowever, we aren’t done yet, as ***It would be helpful if we had some way to VALUE the outcomes – in terms of say, rain at the beach, versus if it rained at home, etc.\n**If you don’t place value on the different outcomes, then we are essentially saying that we value RAIN versus NO RAIN the same among the beach and home options\nBut if I had to guess, this probably isn’t true unless you’re the type of person that likes rain at the beach just as much as rain at home)"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-7",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-7",
    "title": "Decision Trees & Probabilities",
    "section": "Should I go to the beach or stay home?",
    "text": "Should I go to the beach or stay home?\nPayoffs\n\n\n\nScenario\nPayoff\n\n\n\n\nAt beach, no rain\n1.0\n\n\nAt beach, rain\n0.4\n\n\nAt home, no rain\n0.8\n\n\nAt home, rain\n0.6\n\n\n\n\nAt beach, no rain &gt; At home, no rain &gt; At home, rain &gt; At beach, rain\n\n\n\nWe will get into this down the line, but utilities are measured between 0 and 1.\nFor health states, for example, 0 = worst health & 1 = perfect health\nHere, we are valuing “beach, no rain” as the “most ideal state” we want to be in"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-8",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#should-i-go-to-the-beach-or-stay-home-8",
    "title": "Decision Trees & Probabilities",
    "section": "Should I go to the beach or stay home?",
    "text": "Should I go to the beach or stay home?\nDecision Tree:"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#what-is-the-expected-value-of-going-to-the-beach",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#what-is-the-expected-value-of-going-to-the-beach",
    "title": "Decision Trees & Probabilities",
    "section": "What is the expected value of going to the beach?",
    "text": "What is the expected value of going to the beach?\n\n\n\\color{green}{0.82} = \\underbrace{\\color{red}{0.3} * \\color{blue}{0.4}}_{\\text{Rain}} + \\underbrace{\\color{red}{0.7} * \\color{blue}{1.0}}_{\\text{No Rain}}\n\nProbabilities in red.\nPayoffs in blue.\nExpected value in green."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#what-is-the-expected-value-of-staying-home",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#what-is-the-expected-value-of-staying-home",
    "title": "Decision Trees & Probabilities",
    "section": "What is the expected value of staying home?",
    "text": "What is the expected value of staying home?\n\n\n\\color{green}{0.74} = \\underbrace{\\color{red}{0.3} \\cdot \\color{blue}{0.6}}_{\\text{Rain}} + \\underbrace{\\color{red}{0.7} \\cdot \\color{blue}{0.8}}_{\\text{No Rain}}\n\nProbabilities in red.\nPayoffs in blue.\nExpected value in green."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#expected-values",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#expected-values",
    "title": "Decision Trees & Probabilities",
    "section": "Expected Values",
    "text": "Expected Values\n\nExpected value = The sum of the multiplied probabilities for each chance option or intervention\n\n\n\nEquation: 1 to infinity – represents the infinite # of branches in the decision tree. In our example, we only had 2 branches, but if you had 3 or 4 or 5… you would represent it as i=3, 4, 5 and then you multiply the probabilities.\nXi = payoff and P = probability"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#expected-values-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#expected-values-1",
    "title": "Decision Trees & Probabilities",
    "section": "Expected Values",
    "text": "Expected Values\n\n\n\nThe expected value within the context of decision trees are the “payoffs” weighted by their preceding probabilities\nWhat we get is: the result that is expected ON AVERAGE for any one decision alternative (e.g. length of life, quality of life, lifetime costs)\n\nExample: On average, patients given Treatment A will live 0.30 years longer than patients given Treatment B\n\n\n\n\n\n\n\n\n\n\nMaximizing expected value is a reasonable criterion for choice given uncertain prospects; though it does not necessarily promise the best results for any one individual"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability p are the two choices equal?",
    "text": "At what probability p are the two choices equal?\n\nSuppose we want to know at what probability of rain p we are indifferent between going to the beach vs. staying at home…\n\n\n\nWrite the equation for each choice using a variable, p, for the probability in question\nSet the equations equal to to one other and solve for p."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-1",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability p are the two choices equal?",
    "text": "At what probability p are the two choices equal?\nBeach: 0.82 = 0.3 x 0.4 + 0.7 x 1.0\nHome: 0.74 = 0.3 x 0.6 + 0.7 x 0.8"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-2",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-2",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability p are the two choices equal?",
    "text": "At what probability p are the two choices equal?\n\\underbrace{0.3 * 0.4 + 0.7 * 1.0}_{\\text{Beach}} = \\underbrace{0.3 * 0.6 + 0.7 * 0.8}_{\\text{Home}}"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-3",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-3",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability p are the two choices equal?",
    "text": "At what probability p are the two choices equal?\nReplace probability of rain with P and 1-P and solve for “P”\n\np * 0.4 + (1-p) * 1.0 = p * 0.6 + (1-p) * 0.8\n\n\\underbrace{0.3 * 0.4 + 0.7 * 1.0}_{\\text{Beach}} = \\underbrace{0.3 * 0.6 + 0.7 * 0.8}_{\\text{Home}}"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-4",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-4",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability p are the two choices equal?",
    "text": "At what probability p are the two choices equal?\np * 0.4 + (1-p) * 1.0 = p * 0.6 + (1-p) * 0.8"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-5",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-5",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability p are the two choices equal?",
    "text": "At what probability p are the two choices equal?\np * 0.4 + (1-p) * 1.0 = p * 0.6 + (1-p) * 0.8\n\n0.4p + 1-p = 0.6p + 0.8 - 0.8p\n1-0.6p = 0.8 - 0.2p\n1-0.8 = 0.6p - 0.2p\n0.2 = 0.4 * p\n0.5 = p"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-6",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p-are-the-two-choices-equal-6",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability p are the two choices equal?",
    "text": "At what probability p are the two choices equal?\n\nWhen the probability of rain is 50% at BOTH the beach and home, given how we weighted the outcomes, going to the beach would be the same as staying at home\n\n\n\nIn other words, you would be indifferent between the two – staying at home or going to the beach"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability (p_B) of rain for the beach are you indifferent between the two options?",
    "text": "At what probability (p_B) of rain for the beach are you indifferent between the two options?"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-1",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability (p_B) of rain for the beach are you indifferent between the two options?",
    "text": "At what probability (p_B) of rain for the beach are you indifferent between the two options?\n\n\n\nEarlier, we solved for the expected payoff of remaining at home: 0.74 (which was a lower expected value than going to the beach when the chance of rain at both was 30%) \nWhat would p_B need to be to yield an expected payoff at the beach of 0.74?\n\nIn other words, at what probability of rain at the beach would you be indifferent between staying at home & going to the beach?\n\n\n\n\n\n\nNow, let’s ask a slightly different question – At what probabiility….\nLet’s now assume that the probability of rain for the HOME option does not change (so stays at 0.3)\nKEY DIFFERENCE FROM THE LAST EXAMPLE: In the last example, the probabilities were the same & we wanted to get our threshold of indifference between the beach and staying at home\n**Now we are assuming that there’s still a probability of 30% that it rains if you stay home, but at what probability of rain at the beach would you be indifferent between the two options? (Since we CHOSE BEACH when the probabilities both equaled 30%)\n\n\nIn other words, at what probability of RAIN AT THE BEACH would you be indifferent between the beach & home"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-2",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-2",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability (p_B) of rain for the beach are you indifferent between the two options?",
    "text": "At what probability (p_B) of rain for the beach are you indifferent between the two options?\nSet 0.74 (expected value of remaining at home) equal to the beach payoffs and solve for p_B\n\npB * 0.4 + (1 - pB) * 1.0 = 0.74"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-3",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-3",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability (p_B) of rain for the beach are you indifferent between the two options?",
    "text": "At what probability (p_B) of rain for the beach are you indifferent between the two options?\n\npB * 0.4 + (1 - pB) * 1.0 = 0.74\n\n\npB * 0.4 + 1 - pB = 0.74"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-4",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-4",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability (p_B) of rain for the beach are you indifferent between the two options?",
    "text": "At what probability (p_B) of rain for the beach are you indifferent between the two options?\n\npB * 0.4 + 1 - pB = 0.74\n\n\npB * -0.6 = -0.26"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-5",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-5",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability (p_B) of rain for the beach are you indifferent between the two options?",
    "text": "At what probability (p_B) of rain for the beach are you indifferent between the two options?\n\npB * -0.6 = -0.26\n\n\npB = -0.26 / -0.6 = 0.43"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-6",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#at-what-probability-p_b-of-rain-for-the-beach-are-you-indifferent-between-the-two-options-6",
    "title": "Decision Trees & Probabilities",
    "section": "At what probability (p_B) of rain for the beach are you indifferent between the two options?",
    "text": "At what probability (p_B) of rain for the beach are you indifferent between the two options?\n\nWhen the probability of rain at the beach is 43% (probability of rain at home remains at 30%), we would be indifferent between staying at home & going to the beach.\n\n\nIf the probability of rain at the beach in &gt; 43%, then we would stay home"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities-within-decision-trees",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities-within-decision-trees",
    "title": "Decision Trees & Probabilities",
    "section": "Probabilities within Decision Trees",
    "text": "Probabilities within Decision Trees\nMutually exclusive events\n\n\n2 things that cannot occur together (one event cannot occur at the same time as the other event)\n\nExample: 2 events, survive or die; mutually exclusive because a person cannot be both at the same time\nExample: 2 events, cured or not cured"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities-within-decision-trees-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities-within-decision-trees-1",
    "title": "Decision Trees & Probabilities",
    "section": "Probabilities within Decision Trees",
    "text": "Probabilities within Decision Trees\nMutually exclusive events"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities-within-decision-trees-2",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities-within-decision-trees-2",
    "title": "Decision Trees & Probabilities",
    "section": "Probabilities within Decision Trees",
    "text": "Probabilities within Decision Trees\nMutually exclusive events\n\nAssuming events are mutually exclusive, then the probability of 2 events occurring is the sum of the probability of each event occurring individually\n\n\nP(A or B) = P(A) + P(B)"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities-within-decision-trees-3",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities-within-decision-trees-3",
    "title": "Decision Trees & Probabilities",
    "section": "Probabilities within Decision Trees",
    "text": "Probabilities within Decision Trees\n\n\n\n\n\n\nJoint probability\n\n\nP(A and B): The probability of two events occurring at the same time.\n\n\n\n\n\n\n\n\n\nConditional probability\n\n\nP(A|B): The probability of an event A given that an event B is known to have occurred."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#probabilities",
    "title": "Decision Trees & Probabilities",
    "section": "Probabilities",
    "text": "Probabilities\n\n\nMoving from left to right, the first probabilities in the tree show the probability of an event.\nSubsequent probabilities are conditional.\n\nThe probability of an event given that an earlier event did or did not occur.\n\nMultiplying probabilities along pathways estimates the pathway probability, which is a joint probability."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#pathways",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#pathways",
    "title": "Decision Trees & Probabilities",
    "section": "Pathways",
    "text": "Pathways\n\nPathways = sequence of events that lead to a subsequent “pay off”\nIn other words, a sequence of events leads to an outcome/consequence, or payoff\nExample below: Our beach example has 4 pathways."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#pathways-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#pathways-1",
    "title": "Decision Trees & Probabilities",
    "section": "Pathways",
    "text": "Pathways\n\nPathway A: This person goes to the beach but it rains\nPathway B: This person goes to the beach but there is no rain"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-1",
    "title": "Decision Trees & Probabilities",
    "section": "Conditional probability",
    "text": "Conditional probability\nExample: What is the conditional probability of death within a year of birth, given the infant has a mother who smokes?\n(Probability of an event occurring (B) given that another event occurred (A))\n\nP(A|B) = P(A and B) / P(B)"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review",
    "title": "Decision Trees & Probabilities",
    "section": "Conditional probability, 2x2 review",
    "text": "Conditional probability, 2x2 review\n\nWhat is the conditional probability of death within a year of birth, given the infant has a mother who smokes?\n\n*A= death in first year; B=mother who smokes\nP(A|B) = 16,712 / (1,197,142 + 16,712)  = 14 per 1,000 births"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-1",
    "title": "Decision Trees & Probabilities",
    "section": "Conditional probability, 2x2 review",
    "text": "Conditional probability, 2x2 review\n\nOr, if we wanted to use the conditional probability equation\n\nP(A|B) = P(A and B)/P(B)  *A= death in first year; B=mother who smokes \nP(A and B) = 16,712 / 4,111,059 = 0.0041  P(B) = 1,213,854/4,111,059 = 0.295  P(A|B) = 0.0041/0.295 = 0.014"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-2",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-2",
    "title": "Decision Trees & Probabilities",
    "section": "Conditional probability, 2x2 review",
    "text": "Conditional probability, 2x2 review\n\nProbability of A|B is different from that of B|A\n\nIf A = death in first year; B=normal birth weight infant, then the conditional probability of P(A|B) = the probability of an infant death, given that the child has a normal birth weight"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-3",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-3",
    "title": "Decision Trees & Probabilities",
    "section": "Conditional probability, 2x2 review",
    "text": "Conditional probability, 2x2 review\n\nWhat is the conditional probability of an infant death, given that the child has a normal birth weight\n\nIf A = death in first year; B=normal birth weight infant \nP(A|B) = 14,442 / (14,442+ 3,804,294)  = 3.8 deaths per 1,000 births"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-4",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-4",
    "title": "Decision Trees & Probabilities",
    "section": "Conditional probability, 2x2 review",
    "text": "Conditional probability, 2x2 review\n\nOr, if we wanted to use equation\n\nP(A|B) = P(A and B)/P(B)\n\nP(A and B) = 14,442  P(B) = 3,818,736  P(A|B) = 14,442/3,818,736 = 0.0038"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-5",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-5",
    "title": "Decision Trees & Probabilities",
    "section": "Conditional probability, 2x2 review",
    "text": "Conditional probability, 2x2 review\n\nOn the other hand, the conditional probability of P(B|A) is the probability that an infant had normal birth weight, given that the infant died within 1 year from birth\n\n*B=normal birth weight infant; A = death in first year"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-6",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#conditional-probability-2x2-review-6",
    "title": "Decision Trees & Probabilities",
    "section": "Conditional probability, 2x2 review",
    "text": "Conditional probability, 2x2 review\nSolve P(B|A) – the probability that an infant had normal birthweight, given that the infant died within 1 year from birth\n\nP(B|A) = 14,442 / (14,442+ 21,054) = 0.41"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#decision-philosophies",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#decision-philosophies",
    "title": "Decision Trees & Probabilities",
    "section": "Decision Philosophies",
    "text": "Decision Philosophies\n\n\n\n\n\n\nMaximizing expected value is a reasonable criterion for choice given uncertain prospects; though it does not necessarily promise the best results for any one individual.\n\n\n\n\nMini-max regret\nMaxi-max\nExpected utility"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#decision-philosophies-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#decision-philosophies-1",
    "title": "Decision Trees & Probabilities",
    "section": "Decision Philosophies",
    "text": "Decision Philosophies\n\n\n\n\n\n\nMaximizing expected value is a reasonable criterion for choice given uncertain prospects; though it does not necessarily promise the best results for any one individual.\n\n\n\n\nMini-max regret\n\nNever go to the beach unless 0% rain.\n\nMaxi-max gain\nExpected utility\n\n\n\nLet’s quickly touch on decision philosophies when it comes to preference weighting. There are different levels of risk aversion & there are different decision philosophies for these behaviors\nMini-max regret philosophy essentially means that you would never go to the beach unless there was 0% rain\n\n\nFor instance, physicians may be risk averse & therefore minimize max regret"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#decision-philosophies-2",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#decision-philosophies-2",
    "title": "Decision Trees & Probabilities",
    "section": "Decision Philosophies",
    "text": "Decision Philosophies\n\n\n\n\n\n\nMaximizing expected value is a reasonable criterion for choice given uncertain prospects; though it does not necessarily promise the best results for any one individual.\n\n\n\n\nMini-max regret\n\nNever go to the beach unless 0% rain.\n\nMaxi-max\n\nAlways go to the beach unless 100% rain.\n\nExpected utility\n\n\n(3)(a) Maxi-max gain is the reverse – where you would always go to the beach unless there was 100% rain – you are risk seeking – you love the beach so much that you’re going to give it a try.\n(3)(b) Another example of this in a medical context – is the desperate patient example – you’re going to die anyways, so we are going to give you this treatment, but it has nasty side effects – cancer – chemotherapies – even bone marrow transplants, 2nd or third line – a high probability of bad outcome but if you do nothing then you’re going to die."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#decision-philosophies-3",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#decision-philosophies-3",
    "title": "Decision Trees & Probabilities",
    "section": "Decision Philosophies",
    "text": "Decision Philosophies\n\n\n\n\n\n\nMaximizing expected value is a reasonable criterion for choice given uncertain prospects; though it does not necessarily promise the best results for any one individual.\n\n\n\n\nMini-max regret\n\nNever go to the beach unless 0% rain.\n\nMaxi-max\n\nAlways go to the beach unless 100% rain.\n\nExpected utility\n\nDepends on the weather.\n\n\n\n\nIf you’re going to base your decision on expected utility, then your decision depends on the weather & how much value you give to certain outcomes – this is the rationale thinker approach – how much you value sitting at home weighed by the utility loss of not having the beach experience, for example."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#payoffs-1",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#payoffs-1",
    "title": "Decision Trees & Probabilities",
    "section": "Payoffs",
    "text": "Payoffs\n\n\nEach state of the world is assigned a cost or outcome.\nOur goal is often to calculate the expected value of these payoffs.\nWe’ll cover more on the theories and frameworks underlying various payoffs in the next few lectures"
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#strengths",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#strengths",
    "title": "Decision Trees & Probabilities",
    "section": "Strengths",
    "text": "Strengths\n\n\nThey are easy to describe and understand\nWorks well with limited time horizon\nDecision trees are a powerful framework for analyzing decisions and can provide rapid/useful insights, but they have limitations."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#limitations",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#limitations",
    "title": "Decision Trees & Probabilities",
    "section": "Limitations",
    "text": "Limitations\n\n\nNo explicit accounting for the elapse of time.\n\nRecurrent events must be separately built into model.\nFine for short time cycles (e.g., 12 months) but we often want to model over a lifetime.\n\nDifficult to incorporate real clinical detail - Tree structure can quickly become complex."
  },
  {
    "objectID": "lectures/lec_2.decision-trees-and-probabilities.html#preview-of-whats-to-come",
    "href": "lectures/lec_2.decision-trees-and-probabilities.html#preview-of-whats-to-come",
    "title": "Decision Trees & Probabilities",
    "section": "Preview of what’s to come",
    "text": "Preview of what’s to come\n\n\n\nMore complex tree!\n\n\n\n\n\n\nBack to Website"
  }
]